10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended July 31, 2022

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from           to            

Commission file number: 000-56323

WESTERN MAGNESIUM CORPORATION

(Exact name of registrant as specified in its charter)

Delaware	61-1934413
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

8180 Greensboro Drive, Suite 720 McLean, Virginia	22102
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (571) 378-0762

Securities registered pursuant to Section 12(b) of the Act:

None.

Securities registered pursuant to Section 12(g) of the Act:

Title of each class

Common Stock, $0.001 par value

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of September 6, 2022, the registrant had 450,265,776 shares of Common Stock outstanding.

WESTERN MAGNESIUM CORPORATION

Quarterly Report on Form 10-Q

For the Quarterly Period Ended July 31, 2022

Table of Contents

		Page
PART I.	FINANCIAL INFORMATION	3
Item 1.	Financial Statements (Unaudited)	3
	Condensed Consolidated Balance Sheets	3
	Condensed Consolidated Statements of Loss and Comprehensive Loss	4
	Condensed Consolidated Statements of Shareholders’ Deficit	5
	Condensed Consolidated Statements of Cash Flows	6
	Notes to Unaudited Condensed Consolidated Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	34
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	58
Item 4.	Controls and Procedures	58
PART II.	OTHER INFORMATION	59
Item 1.	Legal Proceedings	59
Item 1A.	Risk Factors	61
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	61
Item 3.	Defaults Upon Senior Securities	62
Item 4.	Mine Safety Disclosures	62
Item 5.	Other Information	62
Item 6.	Exhibits	62
	Signatures	63

2

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

WESTERN MAGNESIUM CORPORATION

Condensed Consolidated Balance Sheets

				July 31, 2022			October 31, 2021
	Note		$			$
			(Unaudited)			(Audited)
ASSETS
Current assets
Cash				16,700			462,360
Other receivables				94,696			151,485
Prepayments				337,525			133,647
Deposits held by related parties		8[a]		349,338			486,462
				798,259			1,233,954
Non-current assets
Property, plant and equipment, net		4		4,488,001			2,574,704
Right-of-use assets, net		5		405,321			598,575
Mineral property costs		7		93,453			93,453
Reclamation and other deposits				12,729			12,826
TOTAL ASSETS				5,797,763			4,513,512
LIABILITIES AND SHAREHOLDERS’ DEFICIT
Current liabilities
Accounts payable and accrued liabilities				3,434,539			1,989,316
Due to related parties		8[b]		1,520,834			1,026,817
Lease obligations – current		6		259,936			192,045
Provision for flow through share issuances		11		225,284			233,285
Convertible debenture, net		12		1,942,838			7,449,807
Warrant liability		13		57,080			–
				7,440,511			10,891,270
Non-current liabilities
Lease obligations – non-current		6		195,813			392,280
Total liabilities				7,636,324			11,283,550
Commitments and contingencies [note 9]
Shareholders’ deficit
Capital stock
Authorized: 1 billion common stock at par value of $0.001
Issued and paid: 449,265,776 (2021 – 392,943,398)		14		41,811,321			29,842,167
Additional paid-in-capital		14		23,188,545			15,186,480
Obligations to issue shares		14		–			209,827
Accumulated other comprehensive income				352,345			121,109
Accumulated deficit				(67,190,772	)		(52,129,621	)
Total shareholders’ deficit				(1,838,561	)		(6,770,038	)
TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT				5,797,763			4,513,512

Nature of operations and going concern [note 1]

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3

WESTERN MAGNESIUM CORPORATION

Condensed Consolidated Statements of Loss and Comprehensive Loss

			Three Months Ended July 31,						Nine Months Ended July 31,
			2022			2021			2022			2021
	Note		$			$			$			$
Operating expenses
Bank charges				3,792			4,890			12,444			11,044
Business development				66,883			–			144,212			–
Computer system and software				23,766			11,854			63,120			83,639
Consulting and management fees		8[d]		181,193			274,094			594,829			613,048
Depreciation		4, 5		193,926			62,781			436,253			159,774
Due diligence expenses				–			2,010			–			3,974
Engineering expenses				101,617			17,295			218,425			72,749
Foreign exchange loss (gain)				30,282			(35,499	)		256,417			(121,726	)
Interest and accretion		12		372,295			28,242			1,021,443			64,576
Investor relations				12,872			131,739			228,706			202,675
Legal and professional fees				320,665			257,648			1,897,719			545,234
Office and general				266,407			23,794			343,765			83,405
Property maintenance fees				15,100			15,069			15,100			15,069
Rent and facilities				119,625			68,635			295,746			153,910
Salaries and benefits		8[c]		1,151,045			809,253			3,347,884			2,176,185
Stock-based compensation		14[d]		32,539			1,057,013			466,368			1,057,013
Shareholder communications				7,500			(36,722	)		48,201			49,512
Subsidies and recoveries				223			(477	)		(78,996	)		(41,724	)
Transfer agent and regulatory fees				95,618			37,508			184,355			61,138
Travel expenses				137,548			107,546			359,491			218,222
Total operating expenses				3,132,896			2,836,673			9,855,482			5,407,717
Other income (expense)
Change in fair value of derivative liability		12[e]		–			(806,853	)		359,643			(790,197	)
Loss on recognition of debt host liability		12[e]		–			(140,909	)		(341,553	)		(140,909	)
Change in fair value of warrant liability		13		1,837,031			–			(5,223,759	)		–
Total other income (expense)				1,837,031			(947,762	)		(5,205,669	)		(931,106	)
Net loss				(1,295,865	)		(3,784,435	)		(15,061,151	)		(6,338,823	)
Other comprehensive income (loss)
Foreign currency translation				17,273			16,068			231,236			(174,981	)
Comprehensive loss				(1,278,592	)		(3,768,367	)		(14,829,915	)		(6,513,804	)
Basic and diluted loss per common share				(0.00	)		(0.01	)		(0.03	)		(0.02	)
Weighted average number of common shares outstanding – basic and diluted				444,004,303			365,235,017			494,284,490			340,461,383

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4

WESTERN MAGNESIUM CORPORATION

Condensed Consolidated Statements of Shareholders’ Deficit

	Common shares					Additional paid-in capital			Obligation to issue shares			Accumulated other comprehensive income (loss)			Accumulated deficit			Shareholders’ deficit
	Number		$			$			$			$			$			$
Balance, October 31, 2020		323,419,527		21,322,022			4,182,037			596,872			399,175			(28,580,009	)		(2,079,903	)
Shares issued pursuant to private placements [note 14[b]]		53,151,881		5,754,705			–			(596,872	)		–			–			5,157,833
Shares issued on warrants exercised [note 14[b]]		524,901		33,131			(4,291	)		–			–			–			28,840
Shares issued on options exercised [note 14[b]]		300,000		36,150			(23,879	)		–			–			–			12,271
Shares issued upon conversion of convertible debenture [notes 12[b], 12[c] and 14[b]]		1,360,959		162,829			–			–			–			–			162,829
Shares issued for equipment [note 14[b]]		1,538,461		305,832			–			–			–			–			305,832
Share issue costs [note 14[b]]		–		(573,289	)		–			–			–			–			(573,289	)
Stock-based compensation [note 14[d]]		–		–			1,057,013			–			–			–			1,057,013
Foreign currency translation		–		–			–			–			(174,981	)		–			(174,981	)
Net loss		–		–			–			–			–			(6,338,823	)		(6,338,823	)
Balance, July 31, 2021		380,295,729		27,041,380			5,210,880			–			224,194			(34,918,832	)		(2,442,378	)
Balance, October 31, 2021		392,943,398		29,842,167			15,186,480			209,827			121,109			(52,129,621	)		(6,770,038	)
Shares issued pursuant to private placements [note 14[b]]		3,842,499		1,373,274			–			(598,528	)		–			–			774,746
Shares issued on warrants exercised [notes 13 and 14[b]]		32,633,121		9,604,902			–			–			–			–			9,604,902
Shares issued on options exercised [note 14[b]]		1,750,000		162,443			(70,263	)		–			–			–			92,180
Shares issued upon conversion of convertible debenture [notes 12[b], 12[c] and 14[b]]		8,933,333		888,178			–			–			–			–			888,178
Shares issued for finder’s fees [notes 8[d][v] and 14[b]]		9,163,425		–			–			–			–			–			–
Share issue costs [note 14[b]]		–		(59,643	)		–			–			–			–			(59,643	)
Stock-based compensation [note 14[d]]		–		–			466,368			–			–			–			466,368
Beneficial conversion feature on convertible debentures [note 12[d]]		–		–			240,000			–			–			–			240,000
Effects of change in functional currency on convertible debentures [note 12[e]]		–		–			7,370,158			–			–			–			7,370,158
Effects of change in functional currency on broker warrants [note 13]		–		–			(4,198	)		–			–			–			(4,198	)
Share subscriptions [note 14[f]]		–		–			–			388,701			–			–			388,701
Foreign currency translation		–		–			–			–			231,236			–			231,236
Net loss		–		–			–			–			–			(15,061,151	)		(15,061,151	)
Balance, July 31, 2022		449,265,776		41,811,321			23,188,545			–			352,345			(67,190,772	)		(1,838,561	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

5

WESTERN MAGNESIUM CORPORATION

Condensed Consolidated Statements of Cash Flows

	Nine Months Ended July 31,
	2022			2021
	$			$
OPERATING ACTIVITIES
Net loss		(15,061,151	)		(6,338,823	)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of derivative liability		(359,643	)		790,197
Loss on recognition of debt host liability		341,553			140,909
Change in fair value of warrant liability		5,223,759			–
Cashless warrant exercise		(113,765	)		–
Accrued interest and accretion		196,115			32,124
Amortization of debt discount		814,729			–
Depreciation of property, plant and equipment		258,515			22,355
Depreciation of right-of-use assets		177,738			137,419
Foreign exchange loss (gain)		23,535			(27,812	)
Interest expense on lease obligations		25,905			16,946
Shares issued for equipment		–			165,659
Stock-based compensation		466,368			1,057,013
Changes in operating assets and liabilities:
Other receivables		51,963			(118,276	)
Prepayments		(209,967	)		(32,436	)
Deposits held by related parties		121,301			(653,915	)
Accounts payable and accrued liabilities		1,524,962			877,574
Due to related parties		532,489			(85,623	)
Cash used in operating activities		(5,985,595	)		(4,016,689	)
INVESTING ACTIVITIES
Purchase of property, plant and equipment		(2,252,600	)		(1,779,316	)
Cash used in investing activities		(2,252,600	)		(1,779,316	)
FINANCING ACTIVITIES
Proceeds from issuance of shares, net of share issuance costs		5,943,775			4,773,200
Proceeds from convertible debenture		2,000,000			1,579,475
Payments of promissory note		–			(65,745	)
Payments of lease obligations		(143,672	)		(153,145	)
Cash provided by financing activities		7,800,103			6,133,785
Change in cash for the period		(438,092	)		337,780
Cash, beginning of the period		462,360			39,571
Effect of foreign exchange on cash		(7,568	)		5,892
Cash, end of the period		16,700			383,243
Other non-cash transactions:
Shares issued for conversion of debt and interest		888,178			–
Shares issued for payment of finder’s fees		4,796,832			–
Other cash flow disclosures:
Cash paid during the period for interest		10,581			–

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

6

WESTERN MAGNESIUM CORPORATION

Notes to Unaudited Condensed Consolidated Financial Statements

1. NATURE OF OPERATIONS AND GOING CONCERN

Western Magnesium Corporation (the “Company”, or “WMC”) was incorporated under the laws of British Columbia on March 24, 1966. On May 14, 2019, the Company discontinued from the jurisdiction of the Business Corporations Act (British Columbia) and domesticated under the General Corporation Law of the State of Delaware under the name “Western Magnesium Corporation”. The Company is a reporting issuer in Canada and in the United States, listed for trading in Canada on the TSX Venture Exchange (the “TSX-V”) under the symbol “WMG.V”, in the United States on the OTCQB tier of the OTC Markets (the “OTCQB”) under the symbol “MLYF”, and in Germany on the Frankfurt Stock Exchange under the symbol “3WM”. The Company has developed proprietary magnesium production technology with the aim of becoming a premier low-cost producer of green primary magnesium metal.

As at July 31, 2022, the Company had an accumulated deficit of $67,190,772 (October 31, 2021 – $52,129,621) and working capital deficiency of $6,642,252 (October 31, 2021 – $9,657,316). For the nine months ended July 31, 2022, the Company reported a comprehensive loss of $14,829,915 (2021 – $6,513,804). The Company has not yet achieved profitable operations and expects to incur further losses from operations. The Company has financed its activities and operations through equity issuances and debt financing and expects to continue to do so to the extent such financing is available. There can be no assurance that such financing will be available under terms acceptable to the Company or at all.

These unaudited condensed consolidated financial statements (the “Financial Statements”) have been prepared under the assumption that the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will be able to meet its obligations and continue its operations for the foreseeable future and be able to realize its assets and discharge its liabilities and commitments in the normal course of business. If future financing through share or debt issuances is unavailable or if for any reason the Company is unable to continue as a going concern, it could impact the Company’s ability to realize its assets at their recognized values and to meet its obligations in the ordinary course of business at the amounts stated in these Financial Statements. These Financial Statements do not give effect to adjustments that would be necessary to the carrying values and classifications of assets and liabilities should the Company be unable to continue as a going concern. If the going concern assumption is not used, the adjustments required to report the Company’s assets and liabilities on a liquidation basis could be material to these Financial Statements.

The Company’s management has evaluated whether there is substantial doubt about the Company’s ability to continue as a going concern and has determined that substantial doubt existed as of July 31, 2022. This determination was based on the following factors: (i) the Company used cash of approximately $6 million in operations during the nine months ended July 31, 2022; (ii) the Company’s available cash as of July 31, 2022 will not be sufficient to fund its anticipated level of operations for the next 12 months; (iii) the Company will require additional financing for the fiscal year ending October 31, 2022 to continue at its expected level of operations; and (iv) if the Company fails to obtain the needed capital, it will be forced to delay, scale back, or eliminate some or all of its development activities or perhaps cease operations. In the opinion of management, these factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for at least one year from the date of these Financial Statements are issued.

7

In March 2020, the World Health Organization declared COVID-19 a global pandemic. In order to combat the spread of COVID-19, governments worldwide, including the Unites States and Canada, have enacted emergency measures including travel bans, legally enforced or self-imposed quarantine periods, social distancing and business and organization closures. These measures have adversely affected workforces, economies, and financial markets globally, leading to an economic downturn. The impact on the Company has not been significant but could affect the Company’s ability to raise financings in the future and restrict travel. Management continues to monitor the situation.

2. BASIS OF PRESENTATION

These Financial Statements comprise the financial statements of Western Magnesium Corporation and its wholly owned subsidiaries, Western Magnesium Corp., incorporated in Nevada, United States and Western Magnesium Canada Corporation, incorporated in British Columbia, Canada.

[a] Accounting standards

The accompanying Financial Statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) on the basis that the Company will continue as a going concern, which assumes that the Company will be able to meet its obligations as they become due and continue its operations for at least one year from the date these Financial Statements are issued. Realization values may be substantially different from carrying values as shown and these Financial Statements do not give effect to adjustments that would be necessary to the carrying values and classification of assets and liabilities should the Company be unable to continue as a going concern.

These Financial Statements have been prepared on a historical cost basis except for financial instruments that have been measured at fair value. In addition, these Financial Statements have been prepared using the accrual basis of accounting, except for cash flow information. They do not include all the information required for complete annual financial statements and should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended October 31, 2021 (the “Fiscal 2021 Financial Statements”).

[b] Functional and presentation currency

These Financial Statements are presented in United States dollars (“US dollars” or “US$”), except where otherwise indicated. The functional currency of each entity of the Company is as follows:

Entity	Functional Currency
Western Magnesium Corporation	United States dollars
Western Magnesium Corp.	United States dollars
Western Magnesium Canada Corporation	Canadian dollars (“CA$”)

During the three months ended January 31, 2022, significant changes in economic facts and circumstances have occurred in Western Magnesium Corporation’s operations which resulted in the change of its functional currency to the United States dollar from the Canadian dollar effective November 1, 2021. For both monetary and non-monetary assets and liabilities, translated balances at the end of the prior period became the new accounting basis. The rate on the date of change became the historical rate at which non-monetary assets and liabilities were translated in subsequent years. There was no effect on the cumulative translation adjustment on the consolidated basis. Previously recorded cumulative translation adjustments were not reversed. Effects of change in functional currency included the reclassifications of convertible debentures and warrants and broker warrants [notes 12[d] and [e]].

8

The accounts of the Company’s subsidiary Western Magnesium Canada Corporation have been translated to United States dollars with the exchange translation adjustments recorded in other comprehensive income (loss).

[c] Critical accounting estimates and judgments

The preparation of these Financial Statements in accordance with US GAAP requires the Company to make estimates and assumptions concerning the future that affect the amounts reported in the Financial Statements and accompanying notes. Management reviews these estimates and underlying assumptions on an ongoing basis, based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are adjusted for prospectively in the period in which the estimates are revised.

Estimates and assumptions where there is potential risk of material adjustments to assets and liabilities in future accounting periods include the useful lives of property, plant and equipment, recoverability of the carrying value of exploration and evaluation assets, fair value measurements for financial instruments, discount rates for leases, recoverability and measurement of deferred tax assets and liabilities, and contingent liabilities.

Significant Judgments

The preparation of these Financial Statements in accordance with US GAAP requires the Company to make judgments, apart from those involving estimates, in applying accounting policies. The most significant judgments in applying the Company’s Financial Statements include:

- the assessment of the Company’s ability to continue as a going concern and whether there are events or conditions that may give rise to substantial doubt;

- whether there are indicators of impairment of the Company’s exploration and evaluation assets and other non-current assets;

- the classification of financial instruments; and

- determination of functional currency.

3. RECENT ACCOUNTING PRONOUNCEMENTS

New Accounting Standards Adopted During the Periods

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years, with early adoption permitted. Effective November 1, 2021, the Company adopted the new standard. There was no material impact or adjustment to these Financial Statements.

9

In January 2020, the FASB issued ASU 2020-01, Investments – Equity Securities (Topic 321), Investments – Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) (“ASU 2020-01”), which is intended to clarify the interactions of the accounting for equity securities under Topic 321 and investments accounted for under the equity method of accounting in Topic 323 and the accounting for certain forward contracts and purchased options accounted for under Topic 815. ASU 2020-01 is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years, with early adoption permitted. Effective November 1, 2021, the Company adopted the new standard. There was no material impact or adjustment to these Financial Statements.

New Accounting Standards Not Yet Adopted

In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”). ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments and supersedes the respective guidance within ASC 470-20 and ASC 740-10-55-51, which will result in more instruments to be accounted for as a single instrument rather than having their proceeds allocated between liability and equity accounting units. As smaller reporting companies as defined by the United States Securities and Exchange Commission (the “SEC”), ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the effect this standard will have on its Financial Statements.

4. PROPERTY, PLANT AND EQUIPMENT

	Computer Equipment		Furniture			Leasehold Improvement			Furnace & Plant Equipment			Vehicle			Total
	$		$			$			$			$			$
Cost
Balance, October 31, 2021		109,629		53,542			139,481			2,344,726			–			2,647,378
Additions		14,370		2,171			159,065			2,047,779			29,215			2,252,600
Foreign exchange effect		10		(314	)		(5,708	)		(76,255	)		(374	)		(82,641	)
Balance, July 31, 2022		124,009		55,399			292,838			4,316,250			28,841			4,817,337
Accumulated Depreciation
Balance, October 31, 2021		27,821		16,514			14,147			14,192			–			72,674
Depreciation expense		28,402		5,777			81,553			137,294			5,084			258,515
Foreign exchange effect		403		(52	)		(856	)		(906	)		(37	)		(1,853	)
Balance, July 31, 2022		56,626		22,239			94,844			150,580			5,047			329,336
Net Book Value
Balance, October 31, 2021		81,808		37,028			125,334			2,330,534			–			2,574,704
Balance, July 31, 2022		67,383		33,160			197,994			4,165,670			23,794			4,488,001

10

5. RIGHT-OF-USE ASSETS

As at July 31, 2022, the right-of-use assets were leases for the Company’s offices in Vancouver, British Columbia and McLean, Virginia, and its research and development pilot plant located in Burnaby, British Columbia. These leases terminate on March 31, 2023, February 28, 2025 and September 30, 2023, respectively. The lease for the Company’s office in Las Vegas, Nevada ended on May 31, 2021.

	Vancouver Office		Virginia Office			Nevada Office		Pilot Plant			Total
	$		$			$		$			$
Cost
Balance, October 31, 2021		156,881		292,391			24,580		384,946			858,798
Foreign exchange effect		–		(3,038	)		–		(13,208	)		(16,246	)
Balance, July 31, 2022		156,881		289,353			24,580		371,738			842,552
Accumulated Depreciation
Balance, October 31, 2021		90,277		15,529			24,580		129,837			260,223
Depreciation expense		33,456		50,562			–		93,720			177,738
Prepaid expense		–		4,557			–		–			4,557
Foreign exchange effect		–		(162	)		–		(5,125	)		(5,287	)
Balance, July 31, 2022		123,733		70,486			24,580		218,432			437,231
Net Book Value
Balance, October 31, 2021		66,604		276,862			–		255,109			598,575
Balance, July 31, 2022		33,148		218,867			–		153,306			405,321

6. LEASE OBLIGATIONS

On adoption of ASU 2016-02 on November 1, 2019, the Company recognized lease liabilities of $83,549 which had previously been classified as operating leases. The lease liabilities were measured at the present value of the remaining lease payments and discounted using the lessee’s incremental borrowing rate of approximately 7%.

During the year ended October 31, 2020, the Company entered into a new operating lease with respect to its research and development pilot plant located in Burnaby, British Columbia and recognized a lease liability of $354,263, which was measured by discounting lease payments using an incremental borrowing rate of approximately 6%.

During the year ended October 31, 2021, the Company renewed its operating lease with respect to its office in Vancouver, British Columbia and recognized a lease liability of $91,237, which was measured by discounting lease payments using an incremental borrowing rate of approximately 7%.

During the year ended October 31, 2021, the Company entered into a new operating lease with respect to its corporate head office in McLean, Virginia and recognized a lease liability of $260,649, which was measured by discounting lease payments using an incremental borrowing rate of approximately 7%.

	Vancouver Office			Virginia Office			Nevada Office		Pilot Plant			Total
	$			$			$		$			$
Balance, October 31, 2021		66,604			262,612			–		255,109			584,325
Lease payments		(36,087	)		(4,557	)		–		(103,028	)		(143,672	)
Interest expense		2,631			13,967			–		9,307			25,905
Foreign exchange effect		–			(2,728	)		–		(8,081	)		(10,089	)
Balance, July 31, 2022		33,148			269,294			–		153,307			455,749
Which consist of:
Current lease obligation		33,148			96,043			–		130,745			259,936
Non-current lease obligation		–			173,251			–		22,562			195,813
Balance, July 31, 2022		33,148			269,294			–		153,307			455,749

11

7. MINERAL PROPERTY COSTS

As at July 31, 2022, the Company had the following mining claims:

[a] Silverado Property, Nevada, United States

The Silverado property is located in the Pinto mining district of Nevada, consists of 3 patented mining claims totaling approximately 120 hectares, and is 100% owned by the Company. The carrying value of the property is $1.

[b] Tami Mosi Property, Nevada, United States

The Company holds a 100% interest in 81 unpatented lode mining claims totaling approximately 1,637 acres located in White Pine County, Nevada and four unpatented lode mining claims totaling approximately 10 acres located in the Moor Mining District, Elko County, Nevada. These mining claims are subject to a 2% net smelter royalty in favor of the prior owner of the claims. The carrying value of the property is $93,452.

8. RELATED PARTY TRANSACTIONS

[a] Deposits held by related parties

Pursuant to vendor agreements entered on January 1, 2021, the Company provided related parties with advances that were held as deposits for anticipated future costs related to the Company’s planned magnesium research and development pilot plant and other administrative expenses (the “Pilot Plant Advances”). As at July 31, 2022, the Company had the following deposits held by related parties:

	Related Party A [i]			Related Party B [ii]			Total
	$			$			$
Balance, October 31, 2021		291,481			194,981			486,462
Advances		354,459			1,225,118			1,579,577
Costs and expenses		(312,820	)		(1,420,829	)		(1,733,649	)
Foreign exchange effect		16,218			730			16,948
Balance, July 31, 2022		349,338			–			349,338

[i] Related Party A is a company controlled by a director and officer.

[ii] Related Party B is a company controlled by an officer.

12

[b] Due to related parties

As at July 31, 2022, balances due to related parties totaled $1,520,834 (October 31, 2021 – $1,026,817). All advances are unsecured, non-interest bearing, and have no stated terms of repayment.

	July 31, 2022		October 31, 2021
	$		$
Wages payable to directors and officers		505,544		357,500
Benefits payable to directors and officers		725,261		539,209
Fees and expenses payable to directors and officers		290,029		127,878
Interest due to a shareholder		–		2,230
Total		1,520,834		1,026,817

[c] Key management compensation

As at July 31, 2022, the Company had eleven executives including nine senior management members. Their aggregate annualized compensation is approximately $3.3 million. During the nine months ended July 31, 2022, the Company incurred salaries, benefits, and consulting fees totaling $2,605,352 to directors and officers, and stock-based compensation of $160,700 for options granted to an officer of the Company.

[d] Transactions with related parties

[i] During the nine months ended July 31, 2022, the Company incurred consulting fees of $27,489 (CA$35,000) to a former member of senior management.

[ii] During the nine months ended July 31, 2022, the Company incurred consulting fees of $60,000 to a company controlled by an executive.

[iii] During the nine months ended July 31, 2022, the Company incurred consulting fees of $29,600 to a company controlled by an executive.

[iv] In June 2021, the Company renewed its sublease agreement with a company controlled by a director and officer for its office in Vancouver, British Columbia with a lease term from April 1, 2021 to March 31, 2023 at a monthly rent of $7,656 (CA$9,794).

[v] Pursuant to an agreement entered on August 29, 2018 and which was approved by the TSX-V on September 12, 2018, a company controlled by a director and officer is eligible to receive up to 5% of the issued and outstanding common shares of the Company as at August 28, 2018 for up to $5 million raised. The agreement was amended on January 2, 2019, extending the term from six months to three years and six months. During the year ended October 31, 2021, the commitment was met. On November 3, 2021, the Company issued 9,163,425 common shares at a price of CA$0.65 per share with a total fair value of $4,796,832 (CA$5,956,226) as share issue costs.

13

9. CONTINGENT LIABILITIES AND COMMITMENTS

[a] Contingent liabilities

[i] On September 29, 2020, James Sever filed a Notice of Civil Claim against the Company in the Supreme Court of British Columbia (the “Sever Claim”). The Sever Claim alleges that Mr. Sever had an employment and/or other similar contractual relationship with the Company, and that the Company breached such contractual relationship by way of constructive dismissal or similar conduct. The Sever Claim seeks damages in excess of $2.5 million, certain equity compensation, prejudgment garnishment, costs, interest and other non-monetary relief. On July 27, 2021, the Company filed a response to the Sever Claim. On April 5, 2022, the Company filed an amended response to the Sever Claim, which included the following pleadings: (a) British Columbia is an inappropriate and inconvenient forum for the Sever Claim; (b) to the extent that British Columbia is the appropriate forum for the Sever Claim, nonetheless: (i) the Sever Claim is barred in whole or in part by applicable doctrines of delay / statute of limitations, (ii) the Company did not constructively dismiss Mr. Sever and, instead, it was Mr. Sever that abandoned, quit or resigned from his obligations to the Company, (iii) the Company has no debts, liabilities or obligations to Mr. Sever. The Company intends to vigorously defend against the Sever Claim, and believes that the Sever Claim is without merit. As the Company cannot predict the outcome of the Sever Claim, no provision has been recognized as there is no present obligation and the probability of an outcome cannot be determined.

[ii] On December 31, 2020, GEM Yield Bahamas Limited (“GEM”) served the Company with a Notice of Intention to Arbitrate (the “New York Arbitration Notice”) before the American Arbitration Association in New York (the “GEM New York Arbitration”). The New York Arbitration Notice alleges the Company breached a Share Subscription Agreement dated November 15, 2019 entered into between the Company and GEM (the “GEM Agreement”), among other things, claiming damages of approximately $3.4 million (CA$4.2 million). On January 19, 2021, the Company filed a petition in the New York Supreme Court to stay the GEM New York Arbitration claiming the GEM Agreement was not valid. On March 19, 2021, the Court in the New York State Action ruled that there was an arbitration clause in the GEM Agreement but it was up to the arbitrator to determine if the arbitration clause was valid. Following this ruling, the New York State Action was closed. In June 2021, GEM filed a Statement of Claim in the GEM New York Arbitration, and the Company filed a Statement of Answer denying the existence of any binding agreement between the Company and GEM, among other defenses. In January 2022, the Company filed a Modified Statement of Defense and Counterclaims. On April 8, 2022, the parties agreed to consolidate this arbitration with the GEM Montreal Arbitration. The parties then filed consolidated pleadings, and both matters will be decided via arbitration in Montreal. The Company intends to vigorously defend itself in the GEM New York Arbitration and believes the allegations lack merit. As the Company cannot predict the outcome of this arbitration proceeding, no provision has been recognized in respect to the GEM New York Arbitration as there is no present obligation and the probability of an outcome cannot be determined.

[iii] On February 8, 2021, GEM instituted another arbitration against the Company before the International Centre for Dispute Resolution in Montreal Canada (the “GEM Montreal Arbitration”) and joined GEM’s affiliate, GEM Global Yield LLC SCS (“GEM Global Yield” together with GEM, the “GEM Parties”). The Statement of Claim filed by the GEM Parties alleges the Company breached a Share Subscription Agreement dated November 15, 2019 and promissory note, among other things, claiming damages of approximately $3.9 million (CA$4.9 million), in addition to costs and expenses, stemming from the Company’s alleged failure to issue to GEM Global Yield warrants to purchase up to 33 million shares of the Company’s common stock. The Company filed a Statement of Defense denying the existence of any binding agreement between the Company and GEM, among other defenses. In January 2022, the Company filed an Amended Statement of Defense and Cross-claim. On April 8, 2022, the parties agreed to consolidate this arbitration with the GEM New York Arbitration. The parties then filed consolidated pleadings, and both matters will be decided via arbitration in Montreal. The Company intends to vigorously defend itself in the GEM Montreal Arbitration and believes the allegations lack merit. As the Company cannot predict the outcome of this arbitration proceeding, no provision has been recognized in respect to the GEM Montreal Arbitration as there is no present obligation and the probability of an outcome cannot be determined.

14

[iv] On April 19, 2021, Lampert Advisors, LLC (“Lampert”) filed a Verified Complaint against the Company’s wholly owned subsidiary Western Magnesium Corp., a Nevada corporation (“Western Magnesium – Nevada”) in the Supreme Court of the State of New York, County of New York (the “Lampert Lawsuit”). The complaint filed in the Lampert Lawsuit alleges that Lampert entered into an agreement with Western Magnesium – Nevada to provide various financial advisory services including acquisition advisory services and act as an exclusive placement agent for a combination of debt and equity securities (the “Lampert Agreement”), that it performed all services required under that agreement and that it is owed $367,227 plus interest at the rate of 9% from February 3, 2021 and that it has a right of first refusal to act as financial advisor in connection with any debt, equity or debt restructuring assignments on terms, conditions and compensation customary for Lampert for a transaction of the type contemplated. Although Lampert claims to have personally served Western Magnesium – Nevada, the Company never received the Summons and Complaint and therefore, never submitted a response. On September 9, 2021, Lampert filed a Motion seeking the entry of a default judgment (the “Motion”). The Company opposed the Motion and filed a cross-motion to compel Lampert to accept the Company’s answer. The Court granted the Company’s cross-motion and denied Lampert’s Motion as moot. On March 4, 2022, the Company filed a Verified Amended Answer, Affirmative Defenses, and Counterclaims. The counterclaims seek at least $120,000 in damages from Lampert. The Company intends to vigorously defend against the Lampert Lawsuit and prosecute its counterclaims, and the Company believes that the claims asserted by Lampert are without merit. As the Company cannot predict the outcome of the Lampert Lawsuit, no provision has been recognized as there is no present obligation and the probability of an outcome cannot be determined.

[b] Commitments

[i] On November 1, 2016, the Company signed a contract services agreement with Lodestar Management Group, LLC (“Lodestar”), a US corporate logistics company. Lodestar provides advisory, consulting, negotiation and other management services relating to corporate management, administrative and/or operational activities of the Company. The term of the contract was for one year and has been renewed under the same terms on January 1, 2018 and 2019. The Company has agreed to compensate Lodestar in the amount of $1,800 or CA$2,500 per month by issuance of shares up until December 2019, and by cash from January 2020 onwards. The number of shares issued will be based on the share price on the day of issuance that is not lower than the CA$0.05 per share minimum requirement and will not exceed $1,800 or CA$2,500 in value. The shares will be issued on the last working day of each month for a period of twelve months. During the nine months ended July 31, 2022, the Company did not issue any shares (2021 – nil) and paid $30,624 in cash (2021 – $16,200) to Lodestar. As at July 31, 2022, outstanding owing Lodestar were 634,072 shares and $38,593 (October 31, 2021 – $53,491).

[ii] During the year ended October 31, 2020, the Company entered into a lease agreement for its research and development pilot plant in Burnaby, British Columbia with a lease term from October 1, 2020 to September 30, 2023 at a monthly rent of $16,154 (CA$20,715). In June 2021, the Company renewed its sublease agreement with a company controlled by a director and officer for its office in Vancouver, British Columbia with a lease term from April 1, 2021 to March 31, 2023 at a monthly rent of $7,637 (CA$9,794). In September 2021, the Company entered into a lease agreement for its corporate head office in McLean, Virginia with a lease term from September 14, 2021 to February 28, 2025 at a monthly rent of $9,113. The Company was abated for the first five months and was entitled to a tenant allowance of $41,010 [notes 5 and 6].

15

10. PROMISSORY NOTE

During the year ended October 31, 2019, the Company received a loan of $112,895 (CA$150,000) from a related party. The loan was unsecured, bore interest at 18% and was due on demand. During the year ended October 31, 2020, the loan was increased by an additional $44,588 (CA$60,000) to $157,483 (CA$210,000), and was due on September 24, 2021. During the year ended October 31, 2021, the Company accrued interest expense of $1,639 (2020 – $16,655) and repaid the entire balance and interest totaling $65,761 (2020 – $101,066).

11. PROVISION FOR FLOW THROUGH SHARE ISSUANCES

The Company has recorded a provision in the amount of $225,284 (October 31, 2021 – $233,285) for tax and related obligations relating to flow through share issuances from prior years. The flow through share issuances were a Canadian tax-based financing incentive and the provision was in relation to a tax liability with the Federal Government of Canada and had no statute of limitations.

12. CONVERTIBLE DEBENTURE

[a] July 2020 Convertible Debenture

On July 27, 2020, the Company closed a non-brokered private placement of an unsecured convertible note in the principal amount of $112,124 (CA$150,000, the “July 2020 Convertible Debenture”). The note bears interest at 12% per annum and is due on the date that is one year following the closing date. The note is convertible into common shares of the Company at the price which is the greater of CA$0.15 per common share and the market price on the date of the conversion notice. Any accrued but unpaid interest will be payable on the earlier of the maturity date and the date of conversion in cash or common shares. No finder’s fees were paid in connection with this private placement. On May 18, 2021, the Company issued a total of 1,360,959 common shares on the conversion of the July 2020 Convertible Debenture including conversion of accrued interest, and 263,973 common shares valued at $26,286 in transaction costs. The July 2020 Convertible Debenture had an effective interest rate of 37%.

[b] July 2021 Convertible Debenture

On July 15, 2021, the Company closed a non-brokered private placement of an unsecured convertible note in the principal amount of $79,542 (CA$100,000, the “July 2021 Convertible Debenture”) which it received on April 22, 2021. The note bears interest at 12% per annum and is due on the date that is one year following the closing date. The note is convertible at a price of CA$0.12 per unit, where each unit is comprised of one common share and one common share purchase warrant exercisable at a price of CA$0.20 per common share for a period of two years. Any accrued but unpaid interest will be payable on the earlier of the maturity date and the date of conversion in cash or common shares. On April 22, 2022, the Company issued a total of 933,333 units on the conversion of the July 2021 Convertible Debenture including conversion of accrued interest. The July 2021 Convertible Debenture had an effective interest rate of 594%.

[c] June 2021 Convertible Debenture

On June 15, 2021, the Company closed a non-brokered private placement of an unsecured convertible note in the principal amount of $1,500,000 (the “June 2021 Convertible Debenture”). The note bears interest at 12% per annum and matures on December 10, 2022. The June 2021 Convertible Debenture is convertible into 15,000,000 units, where each unit consists of (i) one share of the Company’ common stock, (ii) one-half of one Class A common stock purchase warrant, with each whole warrant being exercisable at a price of $0.13 until June 10, 2026, and (iii) one-half of one Class B common stock purchase warrant, with each whole warrant being exercisable at a price of $0.19 until June 10, 2026 (collectively, the “Class A and B Warrants”). In addition, the conversion price for accrued interest is the greater of (i) $0.10 and (ii) the minimum conversion price permitted by the TSX-V at the time of conversion.

16

As part of the offering of the June 2021 Convertible Debenture, the Company also entered into a securities purchase agreement dated June 10, 2021 (the “2021 Securities Purchase Agreement”), whereby the Company agreed to use commercially reasonable efforts to file a registration statement with the United States Securities and Exchange Commission (the “SEC”) by August 14, 2021, covering the public resale of the shares of common stock underlying such debenture and, upon its conversion, the Class A and B Warrants issuable upon such conversion (the “Underlying Shares”), and to use its best efforts to cause the registration statement to be declared effective on October 13, 2021. On December 13, 2021, the Company’s Form 10 Registration Statement filed with the SEC was declared effective.

In addition to certain covenants contained in the 2021 Securities Purchase Agreement, the terms of the June 2021 Convertible Debenture contain certain negative covenants by the Company, including, among others, sell or offer to sell any securities with non-fixed or floating price features, issue any common stock or common stock equivalents at a price lower than the conversion price herein then in effect, or issue any equity or debt instruments with anti-dilution provisions.

In the event the Company issues or sells any common stock or common stock equivalents with terms that the purchaser holding the outstanding June 2021 Convertible Debenture or the Class A and B Warrants reasonably believes are more favorable to such holder than the terms of the June 2021 Convertible Debenture or the Class A and B Warrants, then upon notice to the Company by such holder within five trading days after notice to such holder by the Company, the Company will use commercially reasonable efforts to obtain the approval of the TSX-V and any additional required regulatory approval to amend the terms of the June 2021 Convertible Debenture or the Class A and B Warrants as required, as the case may be, so as to give such holder the benefit of such more favorable terms or conditions.

The conversion price of the June 2021 Convertible Debenture and the exercise price of the Class A and B Warrants are subject to proportional adjustment in the event of stock splits, stock dividends and similar corporate events, including merger or consolidation of the Company or in a “Fundamental Transaction” as defined in the June 2021 Convertible Debenture.

The Company has granted the holders certain rights of first refusal on its future offerings for as long as the June 2021 Convertible Debenture or the Class A and B Warrants are outstanding.

The Company may prepay and satisfy the June 2021 Convertible Debenture so long as an event of default has not occurred, upon 20 days’ prior written notice received by the Company to the holder, by paying 125% of the amounts owed on the June 2021 Convertible Debenture, including all principal, interest and other fees. The holder of this debenture may, however, convert all or a portion of the debenture during the 20-day notice period.

During the nine months ended July 31, 2022, the Company issued an aggregate 8,000,000 units on partial conversion of the June 2021 Convertible Debenture, for a total of 8,000,000 common shares, 4,000,000 Class A Warrants exercisable at a price of $0.13 until June 10, 2026, and 4,000,000 Class B Warrants exercisable at a price of $0.19 until June 10, 2026 [note 13[b]]. As at July 31, 2022, the Company incurred contractual interest of $165,140 (October 31, 2021 – $70,521). The June 2021 Convertible Debenture has an effective interest rate of 1,113%.

17

[d] April 2022 Convertible Debenture

On April 14, 2022, the Company entered into a securities purchase agreement (the “2022 Securities Purchase Agreement”) and closed a non-brokered private placement of an unsecured convertible note in the principal amount of $2,000,000 (the “April 2022 Convertible Debenture”). The note bears interest at 15% per annum and matures on October 14, 2023. The April 2022 Convertible Debenture is convertible into 6,666,667 units, where each unit consists of one share of the Company’ common stock and one common stock purchase warrant exercisable at a price of $0.40 per share for a period of five years from the date of issuance.

The April 2022 Convertible Debenture may not be prepaid prior to maturity and contains customary events of default relating to, among other things, payment defaults, breach of representations and warranties, and breach of provisions of the 2022 Securities Purchase Agreement or the April 2022 Convertible Debenture.

In the event of default under the April 2022 Convertible Debenture, the interest rate shall increase to the lesser of 20% per annum or the maximum rate permitted under applicable law until paid and the following “Mandatory Default Amount” shall be paid, if demanded by the purchaser: the sum of (a) the greater of (i) the outstanding principal amount of the April 2022 Convertible Debenture divided by the conversion price on the date the Mandatory Default Amount is either (A) demanded (if demand or notice is required to create an event of default) or otherwise due or (B) paid in full, whichever has a lower conversion price, multiplied by the VWAP on the date the Mandatory Default Amount is either (x) demanded, (y) due, or (z) paid in full, whichever is highest, or (ii) 125% of the outstanding principal amount of the April 2022 Convertible Debenture plus (b) all other amounts, costs, expenses and liquidated damages due in respect of the April 2022 Convertible Debenture.

Pursuant to the terms of the 2022 Securities Purchase Agreement, the Company also entered into a registration rights agreement dated April 14, 2022 (the “2022 Registration Rights Agreement”). Pursuant to the terms of the 2022 Registration Rights Agreement, the Company agreed to prepare and file with the SEC a registration statement covering the resale of all shares issued or issuable upon conversion of the April 2022 Convertible Debenture, upon exercise of the respective warrants of the April 2022 Convertible Debenture, upon conversion of the June 2021 Convertible Debenture, and upon exercise of the respective warrants of the June 2021 Convertible Debenture. The Company agreed to file the registration statement with the SEC within 30 days following April 14, 2022 and to use best efforts to have the registration statement declared effective by the SEC within 60 days following April 14, 2022 if the SEC does not review it or by August 12, 2022 if the SEC reviews it. In the event the Company fails to file the registration statement or such registration statement is not declared effective within the time periods noted above or such registration statement is not kept effective while any of the securities registered pursuant to such registration statement, the Company will be obligated to pay the holder of the debentures a penalty in cash, in the amount of $20,000 on the date of such failure and on the 30th day of each month following such failure. The 2022 Registration Rights Agreement contains customary indemnification provisions. On May 25, 2022, the Company filed a Form S-1 Registration Statement with the SEC. On July 12, 2022, the Company’s Form S-1 Registration Statement filed with the SEC was declared effective.

As at July 31, 2022, the Company incurred contractual interest of $88,767 (October 31, 2021 – $nil). The April 2022 Convertible Debenture has an effective interest rate of 22%.

18

[e] Debt Host Liability and Embedded Derivative Liability

Certain of the Company’s convertible debentures were determined to be hybrid financial instruments comprised of a debt host liability and an embedded derivative liability, as under the conversion feature the number of shares that will or may be issued to settle the notes may vary. The Company uses the Black-Scholes Option Pricing Model based on different default risks and assumptions. The debt host liability of the convertible note will be measured at amortized cost, with the embedded derivative liability measured at fair value.

On issuance date of the July 2020 Convertible Debenture, the fair value of its debt host liability was determined to be $87,083 and the respective embedded derivative liability was valued at $25,041. Fair value adjustments were made to the embedded derivative liability of the July 2020 Convertible Debenture on conversion date of May 18, 2021, resulting in a fair value of $nil.

On issuance date of the July 2021 Convertible Debenture, it was determined to be a convertible debt instrument with a beneficial conversion feature accounted for in accordance with ASU 470-20. The Company allocated the intrinsic value of the beneficial conversion feature of the July 2021 Convertible Debenture capped at the face value of $79,542 (CA$100,000) to additional paid-in capital. On November 1, 2021, the Company’s functional currency change resulted in the reclassification of the July 2021 Convertible Debenture to a hybrid financial instrument accounted for in accordance with ASU 815-15. The embedded derivative liability was valued at $421,095 (CA$529,400), the previous beneficial conversion feature was reversed out of additional paid-in capital, and a loss of $341,553 (CA$429,400) was recognized in the statements of loss and comprehensive loss. Fair value adjustments were made to the embedded derivative liability of the July 2021 Convertible Debenture on conversion date of April 22, 2022, resulting in a fair value of $nil.

On issuance date of the June 2021 Convertible Debenture, it was determined to be a hybrid financial instrument comprised of a debt host liability and an embedded derivative liability. The embedded derivative liability was valued at $1,646,600 which exceeded the face value of the note itself of $1,500,000, the debt host liability was then assigned a face value of $1, with an immediate loss of $146,601 on recognition of the debt host liability. As at October 31, 2021, its combined value was $7,449,744. On November 1, 2021, the Company’s functional currency change resulted in the reclassification of the June 2021 Convertible Debenture from a hybrid financial instrument accounted for in accordance with ASU 815-15 to a convertible debt instrument with a beneficial conversion feature accounted for in accordance with ASU 470-20. The value of the embedded derivative liability was reclassified to additional paid-in capital. The corresponding debt discount is amortized as interest expense over the period from the issuance date to the stated maturity date using the effective interest method. During the nine months ended July 31, 2022, the Company recorded interest expense on debt discount of $814,717 which includes the full amortization of the portions of the debt which were converted in the period. As at July 31, 2022, the debt discount had a carrying value of $685,283.

On issuance date of the April 2022 Convertible Debenture, it was determined to be a convertible debt instrument with a beneficial conversion feature accounted for in accordance with ASU 470-20. The Company allocated the intrinsic value of the beneficial conversion feature of the April 2022 Convertible Debenture of $240,000 to additional paid-in capital, and the corresponding debt discount is amortized as interest expense over the period from the issuance date to the stated maturity date using the effective interest method. During the nine months ended July 31, 2022, the Company recorded interest expense on debt discount of $12. As at July 31, 2022, the debt discount had a carrying value of $239,988.

19

	July 2020 Convertible Debenture			July 2021 Convertible Debenture			June 2021 Convertible Debenture			April 2022 Convertible Debenture			Total
	$			$			$			$			$
Debt Host Liability
Balance, October 31, 2020		96,318			–			–			–			96,318
Fair value of debt host liability recognized		–			–			1			–			1
Accretion and interest expense		23,587			63			43			–			23,693
Conversion		(125,560	)		–			–			–			(125,560	)
Foreign currency translation		5,655			–			–			–			5,655
Balance, October 31, 2021		–			63			44			–			107
Effects of functional currency change		–			–			1,500,000			–			1,500,000
Fair value at inception		–			–			–			2,000,000			2,000,000
Accretion and interest expense		–			28,050			49,406			118,659			196,115
Conversion		–			(28,031	)		(800,000	)		–			(828,031	)
Foreign currency translation		–			(82	)		–			–			(82	)
Balance, July 31, 2022		–			–			749,450			2,118,659			2,868,109
Embedded Derivative Liability
Balance, October 31, 2020		20,123			–			–			–			20,123
Fair value of embedded derivative liability recognized		–			–			1,646,600			–			1,646,600
Fair value adjustment		(16,058	)		–			5,717,328			–			5,701,270
Conversion		(5,247	)		–			–			–			(5,247	)
Foreign currency translation		1,182			–			85,772			–			86,954
Balance, October 31, 2021		–			–			7,449,700			–			7,449,700
Effects of functional currency change		–			421,094			(7,449,700	)		–			(7,028,606	)
Fair value adjustment		–			(259,447	)		–			–			(259,447	)
Conversion		–			(158,169	)		–			–			(158,169	)
Foreign currency translation		–			(3,478	)		–			–			(3,478	)
Balance, July 31, 2022		–			–			–			–			–
Debt Discount
Balance, October 31, 2021		–			–			–			–			–
Effects of functional currency change		–			–			(1,500,000	)		–			(1,500,000	)
Fair value at inception		–			–			–			(240,000	)		(240,000	)
Amortization		–			–			814,717			12			814,729
Balance, July 31, 2022		–			–			(685,283	)		(239,988	)		(925,271	)
Combined Value of Convertible Debenture
Balance, October 31, 2020		116,441			–			–			–			116,441
Balance, October 31, 2021		–			63			7,449,744			7,449,744			7,449,807
Balance, July 31, 2022		–			–			64,167			1,878,671			1,942,838

20

The inputs used in the Black-Scholes Option Pricing Model are as follows:

	April 22,		November 1,		October 31,		June 15,		July 27,
	2022		2021		2021		2021		2020
Risk free rate of interest		2.65%		1.07%		1.08%		0.31%		0.26%
Expected life in years		0.23 years		0.70 years		1.11 years		1.50 year		0.74 year
Conversion exercise price		CA$0.12		CA$0.12		$0.10		$0.10		CA$0.15
Underlying share price of the Company		CA$0.36		CA$0.75		$0.59		$0.19		CA$0.13
Expected volatility		99.90%		124.34%		107.62%		87.17%		82.54%
Expected dividend rate		Nil		Nil		Nil		Nil		Nil

13. WARRANT LIABILITY

On November 1, 2021, the Company’s functional currency change resulted in the reclassification of its outstanding warrants and broker warrants denominated in Canadian dollar as derivative liability measured at fair value. The previous value of outstanding broker warrants of $4,198 was reversed out of additional paid-in capital, and the derivative liability of warrants and broker warrants were valued at $26,956,177 and $76,811, respectively. During the nine months ended July 31, 2022, the Company issued common share purchase warrants denominated in Canadian dollar on conversion of the July 2021 Convertible Debenture and recognized additional derivative liability of $67,155. Upon exercise of warrants and broker warrants, $5,057,112 was reclassified from derivative liability to stockholders’ deficit. Fair value adjustments of $21,985,951 were made to the warrant liability. As at July 31, 2022, the derivative liability of warrants and broker warrants were valued at $57,080 and $nil, respectively. The Company uses the Black-Scholes Option Pricing Model based on default risks and assumptions as appropriate to value its warrants and broker warrants.

	Warrants			Broker Warrants			Total
	$			$			$
Warrant Liability
Balance, October 31, 2021		–			–			–
Effects of functional currency change		26,956,177			76,811			27,032,988
Fair value at inception		67,155			–			67,155
Exercised		(5,036,522	)		(20,590	)		(5,057,112	)
Fair value adjustment		(21,929,730	)		(56,221	)		(21,985,951	)
Balance, July 31, 2022		57,080			–			57,080
Change in Fair Value of Warrant Liability
Effects of functional currency change		(26,956,177	)		(76,811	)		(27,032,988	)
Additional paid-in capital adjustment		–			4,198			4,198
Fair value at inception		(67,155	)		–			(67,155	)
Cashless warrant exercised		(113,765	)		–			(113,765	)
Fair value adjustment		21,929,730			56,221			21,985,951
Total		(5,207,367	)		(16,392	)		(5,223,759	)

14. SHARE CAPITAL

[a] Authorized capital

The authorized share capital consists of 1,000,000,000 common voting shares at par value of $0.001.

21

[b] Common shares issued

Fiscal 2021

[i] In connection with the non-brokered private placement announced on September 10, 2020:

On November 20, 2020, the Company closed the first tranche of the non-brokered private placement, issuing 5,599,171 units at a price of CA$0.13 per unit for gross proceeds of $556,876 (CA$727,892), which had been received prior to October 31, 2020 and recorded as an obligation to issue shares.

On January 15, 2021, the Company closed the second tranche of the non-brokered private placement, consisting of 7,337,914 units at a price of CA$0.13 per unit for gross proceeds of $749,435 (CA$953,930), of which $39,996 had been received prior to October 31, 2020 and recorded as an obligation to issue shares.

On January 29, 2021, the Company closed the third tranche of the non-brokered private placement consisting of 5,382,303 units at a price of CA$0.13 per unit for gross proceeds of $547,496 (CA$699,699).

On March 24, 2021, the Company closed the fourth tranche of the non-brokered private placement consisting of 6,554,172 units at a price of CA$0.13 per unit for gross proceeds of $678,270 (CA$852,042).

On April 27, 2021, the Company closed the fifth and final tranche of the non-brokered private placement consisting of 851,395 units at a price of CA$0.13 per unit for gross proceeds of $89,237 (CA$110,681).

In total, the Company issued an aggregate 25,724,955 units at a price of CA$0.13 per unit for aggregate gross proceeds of $2,621,314 (CA$3,344,244). Each unit issued consists of one common share and one common share purchase warrant entitling the holder to acquire a further common share at a price of CA$0.19 for a period of one year from the closing date of the respective financing tranche. The Company incurred aggregate share issue costs of $195,614.

[ii] On May 5, 2021, the Company announced a non-brokered private placement priced at CA$0.13 per unit to raise gross proceeds of up to CA$3,000,000. On May 28, 2021, the Company closed the first tranche of the non-brokered private placement issuing 5,223,420 units at a price of CA$0.13 per unit for gross proceeds of $561,844 (CA$679,044). On June 17, 2021, the Company closed the second and final tranche of the non-brokered private placement consisting of 17,853,506 units at a price of CA$0.13 per unit for gross proceeds of $1,880,687 (CA$2,320,956). The Company issued total of 23,076,926 units at a price of CA$0.13 per unit for total gross proceeds of $2,442,531 (CA$3,000,000). Each unit issued consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.19 for a period of one year from the date of closing of the respective financing tranche. The Company incurred aggregate share issue costs of $154,336.

[iii] On May 18, 2021, the Company issued a total of 1,360,959 common shares on the conversion of the July 2020 Convertible Debenture including accrued interest and 263,973 common shares valued at $26,286 in transaction costs.

[iv] On June 7, 2021, the Company issued 1,538,461 common shares at a price of CA$0.24 per share with a total fair value of $305,832 (CA$369,231) for equipment.

22

[v] On July 16, 2021, the Company closed a non-brokered private placement and issued 4,350,000 units at a price of CA$0.20 per unit for gross proceeds of $690,860 (CA$870,000). Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.30 for a period of one year from the date of closing. The Company incurred aggregate share issue costs of $48,319.

[vi] On August 11, 2021, the Company closed a non-brokered private placement and issued 3,827,601 units at a price of CA$0.55 per unit for gross proceeds of $1,683,336 (CA$2,105,180). Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.65 for a period of eighteen months from the date of closing. The Company incurred aggregate share issue costs of $124,923, and an additional $8,444 in the following fiscal year.

[vii] During the year ended October 31, 2021, the Company issued a total of 7,014,969 common shares on the exercise of common share purchase warrants at a price ranging from CA$0.05 to CA$0.21 per share for gross proceeds of $887,520 (CA$1,120,130). A total of 525,173 warrants expired unexercised.

[viii] During the year ended October 31, 2021, the Company issued a total of 2,630,000 common shares on the exercise of stock options at a price ranging from CA$0.05 to CA$0.16 per share for gross proceeds of $140,734 (CA$175,800).

[ix] With respect to the exercises of common share purchase warrants and options, the Company reclassified $4,291 and $121,932, respectively, from additional paid-in capital to share capital during the year ended October 31, 2021.

Fiscal 2022

[i] Pursuant to an agreement entered on August 29, 2018 and which was approved by the TSX-V on September 12, 2018, a company controlled by a director and officer was eligible to receive up to 5% of the issued and outstanding common shares of the Company as at August 28, 2018 for up to $5 million raised. The agreement was amended on January 2, 2019, extending the term from six months to three years and six months. During the year ended October 31, 2021, the commitment was met. On November 3, 2021, the Company issued 9,163,425 common shares at a price of CA$0.65 per share with a total fair value of $4,796,832 (CA$5,956,226) as share issue costs.

[ii] On November 4, 2021, the Company issued 1,000,000 units on partial conversion of the June 2021 Convertible Debenture, for a total of 1,000,000 common shares, 500,000 Class A Warrants and 500,000 Class B Warrants. On December 13, 2021, the Company issued a further 1,000,000 units on partial conversion of the June 2021 Convertible Debenture, for a total of 1,000,000 common shares, 500,000 Class A Warrants and 500,000 Class B Warrants. On January 20, 2022, the Company issued a further 1,000,000 units on partial conversion of the June 2021 Convertible Debenture, for a total of 1,000,000 common shares, 500,000 Class A Warrants and 500,000 Class B Warrants. Each Class A Warrant is exercisable at a price of $0.13 until June 10, 2026 and each Class B Warrant is exercisable at a price of $0.19 until June 10, 2026. The Company incurred aggregate share issue costs of $1,361.

23

[iii] On November 26, 2021, the Company closed a non-brokered private placement and issued 1,375,499 units at a price of $0.55 per unit for gross proceeds of $756,524. Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of $0.75 for a period of one year from the date of closing. The Company incurred aggregate share issue costs of $26,656.

[iv] During the three months ended January 31, 2022, upon exercise of common share purchase warrants, the Company issued an aggregate 15,159,448 common shares at a price CA$0.19 per share for gross proceeds of $2,279,136 (CA$2,880,295), 200,000 common shares at a price of CA$0.05 per share for gross proceeds of $7,830 (CA$10,000), and 30,000 common shares at a price of CA$0.30 per share for gross proceeds of $6,981 (CA$9,000). The Company issued a total of 15,389,448 common shares for gross proceeds of $2,293,946 (CA$2,899,295). A total of 2,428,363 warrants expired unexercised.

[v] On March 10, 2022, the Company issued 1,000,000 units on partial conversion of the June 2021 Convertible Debenture, for a total of 1,000,000 common shares, 500,000 Class A Warrants and 500,000 Class B Warrants. On April 27, 2022, the Company issued a further 2,000,000 units on partial conversion of the June 2021 Convertible Debenture, for a total of 2,000,000 common shares, 1,000,000 Class A Warrants and 1,000,000 Class B Warrants. Each Class A Warrant is exercisable at a price of $0.13 until June 10, 2026 and each Class B Warrant is exercisable at a price of $0.19 until June 10, 2026.

[vi] On April 22, 2022, the Company issued a total of 933,333 common shares and 933,333 common share purchase warrants exercisable at a price of CA$0.20 for a period of two years on the conversion the July 2021 Convertible Debenture including CA$100,000 principal amount and CA$12,000 accrued interest.

[vii] During the three months ended April 30, 2022, upon the exercise of common share purchase warrants, the Company issued an aggregate 929,005 common shares at a price of CA$0.19 per share for gross proceeds of $929,005 (CA$1,177,755), 2,082,025 common shares at a price of CA$0.05 per share for gross proceeds of $81,354 (CA$104,101), and 30,960 common shares at a price of CA$0.30 per share for gross proceeds of $7,357 (CA$9,288). A total of 3,191,933 warrants and 40,000 broker warrants expired unexercised.

[viii] During the three months ended April 30, 2022, the Company issued a total of 750,000 common shares on the exercise of stock options at a price of CA$0.05 per share for gross of $29,715 (CA$37,500), and reclassified $22,203 from additional paid-in capital to share capital.

[ix] On April 18, 2022, the Company announced a non-brokered private placement priced at $0.25 per unit to raise gross proceeds of up to $3,000,000. On May 9, 2022, the Company closed the first tranche of the non-brokered private placement and issued 1,727,000 units at a price of $0.25 per unit for gross proceeds of $431,750. On June 3, 2022, the Company closed the second and final tranche of the non-brokered private placement and issued 740,000 units at a price of $0.25 per unit for gross proceeds of $185,000. The Company issued a total of 2,467,000 units for total gross proceeds of $616,750. Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of $0.45 for a period of one year from the date of closing of the respective financing tranche. The Company incurred aggregate share issue costs of $23,182.

[x] On June 8, 2022, the Company issued 1,000,000 units on partial conversion of the June 2021 Convertible Debenture, for a total of 1,000,000 common shares, 500,000 Class A Warrants and 500,000 Class B Warrants. On July 13, 2022, the Company issued a further 1,000,000 units on partial conversion of the June 2021 Convertible Debenture, for a total of 1,000,000 common shares, 500,000 Class A Warrants and 500,000 Class B Warrants. Each Class A Warrant is exercisable at a price of $0.13 until June 10, 2026 and each Class B Warrant is exercisable at a price of $0.19 until June 10, 2026.

24

[xi] During the three months ended July 31, 2022, upon the exercise of common share purchase warrants, the Company issued an aggregate 8,131,975 common shares at a price of CA$0.19 per share for gross proceeds of $1,205,077 (CA$1,545,075) and 800,000 common shares at a price of CA$0.05 per share for gross proceeds of $31,051 (CA$40,000). A total of 17,414,239 warrants and 13,725 broker warrants expired unexercised.

[xii] During the three months ended July 31, 2022, upon the exercise of stock options, the Company issued an aggregate 250,000 common shares at a price of CA$0.13 per share for gross proceeds of $25,340 (CA$32,500), 150,000 common shares at a price of CA$0.12 per share for gross proceeds of $13,853 (CA$18,000) and 600,000 common shares at a price of CA$0.05 per share for gross proceeds of $23,272 (CA$30,000), and reclassified $48,060 from additional paid-in capital to share capital.

[c] Common share purchase warrants

Common share purchase warrants attached to units as part of a unit placement were assigned a $nil value.

A summary of the changes in the Company’s common share purchase warrants during the nine months ended July 31, 2022 are as follows:

Expiry Date	Exercise Price ($)	Weighted Average Life (Years)		October 31, 2021		Granted		Exercised			Expired/ Cancelled			July 31, 2022
November 22, 2021	CA$0.19		–		4,160,021		–		(4,080,573	)		(79,448	)		–
January 17, 2022	CA$0.19		–		7,267,914		–		(5,959,396	)		(1,308,518	)		–
January 31, 2022	CA$0.19		–		5,382,303		–		(4,341,906	)		(1,040,397	)		–
February 21, 2022	CA$0.05		–		1,505,200		–		(200,000	)		(1,305,200	)		–
March 24, 2022	CA$0.19		–		6,341,872		–		(4,515,139	)		(1,826,733	)		–
March 27, 2022	CA$0.05		–		982,025		–		(882,025	)		(100,000	)		–
April 27, 2022	CA$0.19		–		791,395		–		(791,395	)		–			–
May 9, 2022	CA$0.05		–		1,813,725		–		(1,800,000	)		(13,725	)		–
May 30, 2022	CA$0.19		–		5,223,420		–		(4,070,006	)		(1,153,414	)		–
June 17, 2022	CA$0.19		–		17,703,506		–		(5,731,721	)		(11,971,785	)		–
July 18, 2022	CA$0.30		–		4,350,000		–		(60,960	)		(4,289,040	)		–
August 14, 2022	CA$0.05		0.04		200,000		–		(200,000	)		–			–
February 13, 2023	CA$0.65		0.54		3,827,601		–		–			–			3,827,601
April 22, 2024	CA$0.20		1.73		–		933,333		–			–			933,333
Subtotal					59,548,982		933,333		(32,633,121	)		(23,088,260	)		31,120,873
Weighted average exercise price					CA$0.22		CA$0.20		CA$0.18			CA$0.20			CA$0.56
November 27, 2022	US$0.75		0.33		–		1,375,499		–			–			1,375,499
May 9, 2023	US$0.45		0.77		–		1,727,000		–			–			1,727,000
Jun 3, 2023	US$0.45		0.84		–		740,000		–			–			740,000
June 10, 2026	US$0.13		3.86		–		4,000,000		–			–			1,500,000
June 10, 2026	US$0.19		3.86		–		4,000,000		–			–			1,500,000
Subtotal					–		11,842,499		–			–			11,842,499
Weighted average exercise price					–		US$0.29		–			–			US$0.29
Total					59,548,982		12,775,832		(32,633,121	)		(5,660,296	)		38,496,372

25

A summary of the changes in the Company’s common share purchase warrants during the nine months ended July 31, 2021 are as follows:

Expiry Date	Exercise Price ($)	Weighted Average Life (Years)		October 31, 2020		Granted		Exercised			Expired/ Cancelled			July 31, 2021
August 31, 2021*	CA$0.21		0.08		3,643,791		–		–			–			3,643,791
November 22, 2021	CA$0.19		0.31		–		5,599,171		–			–			5,599,171
January 17, 2022	CA$0.19		0.46		–		7,400,214		(70,000	)		(62,300	)		7,267,914
January 31, 2022	CA$0.19		0.50		–		5,382,303		–			–			5,382,303
February 21, 2022	CA$0.05		0.56		1,505,200		–		–			–			1,505,200
March 24, 2022	CA$0.19		0.65		–		6,554,172		–			–			6,554,172
March 27, 2022	CA$0.05		0.65		1,482,025		–		–			–			1,482,025
April 27, 2022	CA$0.19		0.74		–		851,395		–			–			851,395
May 9, 2022	CA$0.05		0.77		2,368,626		–		(54,901	)		–			2,313,725
May 30, 2022	CA$0.19		0.82		–		5,223,420		–			–			5,223,420
June 17, 2022	CA$0.19		0.88		–		17,853,506		–			–			17,853,506
July 18, 2022	CA$0.30		0.96		–		4,350,000		–			–			4,350,000
August 14, 2022	CA$0.05		1.04		1,110,000		–		(400,000	)		–			710,000
Total					10,109,642		53,214,181		(524,901	)		(62,300	)		62,736,622
Weighted average exercise price					CA$0.11		CA$0.19		CA$0.07			CA$0.19			CA$0.19

* The Company received approval of the TSX-V on January 13, 2021 and amended the expiry date of 3,643,791 warrants, extending the expiry date from January 17, 2021 to August 31, 2021, subject to acceleration if the closing price of the Company’s shares exceeds CA$0.30 per common share for at least 10 consecutive trading days.

[d] Stock options

The Company has adopted an incentive stock option plan, effective on August 8, 2017 and as amended on August 8, 2018, under the rules of the TSX-V pursuant to which it is authorized to grant stock options to executive officers, directors, employees and consultants, enabling them to acquire up to 20% of the total shares outstanding of the Company (the “2017 Stock Option Plan”). Under the 2017 Stock Option Plan, the option exercise price of any option granted shall not be less than the discounted market price of the Company’s common shares. For the purposes of the 2017 Stock Option Plan, the discounted market price is calculated in accordance with the policies of the TSX-V at the time of the grant of the options. Stock options granted are subject to a maximum term of 5 years. All options granted shall vest immediately, except for those options granted to persons performing investor relations activities for the Company. Pursuant to the policies of the TSX-V, shares issued upon the exercise of options are restricted from trading during the 4-month period subsequent to the exercise of options.

On June 11, 2021, the Company adopted the 2021 Equity Incentive Plan which replaces the 2017 Stock Option for providing stock-based compensation to directors, officers, employees, consultants, and advisors of the Company and no further options will be granted under the 2017 Stock Option Plan. Under the 2021 Equity Incentive Plan, the Company is authorized to issue up to 27,312,368 shares of the Company. In addition, any common shares reserved for issuance under the 2017 Stock Option Plan that are forfeited as a result of the expiration or termination of any awards under that plan after the date of adoption of the 2021 Equity Incentive Plan will be added to the 2021 Equity Incentive Plan. As of July 31, 2022, 6,780,000 stock options forfeited under the 2017 Stock Option Plan were added to the 2021 Equity Incentive Plan (October 31, 2021 – 1,730,000), resulting in 34,092,368 stock options as the maximum number of common shares available under the 2021 Equity Incentive Plan (October 31, 2021 – 29,042,368). The 2021 Equity Incentive Plan provides for various equity-based and cash-based incentive awards, including incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock and restricted stock units, performance awards, dividend equivalents and other equity-based or cash-based awards.

26

On December 30, 2020, the Company granted 15,650,000 stock options pursuant to its 2017 Stock Option Plan to its directors, officers, employees and consultants at a price of CA$0.13 per share, of which 9,500,000 were exercisable for a period of five years and 6,150,000 were exercisable for a period of two years. However, these options exceeded the maximum allowed under the Company’s 2017 Stock Option Plan. On June 11, 2021, the Company received shareholders’ approval to amend the Company’s 2017 Stock Option Plan to increase the number of common shares reserved for issuance under such plan and rectified the grant of these options.

On August 30, 2021, the Company granted 21,700,000 incentive and non-statutory stock options pursuant to its 2021 Equity Incentive Plan to its directors, officers, employees and consultants. These options are exercisable at a price of CA$0.70 per share for a period of five years.

On October 1, 2021, the Company granted 1,450,000 incentive and non-statutory stock options pursuant to its 2021 Equity Incentive Plan to its officer and employee and consultants. These options are exercisable at a price of CA$0.50 per share for a period of five years.

On December 3, 2021, the Company granted 250,000 incentive stock options pursuant to its 2021 Equity Incentive Plan to an employee. These options are exercisable at a price of CA$0.58 per share for a period of five years.

On March 7, 2022, the Company granted 500,000 incentive stock options pursuant to its 2021 Equity Incentive Plan to an officer. These options are exercisable at a price of CA$0.40 per share for a period of five years.

On April 8, 2022, the Company granted 500,000 incentive stock options pursuant to its 2021 Equity Incentive Plan to employees. These options are exercisable at a price of CA$0.40 per share for a period of five years.

As at July 31, 2022, 10,042,368 common shares remained available for grant under the 2021 Equity Incentive Plan.

During the nine months July 31, 2022, the Company recognized a stock-based compensation totaling $466,368 (2021 – $1,057,013) in relation to the grant of its stock options.

The weighted average grant date fair value of the stock options granted during the nine months ended July 31, 2022 was CA$0.37 (2021 – CA$0.09) per option. Option pricing models require the use of highly subjective estimates and assumptions including expected stock price volatility. Changes in the underlying assumptions can materially affect the fair value estimates. The fair value of stock options was estimated on the measurement date using the Black-Scholes Option Pricing Model. The assumptions used to calculate the fair value were as follows:

	2022	2021
Risk free rate of interest	1.34 – 2.59%	0.20% – 1.07%
Expected life of options	5 years	2 to 5 years
Exercise price of options	CA$0.40 – CA$0.58	CA$0.13 – CA$0.70
Expected annualized volatility	134.93% – 136.08%	130.88% – 140.05%
Expected dividend rate	Nil	Nil

27

A summary of the changes in the Company’s stock options during the nine months ended July 31, 2022 are as follows:

Expiry Date	Exercise Price (CA$)		Weighted Average Life (Years)		Outstanding as at October 31, 2021		Granted		Exercised			Expired/ Cancelled			Outstanding as at July 31, 2022			Vested as at July 31, 2022
March 27, 2022		0.05		–		1,500,000		–		(750,000	)		(750,000	)		–			–
December 30, 2022		0.13		0.42		6,000,000		–		(250,000	)		(650,000	)		5,100,000			5,100,000
August 12, 2023		0.05		1.03		2,290,000		–		–			(750,000	)		1,540,000			1,540,000
December 3, 2023		0.05		1.34		6,450,000		–		(600,000	)		(1,500,000	)		4,350,000			4,350,000
May 22, 2024		0.12		1.81		7,900,000		–		–			(850,000	)		7,050,000			7,050,000
November 3, 2024		0.15		2.26		700,000		–		–			–			700,000			700,000
November 24, 2024		0.16		2.32		320,000		–		–			(300,000	)		20,000			20,000
March 26, 2025		0.11		2.65		100,000		–		–			–			100,000			100,000
April 23, 2025		0.12		2.73		3,350,000		–		(150,000	)		(250,000	)		2,950,000			2,950,000
December 30, 2025		0.13		3.42		9,500,000		–		–			–			9,500,000			9,500,000
August 30, 2026		0.70		4.08		21,700,000		–		–			(350,000	)		21,350,000			21,312,500
October 1, 2026		0.50		4.17		1,450,000		–		–			–			1,450,000			1,450,000
December 3, 2026		0.58		4.35		–		250,000		–			–			250,000			250,000
March 7, 2027		0.40		4.60		–		500,000		–			–			500,000			500,000
April 8, 2027		0.40		4.69		–		500,000		–			–			500,000			500,000
Total						61,260,000		1,250,000		(1,750,000	)		(5,400,000	)		55,360,000			55,322,500
Weighted average exercise price						CA$0.33		CA$0.44		CA$0.07			CA$0.12			CA$0.36			CA$0.36
Aggregate intrinsic value					$	19,994,025									($	8,475,724	)	($	8,459,933	)
Weighted average remaining life						3.46										2.96			2.96

A summary of the changes in the Company’s nonvested stock options during the nine months ended July 31, 2022 are as follows:

Expiry Date	Fair Value Per Share (CA$)		Weighted Average Life (Years)		Nonvested as at October 31, 2021		Granted		Vested			Expired/ Cancelled			Nonvested as at July 31, 2022
December 30, 2022		0.07		0.42		162,500		–		(162,500	)		–			–
August 30, 2026		0.56		4.08		300,000		–		(187,500	)		(75,000	)		37,500
Total						462,500		–		(350,000	)		(75,000	)		37,500
Weighted average grant date fair value – per option						CA$0.39		–		CA$0.33			CA$0.56			CA$0.56
Weighted average grant date fair value – total					$	144,131		–	$	90,209		$	32,652		$	16,326

28

A summary of the changes in the Company’s stock options during the nine months ended July 31, 2021 are as follows:

Expiry Date	Exercise Price (CA$)		Weighted Average Life (Years)		Outstanding as at October 31, 2020		Granted		Exercised			Expired/ Cancelled			Outstanding as at July 31, 2021		Vested as at July 31, 2021
February 11, 2021		0.05		0.03		800,000		–		–			(800,000	)		–		–
August 16, 2021		0.05		0.54		600,000		–		–			–			600,000		600,000
March 27, 2022		0.05		1.15		1,750,000		–		–			–			1,750,000		1,750,000
August 26, 2022		0.13		–		500,000		–		–			(500,000	)		–		–
December 30, 2022		0.13		1.91		–		6,150,000		–			–			6,150,000		5,825,000
April 19, 2023		0.05		2.21		800,000		–		–			–			800,000		800,000
August 12, 2023		0.05		2.53		3,120,000		–		(300,000	)		–			2,820,000		2,820,000
December 3, 2023		0.05		2.84		7,000,000		–		–			–			7,000,000		7,000,000
May 22, 2024		0.12		3.31		7,950,000		–		–			–			7,950,000		7,950,000
November 3, 2024		0.15		3.76		700,000		–		–			–			700,000		700,000
November 24, 2024		0.16		3.82		900,000		–		–			–			900,000		900,000
March 26, 2025		0.11		4.15		300,000		–		–			–			300,000		300,000
April 23, 2025		0.12		4.23		4,000,000		–		–			(300,000	)		3,700,000		3,700,000
December 30, 2025		0.13		4.92		–		9,500,000		–			–			9,500,000		9,500,000
Total						28,420,000		15,650,000		(300,000	)		(1,600,000	)		42,170,000		41,845,000
Weighted average exercise price						CA$0.09		CA$0.13		CA$0.05			CA$0.09			CA$0.10		CA$0.10
Aggregate intrinsic value					$	801,922									$	6,819,812	$	6,774,173
Weighted average remaining life						3.18										2.80		2.81

[e] Share-based payments and other reserves

The share-based payments and other reserves are used to recognize the fair value of stock options granted to directors, officers, employees and consultants as part of their remuneration, as well as those of broker warrants issued in relation to the Company’s financings. When stock options and broker warrants are subsequently exercised, the fair value of such stock options and broker warrants in additional paid-in capit0al is credited to share capital.

On November 1, 2021, the Company’s functional currency change resulted in the reclassification of its outstanding warrants and broker warrants denominated in Canadian dollar as derivative liability measured at fair value. The previous value of outstanding broker warrants was reversed out of additional paid-in capital.

On November 1, 2021, the Company’s functional currency change resulted in the reclassification of the June 2021 Convertible Debenture from a hybrid financial instrument to a convertible debt instrument with a beneficial conversion feature. The value of the embedded derivative liability was reclassified to additional paid-in capital. During the nine months ended July 31, 2022, the Company also allocated the intrinsic value of the beneficial conversion feature of the April 2022 Convertible Debenture to additional paid-in capital.

[f] Obligations to issue shares

The Company received advance share subscriptions in respect of non-brokered private placements closed in a subsequent period.

[g] Dilutive common shares

As at July 31, 2022, potentially dilutive common shares relating to common share purchase warrants and stock options outstanding totaling 71,963,433 (October 31, 2021 – 120,808,982) were not included in the computation of loss per share as the effect would be anti-dilutive.

	July 31, 2022		October 31, 2021
Common share purchase warrants		16,603,433		59,548,982
Stock options		55,360,000		61,260,000
Total		71,963,433		120,808,982

29

15. FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT

The Company’s classification of its financial instruments is as follows:

Financial Instruments	Measurement Method	Associated Risk	Fair Value at July 31, 2022 ($)
Cash	FVTPL	Credit and currency		16,700
Other receivables	Amortized cost	Credit and currency		94,696
Deposits held by related parties	Amortized cost	Credit and currency		349,338
Accounts payable and accrued liabilities	Amortized cost	Currency		3,434,539
Due to related parties	Amortized cost	Currency		1,520,834
Convertible debenture, net	Amortized cost and FVTPL	Currency		1,942,838
Warrants liability	FVTPL	Currency		57,080

[a] Fair value

The fair value of financial instruments is the amount of consideration that would be agreed upon in an arm’s length transaction between knowledgeable, willing parties who are under no compulsion to act. The fair value of current financial instruments except derivative liability approximates their carrying values as long as they are short-term in nature or bear interest at market rates.

[b] Fair value hierarchy

Financial instruments that are held at fair value are categorized based on a valuation hierarchy which is determined by the valuation methodology utilized. The fair value hierarchy under US GAAP is based on the following three levels of inputs, of which the first two are considered observable and the last unobservable:

Level 1 – Quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level 2 – Observable inputs other than Level 1, quoted prices for similar assets or liabilities in active prices whose inputs are observable or whose significant value drivers are observable; and

Level 3 – Assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.

The Company evaluates its financial instruments and other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815. The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market at each balance sheet date and recorded as a liability and the change in fair value is recorded in the consolidated statements of loss and comprehensive loss. Upon conversion or exercise of a derivative instrument, the instrument is marked-to-market at the conversion date and then that fair value is reclassified to equity.

30

The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instruments that become subject to reclassification are reclassified at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified on the consolidated balance sheets as current or non-current based on whether or not settlement of the derivative instrument is expected within 12 months of the balance sheet date.

The Company uses the Black-Scholes Option Pricing Model to value derivative liabilities. This model uses Level 3 inputs in the fair value hierarchy established by ASC 820 Fair Value Measurement. The inputs used in determining the fair value of the embedded derivative are disclosed in note 12[e].

[c] Financial risk management

The Company’s board of directors has the overall responsibility for the establishment and oversight of the Company’s risk management framework. The Company’s risk management policies are established to identify and analyze the risks faced by the Company, to set appropriate risk limits and controls, and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and in response to the Company’s activities. Management regularly monitors compliance with the Company’s risk management policies and procedures and reviews the adequacy of the risk management framework in relation to the risks faced by the Company.

In the normal course of operations, the Company is exposed to various risks such as interest rate, foreign exchange, commodity, credit, and liquidity. To manage these risks, management determines what activities must be undertaken to minimize potential exposure to risks. The objectives of the Company in managing risks are as follows:

● Maintaining sound financial condition;

● Financing operations; and

● Ensuring liquidity to all operations.

In order to satisfy these objectives, the Company has adopted the following policies:

● Recognize and observe the extent of operating risk within the business; and

● Identify the magnitude of the impact of market risk factors on the overall risk of the business and take advantage of natural risk reductions that arise from these relationships.

[i] Interest rate risk

Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in the market interest rates. The Company is exposed to interest rate risk on its cash on deposits with banks and, from time to time, on its holdings of short-term investments. As of July 31, 2022, the Company had $16,700 (October 31, 2021 − $462,360) of cash on deposits with banks. The Company had no short-term investment as at July 31, 2022 and October 31, 2021. Given the level of cash held by the Company, fluctuations in the market interest rates had no significant impact on its interest income for the nine months ended July 31, 2022.

31

[ii] Foreign currency risk

The Company is exposed to foreign currency risk on fluctuations related to cash, other receivables, accounts payable, due to related parties and convertible debenture that are denominated in Canadian dollar. The Company has not entered into foreign exchange derivative contracts. A significant change in the currency exchange rates between the US dollar relative to the Canadian dollar could have a material effect on the Company’s financial position, results of operations, or cash flows.

Based on the Company net exposures as at July 31, 2022, assuming that all other variables remain constant, a 5% appreciation or deterioration of the Canadian dollar against the US dollar would result in an increase or decrease of $124,237 in the Company’s net income (loss) and comprehensive income (loss).

The Company had the following assets and liabilities denominated in Canadian dollar:

	July 31, 2022
	CA$
Cash		4,757
Other receivables		123,701
Accounts payable and accrued liabilities		(2,309,520	)
Due to related parties		(1,005,314	)
Total		(3,186,376	)

[iii] Commodity price risk

The value of the Company’s magnesium production business and its exploration and evaluation assets are dependent on the price of magnesium and the outlook for this mineral. Market prices for these metals historically have fluctuated widely and are affected by numerous factors outside the Company’s control, including but not limited to, levels of worldwide production, short-term changes in supply and demand, industrial and retail demand, as well as certain other factors related specifically to magnesium. If magnesium prices decline for a prolonged period below the cost of production, it may not be economically feasible to continue towards production.

[iv] Credit risk

Credit risk is the risk of loss if counterparties do not fulfill their contractual obligations. The Company’s credit risk is primarily attributable to cash and deposits held by related parties. The Company limits its exposure to credit risk on cash as these financial instruments are held with major Canadian and international banks. Deposits held by related parties were in relation to vendor agreements entered on January 1, 2021 where the Company provided related parties with advances that were held as deposits for anticipated future costs related to the Company’s planned magnesium research and development pilot plant and other administrative expenses [note 8[a]]. Other receivables consist primarily of GST due from the Federal Government of Canada. Management believes the credit risk concentration with respect to other receivables is remote. The carrying amount of financial assets recorded in the financial statements, net of any allowances, represents the Company’s maximum exposure to credit risk.

[v] Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they come due. The Company’s exposure to liquidity risk is dependent on its purchasing commitments and obligations and its ability to raise funds to meet commitments and sustain operations. The Company manages liquidity risk by continuously monitoring its actual and forecasted working capital requirements to ensure there is capital to meet short-term and long-term obligations.

32

As of July 31, 2022 and October 31, 2021, the Company had working capital deficiency of $6,642,252 and $9,657,316, respectively. As disclosed in note 1 to these Financial Statements, the ability of the Company to continue as a going concern is dependent on many factors. The Company’s management has evaluated whether there is substantial doubt about the Company’s ability to continue as a going concern and has determined that substantial doubt existed for at least one year from the date of these Financial Statements are issued. The Company has financed its activities and operations through equity issuances and debt financing and expects to continue to do so to the extent such financing is available. There can be no assurance that such financing will be available under terms acceptable to the Company or at all. Liquidity risk has been assessed as high.

16. SEGMENTED INFORMATION

The Company focuses on plant operations and magnesium production and continues to move towards the buildout of its pilot plant facility and the development of a full-scale commercial magnesium production facility. The Company also owns mining claims for the exploration and development of mineral property interests. Geographic information for the Company’s assets is as follows:

	July 31, 2022		October 31, 2021
	$		$
Canada – property, plant and equipment		4,458,609		2,546,383
United States – property, plant and equipment		29,392		28,321
United States – mineral property costs		93,453		93,453
		4,581,454		2,668,157
Canada – other assets		311,300		1,554,827
United States – other assets		905,009		290,528
		1,216,309		1,845,355
Total Assets		5,797,763		4,513,512

17. SUBSEQUENT EVENTS

On August 5, 2022, the Company granted 1,000,000 non-statutory stock options pursuant to its 2021 Equity Incentive Plan to a consultant. These options are exercisable at a price of CA$0.16 per share for a period of two years.

On August 5, 2022, the Board of Directors of the Company accepted the resignation of a director. The size of the board is effectively reduced from six to five directors.

On August 17, 2022, the Company issued 1,000,000 units on partial conversion of the June 2021 Convertible Debenture, for a total of 1,000,000 common shares, 500,000 Class A Warrants exercisable at a price of $0.13 until June 10, 2026, and 500,000 Class B Warrants exercisable at a price of $0.19 until June 10, 2026.

On August 26, 2022, the Board of Directors of the Company accepted the termination of its independent registered public accounting firm (the “Firm”). During the Firm’s tenure, there were no disagreements on any matter of accounting principles or practices, financial statement disclosure, or auditing scope of procedure which disagreement if not resolved to the satisfaction of the Firm would have caused it to make reference to the subject matter of the disagreement in connection with its reports on the financial statements, and there were no “reportable events” (as defined in Item 304(a)(1)(v) of Regulation S-K).

On August 29, 2022, the Chief Financial Officer’s contract with the Company was terminated and a new interim Chief Financial Officer was appointed effective September 8, 2022.

33

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of our financial condition and results of operations should be read together with our consolidated financial statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q and the consolidated financial statements and accompanying notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended October 31, 2021, filed with the Securities and Exchange Commission, or SEC, on February 15, 2021 (the “2021 Form 10-K”). This discussion contains forward-looking statements and involves numerous risks and uncertainties, including but not limited to those described in the “Risk Factors” section of this Quarterly Report on Form 10-Q and in “Part I, Item 1A—Risk Factors” in our 2021 Form 10-K. Actual results may differ materially from those contained in any forward-looking statements. You should read “Cautionary Note Regarding Forward-Looking Statements” and “Risk Factors” contained herein and in our 2021 Form 10-K. Our financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Financial information presented in this MD&A is presented in United States dollars (“$” or “US$”), unless otherwise indicated.

The information about us provided in this MD&A, including information incorporated by reference, may contain “forward-looking statements” and certain “forward-looking information” as defined under applicable United States securities laws and Canadian securities laws. All statements, other than statements of historical fact, made by us that address activities, events or developments that we expect or anticipate will or may occur in the future are forward-looking statements, including, but not limited to, statements preceded by, followed by or that include words such as “may”, “will”, “would”, “could”, “should”, “believes”, “estimates”, “projects”, “potential”, “expects”, “plans”, “intends”, “anticipates”, “targeted”, “continues”, “forecasts”, “designed”, “goal”, or the negative of those words or other similar or comparable words and includes, among others, information regarding: our ability to become profitable and generate cash in our operating activities; our need for substantial additional financing to operate our business and difficulties we may face acquiring additional financing on terms acceptable to us or at all; our significant indebtedness and significant restrictions on our operations; our ability to construct and operate our planned magnesium research and development pilot plant and obtain necessary permits and authorizations to construct and operate the facility; the impact of global climate change on our ability to conduct future operations; our lack of a diversified portfolio of assets; our dependence on key inputs, suppliers and skilled labor for the production of magnesium; our ability to attract and retain key personnel; growth-related risks, including capacity constraints and pressure on our internal systems and controls; the adverse consequences of litigation we are currently involved in and litigation we may face from time to time; risk related to the protection of our intellectual and our exposure to infringement or misappropriation claims by third parties; risks related to competition; risks related to our lack of internal controls over financial reporting and their effectiveness; increased costs we are subject to as a result of being a public company in Canada and the United States; and other events or conditions that may occur in the future.

34

Forward-looking statements may relate to future financial conditions, results of operations, plans, objectives, performance or business developments. These statements speak only as at the date they are made and are based on information currently available and on the then current expectations of the party making the statement and assumptions concerning future events, which are subject to a number of known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from that which was expressed or implied by such forward-looking statements, including, but not limited to, risks and uncertainties described in the “Risk Factors” section of this Quarterly Report on Form 10-Q and in “Part I, Item 1A—Risk Factors” in our 2021 Form 10-K.

Although we believe that the expectations and assumptions on which such forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements, because no assurance can be given that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to the risks described in the “Risk Factors” section of this Quarterly Report on Form 10-Q and in “Part I, Item 1A—Risk Factors” in our 2021 Form 10-K.

Consequently, all forward-looking statements made in this MD&A and other documents, as applicable, are qualified by such cautionary statements, and there can be no assurance that the anticipated results or developments will actually be realized or, even if realized, that they will have the expected consequences to or effects on us. The cautionary statements contained or referred to in this section should be considered in connection with any subsequent written or oral forward-looking statements that we and/or persons acting on its behalf may issue. We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required under securities legislation.

We are on a fiscal year, as such the three-month period ending July 31, 2022 is our third quarter and the three-month period ending July 31 is referred to as the “three months” or “third quarter”. The nine-month period ending July 31 is referred to as the “nine months” or “year-to-date”. The fiscal year ended October 31, 2021 is referred to as “Fiscal 2021” and the coming fiscal year ending October 31, 2022 is referred to as “Fiscal 2022”.

Overview of the Business

We are a reporting issuer in Canada and in the United States. We are listed for trading on the TSX Venture Exchange (the “TSXV”) under the symbol “WMG”. Our common stock is also traded in the United States on the OTCQB tier of the OTC Markets (the “OTCQB”) under the symbol “MLYF” and in Germany on the Frankfurt Stock Exchange under the symbol “3WM”.

We have developed proprietary magnesium production technology with the aim of becoming a premier low-cost producer of green primary magnesium metal. We are in the final stages of construction and commencing test production of magnesium at a research and development pilot plant in metropolitan Vancouver, British Columbia, Canada. We have commenced testing at this facility in the last calendar quarter of 2021, and our proprietary continuous reactor has begun operation and has produced magnesium metal under our target temperature and pressure in the second calendar quarter of 2022. The remainder of the equipment is undergoing final checks which will allow the plant to enter the demonstration phase. Our proprietary technology utilizes a continuous silicothermic process that is expected to produce high grade magnesium with low labor and energy costs while generating minimal waste and toxic by-products.

35

In addition, we own a 100% interest in 81 unpatented lode mining claims totaling approximately 1,673 acres (the “Tami Mosi Mining Claim”), four unpatented lode mining claims totaling approximately 10 acres located in the Moor Mining District in Elco County, Nevada and a 100% interest in three patented mining claims located in the Pinto mining district of Nevada totaling approximately 296 acres (the “Silverado Mining Claim”). We do not plan on commencing extraction of minerals at this time from any mining claims we hold because we have identified alternative sources of supply of dolomite and ferrosilicon, the primary raw materials used to produce pure magnesium. We may in the future, however, commence extraction of minerals from the Tami Mosi Mining Claim if we are unable to purchase raw materials from the alternative sources we have identified at commercially reasonable rates. In addition, we do not consider our mining claims to be material to our business or financial condition.

Corporate History

We were incorporated under the Company Act (British Columbia) on March 24, 1966 as “Ft. Lauderdale Resources Inc.” We changed our name to Amcorp Industries Inc. on July 20, 1990, to Molycor Gold Corporation on May 17, 1996, to Nevada Clean Magnesium Inc. on April 16, 2012 and to Western Magnesium Corporation on May 14, 2019. On May 14, 2019, we discontinued from the jurisdiction of the Business Corporations Act (British Columbia) and domesticated under the General Corporation Law of the State of Delaware under the name “Western Magnesium Corporation.” In connection with the name change, we also changed our stock symbol to “WMG” on the TSXV. We have two wholly-owned subsidiaries: Western Magnesium Corp., incorporated in the State of Nevada in the United States which owns our mining claims in the Schell Creek Range located southeast of Ely, Nevada and manages the Company’s Nevada properties; and Western Magnesium Canada Corp., incorporated on May 3, 2019 in British Columbia, Canada which manages our Canadian operations.

General Development of Our Business

In 2006, we acquired the Silverado Mining Claim. During the year ended October 31, 2013, an impairment was recorded on this claim for $412,793 reducing its book value to $1.

In 2009, we acquired 27 mining claims totaling approximately 1,744 acres on property located southeast of Beaverdell, British Columbia (the “Beaverdell Mining Claim”). During the year ended October 31, 2013, an impairment was recorded on this claim for $335,133 reducing its book value to $1. During the year ended October 31, 2020, we sold our interest in the Beaverdell Mining Claim for $50,000 and recognized a gain on sale of $37,156.

On October 9, 2006, we acquired the Tami Mosi Mining Claim. On May 1, 2009, an Initial Resource Estimate was completed by Norm Tribe & Associates, Ltd. On June 11, 2010, a Phase 1 Process Development Study for Exploitation of the Tami Mosi Mining Claim was completed by Haze Research, Inc. On August 3, 2011, an updated resource estimate was completed by Tetra Tech, Inc. (“Tetra Tech”), on September 15, 2011 a Preliminary Economic Assessment and Technical Report of the Tami-Mosi Magnesium Project was completed by Tetra Tech and amended on July 4, 2014.

On April 4, 2017, we completed construction of a bench scale test furnace that employed our proprietary continuous silicothermic process and in October 2017, we successfully completed furnace preparations - a major milestone in the testing of our bench scale pilot furnace.

In November 2017, we completed “proof of concept” in the production of magnesium metal from our bench scale test furnace. The metal produced was a result from a partial test charge being conducted in order to identify any operational deficiencies in the furnace prior to a full charge test of dolime material.

In January 2018, we received a final assay report assessing the purity of the raw magnesium metal produced from our bench scale pilot furnace test program. In accordance with ASTM International standard ASTM E1479-16, the testing was analyzed via inductively coupled plasma (ICP). This unrefined magnesium metal was found to have a very good metal purity capable of producing ASTM B92 grade metal with minimal treatment. No impurities were found which would impact food grade applications.

36

In July 2018, we entered into an agreement with Industrial Surplus Ltd. (“ISL”) to build a silicothermic reduction furnace based on our bench scale test furnace.

In December 2018, our technical team produced a magnesium ingot from dolomite obtained from the Tami Mosi Mining Claim. This accomplishment completed the proof-of-concept stage allowing us to develop a pilot magnesium furnace based on the bench scale furnace.

Plan of Operations

In order to complete construction and testing at our planned research and development pilot plant, the following are the key milestones that we expect to achieve over the next 12 months following the date of this Quarterly Report on Form 10-Q:

● Commission the plant and complete final training of operations staff;

● Commence metal production under various scenarios to ensure sufficient data is collected;

● Begin the request for proposal process for commercial engineering, procurement and construction management (“EPCM”) firm;

● Select EPCM firm;

● Review all pilot data with chosen EPCM firm and validate proposed required operational scenarios; and

● Begin geotechnical assessments of proposed full-scale magnesium production facility in Harrison County, Ohio.

We estimate that the costs to complete this work will be approximately $8,000,000. We have commenced testing of the pilot reactor in the last calendar quarter of 2021, and our proprietary continuous reactor has begun operation and has produced magnesium metal under our target temperature and pressure in the second calendar quarter of 2022. Continuous demonstration phase operation will take place throughout the fourth calendar quarter of 2022 and the first calendar quarter of 2023.

Following completion of our magnesium research and development pilot plant, we intend to construct a full-scale magnesium production facility with expected capacity to produce 100,000 metric tons per year that will be scalable for greater production levels located on 122 acre property located in Harrison County, Ohio. The proposed plant will be adjacent to the future home of a modern mixed fuels power plant which is expected to provide power to our planned magnesium production plant. The proposed Harrison County, Ohio location is close to a dolomite supply and has an infrastructure of rail and highway that is capable of transporting our magnesium finished product to industries across the United States. Our plans will require a significant amount of additional capital. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources.” We have no current plans to extract minerals from any of our mining claims.

Magnesium and Its Production

Magnesium is the lightest and strongest of the structural metals, just one-fourth the weight of steel, two-fifths the weight of titanium, and two-thirds the weight of aluminum. Magnesium has multiple industrial and consumer applications. Magnesium ingots are a prime raw material input for the production of titanium and aluminum alloys and magnesium alloys. Magnesium powder and granules are used to remove sulfur in the production of steel. Due to their unique light weight and high strength properties, magnesium alloys are used in a variety of aircraft and automobile parts, as well as in electronic equipment such as computers, cameras and cellular phones.

37

Most magnesium produced globally comes from natural minerals such as dolomite and magnesite in the form of magnesium carbonate. It can also be found in seawater and in salt lakes brines or underground mineral salt deposits. Magnesium can be produced through several different methods including the electrolytic process or thermal-reduction as practiced in the most commonly used Pidgeon process.

The electrolytic process involves the electrolysis of molten magnesium chloride which produces molten magnesium and chlorine. The metal is cast into ingots for further processing as needed and the chlorine by product may be sold for use in the production of polymers such as polyvinyl chloride pipe (PVC).

In the thermal-reduction method, calcined magnesium containing ores (magnesite and dolomite) are broken down into fine powder and mixed with reducing agents and catalyst agent. The mixture is heated in a vacuum chamber producing magnesium vapors which later condense into crystals. The crystals are then melted, refined and poured into ingots for further processing.

The Pidgeon process, using ferrosilicon as a catalyst, is most commonly used for production of magnesium as its operation is relatively easy and has a low capital cost. The traditional process using horizontal retorts is high in energy consumption and has low productivity.

Selected Financial Information

The following table summarizes our consolidated financial information as at July 31, 2022 and October 31, 2021. The selected consolidated financial information set out below may not be indicative of our future performance.

	July 31, 2022			October 31, 2021
	$			$
Total assets		5,797,763			4,513,512
Current liabilities		7,440,511			10,891,270
Non-current liabilities		195,813			392,280
Shareholders’ deficit		(1,838,561	)		(6,770,038	)
Accumulated deficit		(67,190,772	)		(52,129,621	)
Working capital deficiency		(6,642,252	)		(9,657,316	)

Results of Operations

For the three months ended July 31, 2022 (“Q3 2022”), the Company recorded net loss of $1,295,865 ($0.00 per common share), as compared to $3,784,435 ($0.01 per common share) for the same period in the preceding year (“Q3 2021”). The decrease of $2,488,570 in net loss in Q3 2022 compared to Q3 2021 was attributable primarily to a non-cash gain of $2,784,793 in non-operating items including the change in fair value of derivative liability and warrant liability and loss on recognition of debt host liability, partially offset by an increase of $296,223 in operating expenses. On a year-to-date basis, net loss for the nine months ended July 31, 2022 (“YTD 2022”) was $15,061,151 ($0.03 per common share), as compared to $6,338,823 ($0.02 per common share) for the same period in the preceding year (“YTD 2021”). The increase of $8,722,328 in net loss in YTD 2022 compared to YTD 2021 was due primarily to a non-cash loss of $4,274,563 in non-operating items, and an increase of $4,447,765 in operating expenses.

38

The following table summarizes our results of operations for Q3 2022 and YTD 2022, compared to the same periods in the preceding year. The selected consolidated financial information set out below may not be indicative of our future performance.

	Three Months Ended						Nine Months Ended
	July 31,						July 31,
	2022			2021			2022			2021
	$			$			$			$
Operating expenses		(3,132,896	)		(2,836,673	)		(9,855,482	)		(5,407,717	)
Other income (expense)		1,837,031			(947,762	)		(5,205,669	)		(931,106	)
Net loss		(1,295,865	)		(3,784,435	)		(15,061,151	)		(6,338,823	)
Net loss per share		(0.00	)		(0.01	)		(0.03	)		(0.02	)

Three Months Ended July 31, 2022 Compared to Three Months Ended July 31, 2021

Operating Expenses

Operating expenses were $3,132,896 for Q3 2022, as compared to $2,836,673 for Q3 2021. The increase of $296,223 in operating expenditures was due primarily to increases in interest, salaries and benefits, and office and general, partially offset by a decrease in stock-based compensation. The variances were primarily comprised of:

Interest (Q3 2022 – $372,295; Q3 2021 – $28,242; Variance – $344,053)

The Company incurred interest expense of $372,295 during Q3 2022, as compared to $28,242 during Q3 2021. On November 1, 2021, the Company’s functional currency change resulted in the reclassification of the June 2021 Convertible Debenture from a hybrid financial instrument to a convertible debt instrument with a beneficial conversion feature. The Company allocated the intrinsic value of the beneficial conversion feature of the June 2021 Convertible Debenture capped at the face value of $1,500,000 to additional paid-in capital and recognized a debt discount of the same amount to be amortized as interest expense over the period from issuance date to maturity date using the effective interest method. During the quarter ended April 30, 2022, the Company also allocated the intrinsic value of the beneficial conversion feature of the April 2022 Convertible Debenture of $240,000 to additional paid-in capital and recognized a debt discount of the same amount to be amortized as interest expense until its maturity. The increase of $344,053 in interest during Q3 2022 was attributable primarily to the interest expense of $213,948 from the amortization of the debt discount on partial conversion of the June 2021 Convertible Debenture during the period.

Salaries and benefits (Q3 2022 – $1,151,045; Q3 2021 – $809,253; Variance – $341,792)

The Company incurred expenses for salaries and benefits of $1,151,045 during Q3 2022, as compared to $809,253 during Q3 2021, representing an increase of $341,792. This was due mainly to increased personnel headcount as the Company has set up its new headquarters and management team in McLean, Virginia close to the Washington DC metropolitan area and its continued effort in the buildout of its research and development pilot plant. As at July 31, 2022, the Company had 30 employees including 9 senior management members. As at July 31, 2021, the Company had 22 employees including 5 senior management members. Certain senior management members’ salaries were also adjusted to be in line with industry standards.

39

Office and general (Q3 2022 – $266,407; Q3 2021 – $23,794; Variance – $242,613)

The Company incurred office and general expenses of $266,407 during Q3 2022, as compared to $23,794 during Q3 2021. The increase of $242,613 in office and general expenses was attributable primarily to directors’ and officers’ and corporate liability insurance of $216,734 incurred in Q3 2022, as compared to $2,589 incurred in Q3 2021, for increased coverage as the Company planned for up-listing in the US.

Stock-based compensation [Q3 2022 – $32,539; Q3 2021 –$1,057,013; Variance – ($1,024,474)]

Stock-based compensation fluctuated depending on timing of option grant. During Q3 2022, the Company recorded stock-based compensation of $32,539 upon the vesting of stock options of certain employees. On December 30, 2020, the Company approved the grant of an aggregate 15,650,000 stock options to certain directors, officers, employees and consultants. However, these options exceeded the maximum allowed under the Company’s stock option plan. On June 11, 2021, the Company received shareholders’ approval on the amendment to the Company’s stock option plan to increase the number of common shares reserved for issuance under such plan and rectified the grant of these options. Accordingly, the Company recognized stock-based compensation of $1,057,013 in Q3 2021. This resulted in a non-cash variance of $1,024,474 between the two reporting periods.

Other Income (Expense)

Other income was $1,837,031 for Q3 2022, as compared to other expense of $947,762 for Q3 2021. The positive variance of $2,784,793 in other income (expense) was non-cash and was due to the gain in the change in fair value of warrant liability in Q3 2022, and the loss in the change in fair value of derivative liability and the loss on recognition of debt host liability in Q3 2021. The variances were comprised of:

Change in fair value of warrant liability (Q3 2022 – $1,837,031; Q3 2021 – $nil; Variance – $1,837,031)

On November 1, 2021, the Company’s functional currency change resulted in the reclassification of its outstanding warrants and broker warrants denominated in Canadian dollar as derivative liability measured at fair value through other income (expense) in the Company’s consolidated statements of loss and comprehensive loss at the end of each reporting period. The Company issued common share purchase warrants denominated in Canadian dollar on conversion of the July 2021 Convertible Debenture and recognized additional derivative liability of $67,155 in Q3 2022. For Q3 2022, the Company recognized a non-cash gain of $1,904,186 on re-measurement of its derivative liability of warrants and broker warrants. There was no warrant liability in Q3 2021.

Change in fair value of derivative liability [Q3 2022 – $nil; Q3 2021 – ($806,853); Variance – ($806,853)]

For Q3 2022, the Company had no hybrid financial instrument which comprised of a debt host liability and an embedded derivative liability requiring remeasurement at fair value through other income (expense) in the Company’s consolidated statements of loss and comprehensive loss at the end of each reporting period. For Q3 2021, the Company recognized a non-cash loss of $806,853 on re-measurement of its July 2020 Convertible Debenture, June 2021 Convertible Debenture and July 2021 Convertible Debenture.

Loss on recognition of debt host liability [Q3 2022 – $nil; Q3 2021 – ($140,909); Variance – ($140,909)]

On issuance date of the June 2021 Convertible Debenture in Q3 2021, its embedded derivative liability was valued at $1,646,600 which exceeded the face value of the note itself of $1,500,000, the fair value of the debt host liability was then determined to be $1, with an immediate loss of $140,909 on recognition of the debt host liability during Q3 2021.

40

Nine Months Ended July 31, 2022 Compared to Nine Months Ended July 31, 2021

Operating Expenses

Operating expenses were $9,855,482 for YTD 2022, as compared to $5,407,717 for YTD 2021. The increase of $4,447,765 in operating expenditures was due primarily to increases in legal and professional fees, salaries and benefits, and interest, partially offset by a decrease in stock-based compensation. The variances were primarily comprised of:

Legal and professional fees (YTD 2022 – $1,897,719; YTD 2021 – $545,234; Variance – $1,352,485)

The Company incurred legal and professional fees of $1,897,719 for YTD 2022, as compared to $545,234 for YTD 2021. The significant increase of $1,352,485 in legal and professional fees was attributable mainly to litigations discussed elsewhere in this Quarterly Report on Form 10-Q, the Company’s registration of its Common Stock with the US Securities and Exchange Commission and other securities related matters, the setup of the new headquarter and management team in McLean, Virginia close to the Washington DC metropolitan area, U.S. site selection and government incentives advance strategies, as well as for audit and valuation services rendered during YTD 2022.

Salaries and benefits (YTD 2022 – $3,347,884; YTD 2021 – $2,176,185; Variance – $1,171,699)

The Company incurred expenses for salaries and benefits of $3,347,884 for YTD 2022, as compared to $2,176,185 for YTD 2021, representing an increase of $1,171,699. This was due mainly to increased personnel headcount as the Company has set up its new headquarters and management team in McLean, Virginia close to the Washington DC metropolitan area and its continued effort in the buildout of its research and development pilot plant. As at July 31, 2022, the Company had 30 employees including 9 senior management members. As at July 31, 2021, the Company had 22 employees including 5 senior management members. Certain senior management members’ salaries were also adjusted to be in line with industry standards.

Interest (YTD 2022 – $1,021,443; YTD 2021 – $64,576; Variance – $956,867)

The Company incurred interest expense of $1,021,443 during YTD 2022, as compared to $64,576 during YTD 2021. On November 1, 2021, the Company’s functional currency change resulted in the reclassification of the June 2021 Convertible Debenture from a hybrid financial instrument to a convertible debt instrument with a beneficial conversion feature. The Company allocated the intrinsic value of the beneficial conversion feature of the June 2021 Convertible Debenture capped at the face value of $1,500,000 to additional paid-in capital and recognized a debt discount of the same amount to be amortized as interest expense over the period from issuance date to maturity date using the effective interest method. During the quarter ended April 30, 2022, the Company also allocated the intrinsic value of the beneficial conversion feature of the April 2022 Convertible Debenture of $240,000 to additional paid-in capital and recognized a debt discount of the same amount to be amortized as interest expense until its maturity. The increase of $956,867 in interest in YTD 2022 was attributable primarily to the interest expense of $814,717 from the amortization of the debt discount on partial conversion of the June 2021 Convertible Debenture during the period.

41

Stock-based compensation [YTD 2022 – $466,368; YTD 2021 – $1,057,013; Variance – ($590,645)]

In YTD 2022, the Company recorded stock-based compensation of $466,368 upon the grant of 1,250,000 stock options to an officer and certain employees, and the vesting of stock options of certain employees. In YTD 2021, the Company recorded $1,057,013 in stock-based compensation on stock options granted to certain directors, officers, employees and consultants. This resulted in a non-cash variance of $590,645 between the two reporting periods. The adoption of our 2021 Equity Incentive Plan which was approved by our shareholders during Fiscal 2021 is intended to promote our long-term financial interests and growth by attracting and retaining management and other personnel and key service providers with the training, experience and ability to enable them to make a substantial contribution to the success of our business. Moreover, our 2021 Equity Incentive Plan aims to align the interests of eligible participants with those of our shareholders through opportunities for increased equity-based ownership in our company.

Other Income (Expense)

Other expense was $5,205,669 for YTD 2022, as compared to $931,106 for YTD 2021. The negative variance of $8,722,328 in other expense was non-cash and was due mainly to the reclassification of warrants and broker warrants as derivative liability and the subsequent fair value re-measurement, and the accounting treatment of its convertible debentures resulted from the Company’s functional currency change. The variances were comprised of:

Change in fair value of warrant liability [YTD 2022 – ($5,223,759); YTD 2021 – $nil; Variance – ($5,223,759)]

On November 1, 2021, the Company’s functional currency change resulted in the reclassification of its outstanding warrants and broker warrants denominated in Canadian dollar as derivative liability measured at fair value through other income (expense) in the Company’s consolidated statements of loss and comprehensive loss at the end of each reporting period. The Company issued common share purchase warrants denominated in Canadian dollar on conversion of the July 2021 Convertible Debenture and recognized additional derivative liability of $67,155 in Q3 2022. For YTD 2022, the Company recognized a net non-cash loss of $5,223,759 on reclassification, new recognition and re-measurement of its derivative liability of warrants and broker warrants. There was no warrant liability in YTD 2021.

Change in fair value of derivative liability [YTD 2022 – $359,643; YTD 2021 – ($790,197); Variance – $1,149,840]

On November 1, 2021, the Company’s functional currency change resulted in the reclassification of the July 2021 Convertible Debenture from a convertible debt instrument with a beneficial conversion feature to a hybrid financial instrument comprised of a debt host liability and an embedded derivative liability. The debt host liability of the convertible note will be amortized at cost, with the embedded derivative liability measured at fair value through other income (expense) in the Company’s consolidated statements of loss and comprehensive loss at the end of each reporting period. For YTD 2022, the Company recognized a non-cash gain of $359,643 on re-measurement and conversion of its July 2021 Convertible Debenture on its conversion on April 22, 2021. For YTD 2021, the Company recognized a non-cash loss $790,197 on re-measurement of its July 2020 Convertible Debenture, June 2021 Convertible Debenture and July 2021 Convertible Debenture.

Loss on recognition of debt host liability [YTD 2022 – ($341,553); YTD 2021 – ($140,909); Variance – ($200,644)]

On November 1, 2021, the Company’s functional currency change resulted in the reclassification of the July 2021 Convertible Debenture from a convertible debt instrument with a beneficial conversion feature to a hybrid financial instrument. The embedded derivative liability was valued at $421,095 (CA$529,400) which exceeded the face value of the note itself of $79,542 (CA$100,000), the debt host liability was then assigned a face value of $1, with an immediate loss of $341,553 (CA$429,400) on recognition of the debt host liability during YTD 2022. On issuance date of the June 2021 Convertible Debenture in Q3 2021, its embedded derivative liability was valued at $1,646,600 which exceeded the face value of the note itself of $1,500,000, the fair value of the debt host liability was then determined to be $1, with an immediate loss of $140,909 on recognition of the debt host liability during YTD 2021.

42

Components of our Results of Operations

Operating Expenses

Operating expenses consist of general and administrative, research and development, business development, stock-based compensation, interest and accretion, and depreciation and amortization.

General and administrative expenses primarily include salaries and benefits, legal and professional fees, consulting, management, travel expenses, investor relations, shareholder communications, regulatory fees, facilities and rent, computer system and software, and office and other general and administrative expenses.

Research and development expenses include engineering expenses which are in relation to the design and modeling of the magnesium pilot plant facility and the magnesium furnace reactor, as well as the commercialization of our technology, and due diligence expenses which pertain to those incurred in the potential acquisition of a smelter site for magnesium metal production.

Business development expenses include expenses in relation to U.S. site selection, government incentives advance strategies, and other federal and industry advocacy to accelerate the development of the Company’s pioneering technologies and efforts to manufacture magnesium metal in the U.S. in an eco-friendly manner that will help meet the U.S. demand for magnesium metal.

Stock-based compensation on stock options issued to directors, officers and employees is measured at the fair value on the date of grant and expensed over the vesting period. For stock options issued to consultants, the fair value is periodically re-measured until the counterparty performance is complete.

Interest and accretion relate to convertible debt instruments, right-of-use assets, and other general vendor accounts.

Depreciation and amortization includes recognition of depreciation of property, plant and equipment and right-of-use assets over their depreciable lives.

Other Income (Expense)

Other income (expense) consists of non-cash change in fair value of derivative liability of convertible debentures, warrants and broker warrants, and non-cash loss on recognition of debt host liability.

Working Capital Deficiency

The calculation of working capital deficiency provides additional information and is not defined under GAAP. We define working capital deficiency as current assets less current liabilities. This measure should not be considered in isolation or as a substitute for any standardized measure under GAAP. This information is intended to provide investors with information about our liquidity. Other companies in our industry may calculate this measure differently than we do, limiting its usefulness as a comparative measure.

43

Liquidity and Capital Resources

As of July 31, 2022 and October 31, 2021, we had total current liabilities of $7,440,511 and $10,891,270, respectively, and current assets of $798,259 and $1,233,954, respectively, to meet our current obligations. As of July 31, 2022, we had a working capital deficiency of $6,642,252, an increase of working capital of $3,015,064 as compared to October 31, 2021, driven primarily by non-cash items including the reclassification of warrants and broker warrants as derivative liability resulted from the Company’s functional currency change and the periodic re-measurement at fair value through other income (expense) in the Company’s consolidated statements of loss and comprehensive loss, partly offset by a decrease in derivative liability due to reclassifications of convertible debentures also resulted from the Company’s functional currency change.

On November 1, 2021, the Company’s functional currency change resulted in the reclassification of its outstanding warrants and broker warrants denominated in Canadian dollar as derivative liability measured at fair value through other income (expense) at the end of each reporting period. As at July 31, 2022, the derivative liability of warrants and broker warrants were valued at $57,080 (October 31, 2021 – $nil) and $nil (October 31, 2021 – $nil), respectively.

On November 1, 2021, the Company’s functional currency change resulted in the reclassification of the June 2021 Convertible Debenture from a hybrid financial instrument accounted for in accordance with ASU 815-15 to a convertible debt instrument with a beneficial conversion feature accounted for in accordance with ASU 470-20. The value of the embedded derivative liability of $7,449,700 was reclassified to additional paid-in capital. The Company’s functional currency change also resulted in the reclassification of the July 2021 Convertible Debenture from a convertible debt instrument with a beneficial conversion feature accounted for in accordance with ASU 470-20 to a hybrid financial instrument accounted for in accordance with ASU 815-15. Fair value adjustments were made to the embedded derivative liability of the July 2021 Convertible Debenture on conversion date of April 22, 2022, resulting in a value of $nil.

We have a history of operating losses. We have not yet achieved profitable operations and expect to incur further losses. We have funded our operations primarily from equity and debt financing. As of July 31, 2022, cash generated from financing activities was not sufficient to fund operations and, in particular, to fund our growth strategy in the short-term or long-term. As a result, we raised additional funds from equity and debt financing transactions during YTD 2022 and Fiscal 2021 as discussed below under “Recent Financing Transactions.” The primary need for liquidity is to fund working capital requirements of the business, including operational and business development expenses, develop and construct our planned research and development pilot magnesium production facility and the capital expenditures associated with that project. The primary source of liquidity has primarily been private financing transactions. The ability to fund operations, to make planned capital expenditures, to execute on the development and operation of our planned research and development pilot facility, to develop a full-scale commercial magnesium production facility and to make scheduled debt and rent payments and to repay or refinance indebtedness depends on our ability to raise funds from debt and/or equity financing which is subject to prevailing economic conditions and financial, business and other factors, some of which are beyond our control. There can be no assurance that additional financing will be available to us when needed or at all, or obtained on commercially reasonable terms acceptable to us.

As of July 31, 2022, there have not been any meaningful impact or disruptions to our operations as a result of the COVID-19 pandemic. We continue to assess the impact of COVID-19 on an ongoing basis.

44

Recent Financing Transactions

On September 10, 2020, we announced a non-brokered private placement of up to 53,846,154 units priced at CAD$0.13 per unit (the “Unit”) for an aggregate offering of up to CAD$7,000,000 (the “September 2020 Private Placement”). Each Unit is comprised of one share of our common stock and one common share purchase warrant exercisable at CAD$0.19 per share for a period of one year from the date of issuance. On November 20, 2020, we closed the first tranche of the September 2020 Private Placement of 5,599,171 Units for gross proceeds of $556,876 (CAD$727,892). On January 15, 2021, we closed the second tranche of the September 2020 Private Placement consisting of 7,337,914 Units for gross proceeds of $749,435 (CAD$953,930). On January 29, 2021, we closed the third tranche of the September 2020 Private Placement consisting of 5,382,303 Units for gross proceeds of $547,496 (CAD$699,699). On March 24, 2021, we closed the fourth tranche of this offering and issued 6,554,172 Units for gross proceeds of $678,270 (CAD$852,042). On April 27, 2021, we closed the fifth and final tranche of this offering and issued 851,395 Units for gross proceeds of $89,237 (CAD$110,681). We closed an aggregate 25,724,955 Units for aggregate gross proceeds of $2,621,314 (CAD$3,344,244) and incurred aggregate share issue costs of $195,614 in connection to this offering.

On May 5, 2021, we announced a non-brokered private placement priced at CAD$0.13 per unit (the “Unit”) to raise gross proceeds of up to CAD$3,000,000 (the “May 2021 Private Placement”). Each Unit in this offering consists of one share of our common stock and one common share purchase warrant exercisable at a price of CAD$0.19 per share for a period of one year from the date of issuance. On May 28, 2021, we closed the first tranche of the May 2021 Private Placement issuing 5,223,420 Units for gross proceeds of $561,844 (CAD$679,044). On June 17, 2021, we closed the second and final tranche of this offering consisting of 17,853,506 Units for gross proceeds of $1,880,687 (CAD$2,320,956). We closed at the maximum offering and issued an aggregate 23,076,926 Units for aggregate gross proceeds of $2,442,531 (CAD$3,000,000). We incurred aggregate share issue costs of $154,336 in connection with this offering.

On May 18, 2021, we issued 1,360,959 common shares on the conversion of the July 2020 Convertible Debenture including conversion of accrued interest and 263,973 common shares valued at $26,286 in transaction costs.

On June 7, 2021, we received final approval from the TSX-V for an agreement with Industrial Surplus Supplies Ltd. (“ISL”), pursuant to which ISL will build a prototype internally heated testing lab furnace for the testing of a magnesium production process. We issued 1,538,461 common shares at a price of CAD$0.24 per share with a total fair value of $305,832 (CAD$369,231) for equipment.

On June 15, 2021, we closed a non-brokered private placement of an unsecured convertible note in the principal amount of $1,500,000 (the “June 2021 Convertible Debenture”). The June 2021 Convertible Debenture bears interest at 12% per annum and matures on December 10, 2022. The June 2021 Convertible Debenture is convertible into 15,000,000 units, where each unit consists of (I) one share of our common stock, (ii) one-half of one Class A common stock purchase warrant, with each whole warrant being exercisable at a price of $0.13 until June 10, 2026, and (iii) one-half of one Class B common stock purchase warrant, with each whole warrant being exercisable at a price of $0.19 until June 10, 2026 (collectively, the “Class A and B Warrants”). In addition, the conversion price for accrued interest is the greater of (i) $0.10 and (ii) the minimum conversion price permitted by the TSX Venture Exchange at the time of conversion (should our common stock then be listed on such exchange).

45

Under the terms of the June 10, 2021 Securities Purchase Agreement we entered into as part of the offering of the June 2021 Convertible Debenture (the “2021 Securities Purchase Agreement”), we agreed to use commercially reasonable efforts to file a registration statement with the SEC by August 14, 2021, covering the public resale of the shares of common stock underlying such debenture and, upon its conversion, the Class A and Class B Warrants issuable upon such conversion (the “Underlying Shares”), and to use our best efforts to cause the registration statement to be declared effective on October 13, 2021. In addition, we agreed to provide the holder to the June 2021 Convertible Debenture certain piggy-back registration rights if we do not have an effective registration statement covering the Underlying Shares and we propose to file any registration statement under the Securities Act with respect to our common stock. We will pay all costs associated with the registration statements, other than underwriting commissions and discounts. On December 13, 2021, our Form 10 Registration Statement filed with the SEC was declared effective.

In addition to certain covenants contained in the 2021 Securities Purchase Agreement, the terms of the Convertible Debenture contain certain negative covenants by us, including:

● other than certain permitted indebtedness, enter into, create, incur, assume, guarantee or suffer to exist any indebtedness for borrowed money of any kind, including, but not limited to, a guarantee, on or with respect to any of our property or assets now owned or hereafter acquired or any interest therein or any income or profits therefrom;

● other than certain permitted liens, enter into, create, incur, assume or suffer to exist any liens of any kind, on or with respect to any of our property or assets now owned or hereafter acquired or any interest therein or any income or profits therefrom;

● amend our charter documents, including, without limitation, our certificate of incorporation and bylaws, in any manner that materially adversely affects any rights of the Convertible Debenture Holder (notwithstanding the foregoing, we are entitled to proceed with the amendments to the charter documents as set out in our proxy materials for our shareholder meeting to be held in 2021);

● repay, repurchase or offer to repay, repurchase or otherwise acquire more than a de minimis number of shares of our common stock or common stock equivalents other than as to the Underlying Shares;

● redeem, defease, repurchase, repay or make any payments in respect of, by the payment of cash or cash equivalents (in whole or in part, whether by way of open market purchases, tender offers, private transactions or otherwise), all or any portion of any of our indebtedness (other than the Convertible Debentures if on a pro-rata basis), whether by way of payment in respect of principal of (or premium, if any) or interest on, such indebtedness, in any case unless such indebtedness or interest is due and payable in accordance with the initial terms of such debt prior to any default thereunder;

● declare or make any dividend or other distribution of our assets or rights to acquire our assets to holders of shares of our common stock, preferred stock, or any other equity security by way of return of capital or otherwise including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction;

● sell or offer to sell any securities with non-fixed or floating price features, issue any common stock or common stock equivalents at a price lower than the conversion price herein then in effect, or issue any equity or debt instruments with anti-dilution provisions; or

● enter into any agreement with respect to any of the foregoing.

46

In the event we issue or sell any common stock or common stock equivalents with terms that the purchaser then holding outstanding June 2021 Convertible Debenture (the “Convertible Debenture Holder”) or the Class A and B Warrants reasonably believes are more favorable to such holder than are the terms of the June 2021 Convertible Debenture or the Class A and B Warrants (the “MFN Securities”), then upon notice to us by such holder within five trading days after notice to such holder by us, we will use commercially reasonable efforts to obtain the approval of the TSX-V and any additional required regulatory approval to amend the terms of the June 2021 Convertible Debenture or the Class A and B Warrants as required, as the case may be, so as to give such holder the benefit of such more favorable terms or conditions. If we fail to obtain such regulatory approvals and the approval of the TSX-V, then absent such approval we are forbidden to issue the MFN Securities.

The conversion price of the June 2021 Convertible Debenture is subject to proportional adjustment in the event of stock splits, stock dividends and similar corporate events.

In addition, if, at any time while the June 2021 Convertible Debenture is outstanding, we, directly or indirectly, effect any merger or consolidation of our company with or into another person or engage in a “Fundamental Transaction” as defined in the June 2021 Convertible Debenture, the Convertible Debenture Holder shall have the right to receive, for each conversion share that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction, the number of shares of our Common Stock of the successor or acquiring corporation or us, if we are the surviving corporation, and any additional consideration (the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of shares of our Common Stock for which the June 2021 Convertible Debenture is convertible immediately prior to such Fundamental Transaction. In addition, the conversion price will be subject to certain adjustments so that the economic value of such shares and such conversion price are protected and which is reasonably satisfactory in form and substance to the Convertible Debenture Holder. Alternatively, the Convertible Debenture Holder may demand that we redeem the June 2021 Convertible Debenture at a rate equal to 125% of the principal and interest due thereon, to be paid in full contemporaneously with consummation of the Fundamental Transaction.

We granted the investors certain rights of first refusal on our future offerings for so long as the June 2021 Convertible Debenture or the Class A and B Warrants are outstanding.

We may prepay and satisfy the June 2021 Convertible Debenture so long as an event of default has not occurred, upon 20 days’ prior written notice received by us to the holder, by paying 125% of the amounts owed on the June 2021 Convertible Debenture, including all principal, interest and other fees. The holder of this debenture may, however, convert all or a portion of the debenture during the 20 day notice period.

The June 2021 Convertible Debenture is not exercisable if the number of shares to be issued to the holder upon such exercise, together with all other shares then owned by the holder and our affiliates, would result in the holder beneficially owning more than 9.99% of our outstanding common stock. The holder may increase or decrease this ownership limitation to any percentage not exceeding 9.99% upon 61 days prior written notice to us.

Class A and Class B Warrants

Upon conversion of the June 2021 Convertible Debenture, we will issue the Class A and B Warrants. The holders may exercise the Class A and B Warrants on a cashless basis at any time that there is not an effective registration statement covering the underlying shares of common stock and the volume weighted average price of our common stock is greater than the exercise price at the time of exercise. The Class A and Class B Warrants are not exercisable, however, if the number of shares to be issued to the holder upon such exercise, together with all other shares then owned by the holder and our affiliates, would result in the holder beneficially owning more than 9.99% of our outstanding common stock. The holder may increase or decrease this ownership limitation to any percentage not exceeding 9.99% upon 61 days prior written notice to us.

47

The exercise price of the Class A and Class B Warrants is subject to proportional adjustment in the event of stock splits, recapitalizations and similar corporate events. In addition, the exercise price are each subject to adjustment if we issue or sell shares of our common stock for a consideration per share less than the exercise price then in effect, or issue options, warrants or other securities convertible or exchange for shares of our common stock at an exercise price less than the exercise price then in effect. If any of these events should occur, the exercise price each will be reduced to the lowest price at which these securities were issued or are exercisable.

In addition, if, at any time while the Class A and Class B Warrants are outstanding, we engage in a Fundamental Transaction, the exercise price thereof is subject to adjustment similar to the adjustment as provided for in the June 2021 Convertible Debenture. In addition, we may not enter into a Fundamental Transaction unless the holders of our common stock receive securities of an entity that is listed on a stock exchange in Canada or the United States, or cash, equal to the Black Scholes value of the remaining unexercised portion of the Class A and Class B Warrants on the date of the consummation of such Fundamental Transaction.

On July 15, 2021, we closed a non-brokered private placement of an unsecured convertible note in the principal amount of $79,542 (CAD$100,000, the “July 2021 Convertible Debenture”). The note bears interest at 12% per annum and is due on the date that is one year following the closing date. The note is convertible into common shares of the Company at the price of CAD$0.12 per share and will have warrants exercisable for a price of CAD$0.20 for a period of two years. Any accrued but unpaid interest will be payable on the earlier of the maturity date and the date of conversion in cash or common shares. No finder’s fees were paid in connection with this offering.

On July 16, 2021, we closed a non-brokered private placement and issued 4,350,000 units at a price of CAD$0.20 per unit (the “Unit”) for gross proceeds of $690,860 (CAD$870,000, the “July 2021 Private Placement”). Each Unit in this offering consists of one share of our common stock and one common share purchase warrant exercisable at a price of CAD$0.30 per share for a period of one year from the date of issuance. We incurred aggregate share issue costs of $48,319 in connection with this offering.

On August 11, 2021, we closed a non-brokered private placement and issued 3,827,601 units at a price of CAD$0.55 ($0.44) per unit (the “Unit”) for gross proceeds of $1,683,336 (CAD$2,105,180, the “August 2021 Private Placement”). Each Unit in this offering consists of one share of our common stock and one common share purchase warrant exercisable at a price of CAD$0.65 ($0.52) per share for a period of eighteen months from the date of issuance. We incurred aggregate share issue costs of $124,923, and an additional $8,444 in the following fiscal year, in connection with this offering.

During the fiscal year ended October 31, 2021, upon the exercise of common share purchase warrants we issued an aggregate 1,964,901 common shares at a price of CAD$0.05 per share for gross proceeds of $77,896 (CAD$98,245), an aggregate 1,931,450 common shares at a price of CAD$0.19 per share for gross proceeds of $292,890 (CAD$366,976), and an aggregate 3,118,618 common shares at a price of CAD$0.21 per share for gross proceeds of $516,735 (CAD$654,910). Upon exercise, $4,291 (CAD$5,333) previously recorded in additional paid-in capital was reclassified to share capital.

48

During the fiscal year ended October 31, 2021, upon the exercise of stock options we issued an aggregate 2,000,000 common shares at a price of CAD$0.05 per share for gross proceeds of $80,058 (CAD$100,000), an aggregate 200,000 common shares at a price of CAD$0.11 per share for gross proceeds of $17,456 (CAD$22,000), an aggregate 300,000 common shares at a price of CAD$0.12 per share for gross proceeds of $29,096 (CAD$36,000), an aggregate 100,000 common shares at a price of CAD$0.13 per share for gross proceeds of $10,315 (CAD$13,000), and an aggregate 30,000 common shares at a price of CAD$0.16 per share for gross proceeds of $3,809 (CAD$4,800). Upon exercise, $121,932 (CAD$152,218) previously recorded in additional paid-in capital was reclassified to share capital.

Pursuant to an agreement entered on August 29, 2018 and which was approved by the TSX-V on September 12, 2018, a company controlled by Sam Ataya, a director and officer of our Company, is eligible to receive up to 5% of the issued and outstanding common shares of the Company as at August 28, 2018 for up to $5 million raised. The agreement was amended on January 2, 2019, extending the term from six months to three years and six months. During the fiscal year ended October 31, 2021, the commitment was met. On November 3, 2021, the Company issued 9,163,425 common shares at a price of CAD$0.65 per share for a fair value of $4,796,832 (CAD$5,956,226) as share issue costs.

On November 4, 2021, we issued 1,000,000 units on partial conversion of the June 2021 Convertible Debenture, for a total of 1,000,000 common shares, 500,000 Class A Warrants and 500,000 Class B Warrants. On December 13, 2021, we issued 1,000,000 units on partial conversion of the June 2021 Convertible Debenture, for a total of 1,000,000 common shares, 500,000 Class A Warrants and 500,000 Class B Warrants. On January 20, 2022, we issued a further 1,000,000 units on partial conversion of the June 2021 Convertible Debenture, for a total of 1,000,000 common shares, 500,000 Class A Warrants and 500,000 Class B Warrants. Each Class A Warrant is exercisable at a price of $0.13 until June 10, 2026 and each Class B Warrant is exercisable at a price of $0.19 until June 10, 2026. We incurred aggregate share issue costs of $1,361.

On November 26, 2021, we closed a non-brokered private placement and issued 1,375,499 units at a price of $0.55 per unit (the “Unit”) for gross proceeds of $756,524 (the “November 2021 Private Placement”). Each Unit in this offering consists of one share of our common stock and one common share purchase warrant exercisable at a price of $0.75 per share for a period of one year from the date of issuance. We incurred aggregate share issue costs of $26,656 in connection with this offering.

During the three months ended January 31, 2022, upon the exercise of common share purchase warrants we issued an aggregate 15,159,448 common shares at a price of CAD$0.19 per share for gross proceeds of $2,279,136 (CAD$2,880,295), 200,000 common shares at a price of CAD$0.05 per share for gross proceeds of $7,830 (CAD$10,000), and 30,000 common shares at a price of CAD$0.30 per share for gross proceeds of $6,981 (CAD$9,000). We issued a total of 15,389,448 common shares for gross proceeds of $2,293,946 (CAD$2,899,295). A total of 2,428,363 warrants expired unexercised.

On March 10, 2022, we issued 1,000,000 units on partial conversion of the June 2021 Convertible Debenture, for a total of 1,000,000 common shares, 500,000 Class A Warrants and 500,000 Class B Warrants. On April 27, 2022, we issued a further 2,000,000 units on partial conversion of the June 2021 Convertible Debenture, for a total of 2,000,000 common shares, 1,000,000 Class A Warrants and 1,000,000 Class B Warrants. Each Class A Warrant is exercisable at a price of $0.13 until June 10, 2026 and each Class B Warrant is exercisable at a price of $0.19 until June 10, 2026.

On April 14, 2022, we entered into a securities purchase agreement (the “2022 Securities Purchase Agreement”) and closed a non-brokered private placement of an unsecured convertible note in the principal amount of $2,000,000 (the “April 2022 Convertible Debenture”). The note bears interest at 15% per annum and matures on October 14, 2023. The April 2022 Convertible Debenture is convertible into 6,666,667 units, where each unit consists of one share of the Company’ common stock and one common stock purchase warrant exercisable at a price of $0.40 per share for a period of five years from the date of issuance.

49

The April 2022 Convertible Debenture may not be prepaid prior to maturity and contains customary events of default relating to, among other things, payment defaults, breach of representations and warranties, and breach of provisions of the 2022 Securities Purchase Agreement or the April 2022 Convertible Debenture.

In event of default under the April 2022 Convertible Debenture, the interest rate shall increase to the lesser of 20% per annum or the maximum rate permitted under applicable law until paid and the following “Mandatory Default Amount” shall be paid, if demanded by the purchaser: the sum of (a) the greater of (i) the outstanding principal amount of the April 2022 Convertible Debenture divided by the conversion price on the date the Mandatory Default Amount is either (A) demanded (if demand or notice is required to create an event of default) or otherwise due or (B) paid in full, whichever has a lower conversion price, multiplied by the VWAP on the date the Mandatory Default Amount is either (x) demanded, (y) due, or (z) paid in full, whichever is highest, or (ii) 125% of the outstanding principal amount of the April 2022 Convertible Debenture plus (b) all other amounts, costs, expenses and liquidated damages due in respect of the April 2022 Convertible Debenture.

Pursuant to the terms of the 2022 Securities Purchase Agreement, we also entered into a registration rights agreement dated April 14, 2022 (the “2022 Registration Rights Agreement”). Pursuant to the terms of the 2022 Registration Rights Agreement, we agreed to prepare and file with the SEC a registration statement covering the resale of all shares issued or issuable upon conversion of the April 2022 Convertible Debenture, upon exercise of the respective warrants of the April 2022 Convertible Debenture, upon conversion of the June 2021 Debenture, and upon exercise of the respective warrants of the June 2021 Convertible Debenture. We agreed to file the registration statement with the SEC within 30 days following April 14, 2022 and to use best efforts to have the registration statement declared effective by the SEC within 60 days following April 14, 2022 if the SEC does not review it or by August 12, 2022 if the SEC reviews it. In the event we fail to file the registration statement or such registration statement is not declared effective within the time periods noted above or such registration statement is not kept effective while any of the securities registered pursuant to such registration statement, we will be obligated to pay the holder of the debentures a penalty in cash, in the amount of $20,000 on the date of such failure and on the 30^th day of each month following such failure. The 2022 Registration Rights Agreement contains customary indemnification provisions. On May 25, 2022, we filed a Form S-1 Registration Statement with the SEC. On July 12, 2022, the Company’s Form S-1 Registration Statement filed with the SEC was declared effective.

On April 22, 2022, we issued a total of 933,333 common shares and 933,333 common share purchase warrants exercisable at a price of CAD$0.20 for a period of two years on the conversion the July 2021 Convertible Debenture including CAD$100,000 principal amount and CAD$12,000 accrued interest.

During the three months ended April 30, 2022, upon the exercise of common share purchase warrants, we issued an aggregate 929,005 common shares at a price of CAD$0.19 per share for gross proceeds of $929,005 (CAD$1,177,755), 2,082,025 common shares at a price of CAD$0.05 per share for gross proceeds of $81,354 (CAD$104,101), and 30,960 common shares at a price of CAD$0.30 per share for gross proceeds of $7,357 (CAD$9,288). A total of 3,191,933 warrants and 40,000 broker warrants expired unexercised.

50

During the three months ended April 30, 2022, we issued a total of 750,000 common shares on the exercise of stock options at a price of CAD$0.05 per share for gross of $29,715 (CAD$37,500). Upon exercise, $22,203 previously recorded in additional paid-in capital was reclassified to share capital.

On April 18, 2022, we announced a non-brokered private placement priced at $0.25 per unit (the “Unit”) to raise gross proceeds of up to $3,000,000 (the “April 2022 Private Placement”). Each Unit in this offering consists of one share of our common stock and one common share purchase warrant exercisable at a price of $0.45 per share for a period of one year from the date of issuance. On May 9, 2022, we closed the first tranche of the April 2022 Private Placement issuing 1,727,000 Units for gross proceeds of $431,750. On June 3, 2022, we closed the second and final tranche of this offering consisting of 740,000 Units for gross proceeds of $185,000. We issued an aggregate 2,467,000 Units for aggregate gross proceeds of $616,750. We incurred aggregate share issue costs of $23,182 in connection with this offering.

On June 8, 2022, we issued 1,000,000 units on partial conversion of the June 2021 Convertible Debenture, for a total of 1,000,000 common shares, 500,000 Class A Warrants and 500,000 Class B Warrants. On July 13, 2022, we issued a further 1,000,000 units on partial conversion of the June 2021 Convertible Debenture, for a total of 1,000,000 common shares, 500,000 Class A Warrants and 500,000 Class B Warrants. Each Class A Warrant is exercisable at a price of $0.13 until June 10, 2026 and each Class B Warrant is exercisable at a price of $0.19 until June 10, 2026.

During the three months ended July 31, 2022, upon the exercise of common share purchase warrants, we issued an aggregate 8,131,975 common shares at a price of CA$0.19 per share for gross proceeds of $1,205,077 (CA$1,545,075) and 800,000 common shares at a price of CA$0.05 per share for gross proceeds of $31,051 (CA$40,000). A total of 17,414,239 warrants and 13,725 broker warrants expired unexercised.

During the three months ended July 31, 2022, upon the exercise of stock options, we issued an aggregate 250,000 common shares at a price of CA$0.13 per share for gross proceeds of $25,340 (CA$32,500), 150,000 common shares at a price of CA$0.12 per share for gross proceeds of $13,853 (CA$18,000) and 600,000 common shares at a price of CA$0.05 per share for gross proceeds of $23,272 (CA$30,000). Upon exercise, $48,060 previously recorded in additional paid-in capital was reclassified to share capital.

Cash Flows

Cash Used in Operating Activities

Net cash used in operating activities for the nine months ended July 31, 2022 and 2021, were as follows:

	Nine Months Ended
	July 31,
	2022			2021
	$			$
Net Cash Used in Operating Activities		(5,985,595	)		(4,016,689	)

51

Cash Used in Investing Activities

Net cash used in investing activities for the nine months ended July 31, 2022 and 2021, were as follows:

	Nine Months Ended
	July 31,
	2022			2021
	$			$
Net Cash Used in Investing Activities		(2,252,600	)		(1,779,316	)

Cash Flow from Financing Activities

Net cash provided by financing activities for the six months ended July 31, 2022 and 2021, were as follows:

	Nine Months Ended
	July 31,
	2022		2021
	$		$
Net Cash Provided by Financing Activities		7,800,103		6,133,785

Off-Balance Sheet Arrangements

As of the date of this Quarterly Report on Form 10-Q, we do not have any off-balance-sheet arrangements that have, or are reasonably likely to have, a current or future effect on our results of operations or financial condition, including, and without limitation, such considerations as liquidity and capital resources.

Contractual Obligations

As of July 31, 2022, we have the following obligations to make future payments, representing contracts and other commitments that are known and committed.

	Payments Due by Period
	Total		Less than 1 Year		1 – 3 Years		3 – 5 Years		More than 5 Years
	$		$		$		$		$
Lease obligations – premises		588,939		344,839		244,100		–		–
Lease obligations – machines		22,222		13,781		7,886		555		–
Debt and interest obligations		3,345,929		895,518		2,450,411		–		–
Total		3,957,090		1,254,138		2,702,397		555		–

Real Estate Option Agreement

Effective as of August 4, 2021, we entered into a Real Estate Option Agreement (the “Option”) with Harrison County Community Improvement Corporation, an unrelated party (the “Seller”), to purchase a parcel of land comprising approximately 122 acres in the Village of Cadiz, Harrison County, Ohio (the “Property”). We are entitled to exercise the Option at any time up until its expiration on August 3, 2023. The Option contains covenants, representations and warranties that are customary of real estate purchase and sale agreements including, but not limited to, completion of title work and a survey of the Property, an environmental audit, an engineering feasibility study of the Property, availability of certain utilities, obtaining permits, approval of the Option by our Board of Directors, our exercise of the Option and obtaining certain state and local economic incentives and tax abatements.

52

Transactions with Related Parties

Deposits held by related parties

Included in our current assets are the following amounts due from related parties:

	As of July 31, 2022		As of October 31, 2021
	$		$
Deposits held by a director and officer		349,338		291,481
Deposits held by an officer		–		194,981
Deposits held by related parties		349,338		486,462

Due to related parties

Included in our current liabilities are the following amounts due to related parties:

	As of July 31, 2022		As of October 31, 2021
	$		$
Wages payable to directors and officers		505,544		357,500
Benefits payable to directors and officers		725,261		539,209
Fees and expenses payable to directors and officers		290,029		127,878
Interest due to a shareholder		–		2,230
Total due to related parties		1,520,834		1,026,817

Leases

We have entered into a sublease agreement with a company controlled by Sam Ataya, a director and officer of our Company, for our Canadian office at 580 Hornby Street, Suite 900, Vancouver, British Columbia, Canada V6C 3B6. The lease had a two-year term from April 1, 2021 to March 31, 2023 and required a monthly payment of CAD$9,794 for a total of CAD$235,056.

Scope of Work Agreement

Pursuant to an agreement entered on August 29, 2018 and which was approved by the TSX-V on September 12, 2018, a company controlled by Sam Ataya, a director and officer of our Company, is eligible to receive up to 5% of the issued and outstanding common shares of the Company as at August 28, 2018 for up to $5 million raised. The agreement was amended on January 2, 2019, extending the term from six months to three years and six months. During Fiscal 2021, the commitment was met. On November 3, 2021, the Company issued 9,163,425 common shares at a price of CAD$0.65 per share for a fair value of $4,796,832 (CAD$5,956,226) as share issue costs.

53

Recent Accounting Pronouncements

The following GAAP standards have been recently issued by the Financial Accounting Standards Board (the “FASB”). We are assessing the impact of these new standards on our consolidated financial statements. We have elected to take advantage of the extended transition period allowed for emerging growth companies for complying with new or revised accounting guidance as allowed by Section 107 of the JOBS Act and Section 7(a)(2)(B) of the Securities Act. Pronouncements that are not applicable or where it has been determined do not have a significant impact on us have been excluded herein.

(i) In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires the measurement of current expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. Adoption of ASU 2016-13 will require financial institutions and other organizations to use forward-looking information to better formulate their credit loss estimates. In addition, the ASU amends the accounting for credit losses on available for sale debt securities and purchased financial assets with credit deterioration. In May 2019, the FASB issued ASU 2019-05, Financial Instruments – Credit Losses (Topic 326): Targeted Transition Relief (“ASU 2019-05”), which provides transition relief to entities adopting ASU 2016-13. As smaller reporting companies as defined by the SEC, these updates are effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the effect of adoption of these updates on its Financial Statements.

(ii)	In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”). ASU 2018-13 adds, modifies, and removes certain fair value measurement disclosure requirements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years, with early adoption permitted. Effective November 1, 2020, the Company adopted the new standard. There was no material impact or adjustment to its Financial Statements.
(iii)	In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years, with early adoption permitted. Effective November 1, 2021, the Company adopted the new standard. There was no material impact or adjustment to its Financial Statements.
(iv)	In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”). ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments and supersedes the respective guidance within ASC 470-20 and ASC 740-10-55-51, which will result in more instruments to be accounted for as a single instrument rather than having their proceeds allocated between liability and equity accounting units. As smaller reporting companies as defined by the United States Securities and Exchange Commission (the “SEC”), ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the effect of adopting these updates on its Financial Statements.

54

Critical Accounting Estimates

The preparation of our consolidated financial statements requires management to make judgments, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised, if the revision affects only that period, or in the period of the revision and future periods, if the revision affects both current and future periods.

Significant judgments, estimates and assumptions that have the most significant effect on the amounts recognized in our consolidated financial statements are described below.

Functional Currency

The functional currency of each entity of the Company is as follows:

Entity	Functional Currency
Western Magnesium Corporation	United States dollars
Western Magnesium Corp.	United States dollars
Western Magnesium Canada Corporation	Canadian dollars (“CA$”)

Significant changes in economic facts and circumstances have occurred in Western Magnesium Corporation’s operations which resulted in the change of its functional currency to the United States dollar from the Canadian dollar effective November 1, 2021. For both monetary and non-monetary assets and liabilities, translated balances at the end of the prior period become the new accounting basis. The rate on the date of change becomes the historical rate at which non-monetary assets and liabilities are translated in subsequent years. There is no effect on the cumulative translation adjustment on the consolidated basis. Previously recorded cumulative translation adjustments are not reversed. Effects of change in functional currency included the reclassifications of convertible debentures and warrants and broker warrants.

Estimated Useful Lives of Property Plant and Equipment

Depreciation of property, plant and equipment is dependent upon estimates of useful lives which are determined through the exercise of judgment. The assessment of any impairment of these assets is dependent upon estimates of recoverable amounts that consider factors such as economic and market conditions and the useful lives of assets.

Estimated Useful Lives of and Amortization of Intangible Assets

Amortization of intangible assets is recorded over their estimated useful lives which do not exceed any contractual periods, if any. Intangible assets that have indefinite useful lives are not subject to amortization and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired.

Consolidation

Judgment is applied in assessing whether we exercise control and have significant influence over entities in which we directly or indirectly own an interest. We have control when we have the power over the subsidiary, have exposure or rights to variable returns, and have the ability to use our power to affect the returns. Significant influence is defined as the power to participate in the financial and operating decisions of the subsidiaries. Where we are determined to have control, these entities are consolidated. Additionally, judgment is applied in determining the effective date on which control was obtained.

55

Stock-Based Compensation

Valuation of stock-based compensation and warrants requires management to make estimates regarding the inputs for option pricing models, such as the expected life of the option, the volatility of our stock price, the vesting period of the option and the risk-free interest rate are used. Actual results could differ from those estimates. The estimates are considered for each new grant of stock options or warrants.

Leases

We use the following policies to evaluate our leases:

Determining a lease: At contract inception, we review the facts and circumstances of the arrangement to determine if the contract is or contains a lease. We follow the guidance in ASU 2016-02, Leases (Topic 842), ASU 2018-11, Leases (Topic 842): Targeted Improvements, and ASU 2019-01, Leases (Topic 842): Codification Improvements to evaluate if:

● the contract has an identified asset;

● we have the right to obtain substantially all economic benefits from the asset; and

● we have the right to direct the use of the underlying asset.

When determining if a contract has an identified asset, we consider both explicit and implicit assets, and whether the vendor has the right to substitute the asset. When determining if we have the right to direct the use of an underlying asset, we consider if we have the right to direct how and for what purpose the asset is used throughout the period of use and if we control the decision-making rights over the asset.

Discount rate: At commencement, lease-related assets and liabilities are measured at the present value of future lease payments over the lease term using an incremental borrowing rate. As most of our leases do not provide an implicit rate, we exercise judgment in determining the incremental borrowing rate based on information available at the time the lease commences.

Rent increases or escalation clauses: Certain leases contain scheduled rent increases or escalation clauses. We assess each contract individually and apply appropriate payments based on the terms of the agreement.

Renewal, purchase and termination options: Our lease terms may include options to extend or terminate the lease. We exercise judgment in determining the term of these leases when extension or termination options are present and include such options in the calculation of the lease terms when it is reasonably certain that we will exercise these options.

Recognizing leases: We do not recognize leases with a contractual term of less than 12 months or low value leases on our financial statements. Lease payments are expensed on a straight-line basis over the lease terms.

Residual value guarantees, restrictions or covenants: Our lease agreements do not contain residual value guarantees, restrictions or covenants.

56

Other Estimates and Assumptions

Other estimates and assumptions where there are potential risk of material adjustments to assets and liabilities in future accounting periods include the recoverability of the carrying value of exploration and evaluation assets, fair value measurements for financial instruments, the recoverability and measurement of deferred tax assets and liabilities and contingent liabilities.

Significant Judgments

The most significant judgments, apart from those involving estimates, in applying accounting policies in our consolidated financial statements include:

● the assessment of the Company’s ability to continue as a going concern and whether there are events or conditions that may give rise to substantial doubt;

● whether there are indicators of impairment of the Company’s exploration and evaluation assets and other non-current assets;

● the classification of financial instruments; and

● determination of functional currency.

Financial Instruments and Financial Risk Management

Our financial instruments consist of cash, other receivables, deposits held by related parties, accounts payable, due to related parties, convertible debenture, and derivative liability.

The fair value of financial instruments is the amount of consideration that would be agreed upon in an arm’s length transaction between knowledgeable, willing parties who are under no compulsion to act. The fair value of current financial instruments approximates their carrying values as long as they are short-term in nature or bear interest at market rates.

Financial instruments recorded at fair value are classified using a fair value hierarchy that prioritizes inputs used in determining the fair value and depending on the extent to which they are observable. The three levels of hierarchy are:

Level 1 — Unadjusted quoted prices in active markets for identical assets or liabilities;

Level 2 — Inputs other than quoted prices that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. from derived prices); and

Level 3 — Inputs for the asset or liability that are not based on observable market data.

There were no transfers between the levels during the reporting periods.

Financial Risk Management

The Company’s board of directors has the overall responsibility for the establishment and oversight of the Company’s risk management framework. The Company’s risk management policies are established to identify and analyze the risks faced by the Company, to set appropriate risk limits and controls, and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and in response to the Company’s activities. Management regularly monitors compliance with the Company’s risk management policies and procedures and reviews the adequacy of the risk management framework in relation to the risks faced by the Company.

57

In the normal course of operations, the Company is exposed to various risks such as interest rate, foreign exchange, commodity, credit, and liquidity. To manage these risks, management determines what activities must be undertaken to minimize potential exposure to risks. The objectives of the Company in managing risks are as follows:

● Maintaining sound financial condition;

● Financing operations; and

● Ensuring liquidity to all operations.

In order to satisfy these objectives, the Company has adopted the following policies:

● Recognize and observe the extent of operating risk within the business; and

● Identify the magnitude of the impact of market risk factors on the overall risk of the business and take advantage of natural risk reductions that arise from these relationships.

There have been no changes in risks that have arisen or how the Company manages those risks during the nine months ended July 31, 2022.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not required for smaller reporting companies.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in company reports filed or submitted under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

As required by Rules 13a-15 and 15d-15 under the Exchange Act, our Chief Executive Officer and Chief Financial Officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of July 31, 2022. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were not effective as of July 31, 2022.

The ineffectiveness of our disclosure controls and procedures was due to material weaknesses, which we identified, in our report on internal control over financial reporting.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

The Company expects to implement changes to its internal control over financial reporting to enhance the evaluation of accounting transactions and its financial reporting process over the next year. The Company is in the process of hiring additional resources, either in the form of an independent counsel or as consultants, to help identify processes that will strengthen our internal controls.

58

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Except as set forth below, there are no actual or to our knowledge contemplated legal proceedings material to us or to which any of our or any of our subsidiaries’ property is the subject matter.

As of the date of this Quarterly Report on Form 10-Q, to our knowledge, there are no legal proceedings or regulatory actions material to us to which we are a party, or have been a party to, or of which any of our property is or was the subject matter of, and no such proceedings or actions are known by us to be contemplated except as provided below:

James Sever Claim. On September 29, 2020, James Sever filed a Notice of Civil Claim against us in the Supreme Court of British Columbia (Court File No. S-209728) (the “Sever Claim”). The Sever Claim alleges that Mr. Sever had an employment and/or other similar contractual relationship with us, and that we breached such contractual relationship by way of constructive dismissal or similar conduct. The Sever Claim seeks damages in excess of $2,500,000, certain equity compensation, prejudgment garnishment, costs, interest and other non-monetary relief. On July 27, 2021, we filed a response to the Sever Claim. On April 5, 2022, we filed an amended response to the Sever Claim, which included the following pleadings: (a) British Columbia is an inappropriate and inconvenient forum for the Sever Claim; (b) to the extent that British Columbia is the appropriate forum for the Sever Claim, nonetheless: (i) the Sever Claim is barred in whole or in part by applicable doctrines of delay / statute of limitations, (ii) the Company did not constructively dismiss Mr. Sever and, instead, it was Mr. Sever that abandoned, quit or resigned from his obligations to the Company, (iii) the Company has no debts, liabilities or obligations to Mr. Sever.

We intend to vigorously defend against the Sever Claim, and we believe that the Sever Claim is without merit. We cannot predict the outcome of the claim, however.

GEM Yield Bahamas Limited Arbitration. On December 31, 2020, GEM Yield Bahamas Limited (“GEM”) served us with a Notice of Intention to Arbitrate (the “New York Arbitration Notice”) before the American Arbitration Association in New York, New York (Case No. 01-21-0004-2162) (the “GEM New York Arbitration”). The New York Arbitration Notice alleges we breached a Share Subscription Agreement dated November 15, 2019 entered into between us and GEM (the “GEM Agreement”), among other things, claiming damages of $3.4 million (CAD$4.2 million). On January 19, 2021, we filed a petition in the New York Supreme Court (Index No. 650401/2021 (the “New York State Action”) to stay the GEM New York Arbitration claiming the GEM Agreement was not valid. The Court in the New York State Action ruled on March 19, 2021 that there is an arbitration clause in the GEM Agreement but it is up the arbitrator in the GEM New York Arbitration to determine if the arbitration clause is valid. Following this ruling, the New York State Action was closed. GEM filed a Statement of Claim in the GEM New York Arbitration on June 9, 2021 and on June 25, 2021, we filed a Statement of Answer denying the existence of any binding agreement between us and GEM, among other defenses. In January 2022, we filed a Modified Statement of Defense and Counterclaims. On April 8, 2022, the parties agreed to consolidate this arbitration with the GEM Montreal Arbitration. The parties then filed consolidated pleadings, and both matters will be decided via arbitration in Montreal. Furthermore, we intend to vigorously defend ourselves and believe the allegations against us in the GEM New York Arbitration lack merit. We cannot predict the outcome of this arbitration proceeding, however.

There have been no substantive motions or pleadings in the GEM New York Arbitration aside from the Statement of Claim and Statement of Answer discussed above.

59

GEM Yield Bahamas Limited and GEM Global Yield LLC SC Arbitration. On or about February 8, 2021, GEM instituted another arbitration against us before the International Centre for Dispute Resolution in Montreal Canada (Case No. 01-21-0001-1245) (the “GEM Montreal Arbitration”) and joined, GEM’s affiliate, GEM Global Yield LLC SCS (“GEM Global Yield” together with GEM, the “GEM Parties”). Similar to the allegations in the GEM New York Arbitration, the Statement of Claim filed by the GEM Parties alleges we breached a Share Subscription Agreement dated November 15, 2019 and promissory note, among other things, claiming damages of $3.9 million (CAD$4.9 million), in addition to costs and expenses stemming from our alleged failure to issue to GEM Global Yield warrants to purchase up to 33,000,000 shares of our common stock. We filed a Statement of Defense, denying the existence of any binding agreement between us and GEM, among other defenses. In January 2022, we filed an Amended Statement of Defense and Cross-claim. On April 8, 2022, the parties agreed to consolidate this arbitration with the GEM New York Arbitration. The parties then filed consolidated pleadings, and both matters will be decided via arbitration in Montreal. We intend to vigorously defend ourselves in the GEM Montreal Arbitration and believe the allegations against us in this arbitration proceeding lack merit. We cannot predict, however, the outcome of this arbitration proceeding.

There have been no substantive motions or pleadings or rulings aside from the Statement of Claim and Statement of Answer.

Lampert Advisors, LLC Claim. On April 19, 2021, Lampert Advisors, LLC (“Lampert”) filed a Verified Complaint against our wholly owned subsidiary Western Magnesium Corporation, a Nevada corporation (“Western Magnesium – Nevada”) in the Supreme Court of the State of New York, County of New York (Index No. 652738/2021) (the “Lampert Lawsuit”). The complaint filed in the Lampert Lawsuit alleges that Lampert entered into an agreement with Western Magnesium – Nevada to provide various financial advisory services including acquisition advisory services and act as an exclusive placement agent for a debt and equity securities (the “Lampert Agreement”), that it performed all services required under that agreement and such services were received and accepted by our subsidiary, that it is owed $367,227.32 plus interest at the rate of 9% from February 3, 2021 and that it has a right of first refusal to act as financial advisor in connection with any debt, equity or debt restructuring assignments on terms, conditions and compensation customary for Lampert for a transaction of the type contemplated. Although Lampert claims to have personally served Western Magnesium – Nevada, the company never received the Summons and Complaint and therefore, never submitted a response.

On September 9, 2021, Lampert filed a Motion seeking the entry of a default judgment (the “Motion”) alleging that Western Magnesium – Nevada failed to file an answer or motion with respect to the complaint in this lawsuit within the time period provided under the civil rules of procedure. We opposed Lampert’s motion for entry of a default judgment and filed a cross-motion to compel Lampert to accept our answer. The Court granted our cross-motion seeking to compel Lampert to accept our answer and denied Lampert’s Motion seeking the entry of a default judgment as moot. On March 4, 2022, the Company filed a Verified Amended Answer, Affirmative Defenses, and Counterclaims. The counterclaims seek at least $120,000 in damages from Lampert.

We intend to vigorously defend ourselves and believe the allegations against us in the Lampert Lawsuit lack merit. We cannot predict the outcome of this lawsuit, however.

Litigation Assessment

We have evaluated the foregoing claims to assess the likelihood of any unfavorable outcome and to estimate, if possible, the amount of potential loss as it relates to the litigation discussed above. Based on this assessment and estimate, which includes an understanding of our intention to vigorously defend the claims against us, we believe that the claims of any of the plaintiffs lack merit, however, and we cannot predict the likelihood of any recoveries by any of the plaintiffs against us. This assessment and estimate is based on the information available to management as of the date of this Quarterly Report on Form 10-Q and involves a significant amount of management judgment, including the inherent difficulty associated with assessing litigation matters in their early stages. As a result, the actual outcome or loss may differ materially from those envisioned by the current assessment and estimate. Our failure to successfully defend or settle these claims could have a material adverse effect on our financial condition, revenue and profitability and could cause the market value of our common stock to decline.

60

ITEM 1A. RISK FACTORS

There have been no material changes to the risk factors disclosed in the 2021 Form 10-K.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

The following information represents securities sold by us during the quarter ended July 31, 2022 which were not registered under the Securities Act. Included are new issues, securities issued in exchange for property, services or other securities, securities issued upon conversion from our other share classes and new securities resulting from the modification of outstanding securities. We sold all of the securities listed below pursuant to the exemption from registration provided by Section 4(a)(2) of the Securities Act, or Regulation D or Regulation S promulgated thereunder and Section 3(a)(10) of the Securities Act.

Common Stock

On May 9, 2022, in connection with a non-brokered private placement, 1,727,000 units were issued to private investors at a price of $0.25 per share for gross proceeds of $431,750. Each unit consists of one common share and one common share purchase warrant exercisable into one common share at a price of $0.45 per share for a period of one year.

On June 3, 2022, in connection with a non-brokered private placement, 740,000 units were issued to private investors at a price of $0.55 per share for gross proceeds of $185,000. Each unit consists of one common share and one common share purchase warrant exercisable into one common share at a price of $0.45 per share for a period of one year.

On June 8, 2022, in connection with a partial conversion of the June 2021 Convertible Debenture, we issued 1,000,000 units to a private investor for a total of 1,000,000 common shares, 500,000 Class A Warrants exercisable at a price of $0.13 until June 10, 2026, and 500,000 Class B Warrants exercisable at a price of $0.19 until June 10, 2026. On July 12, 2022, the Form S-1 Registration Statement we filed with the SEC was declared effective, effectively covering the resale of the above shares and warrants issued in connection with the conversion of the June 2021 Convertible Debenture.

During the three months ended July 31, 2022, upon the exercise of common share purchase warrants, we issued an aggregate 8,131,975 common shares at a price of CA$0.19 per share for gross proceeds of $1,205,077 (CA$1,545,075) and 800,000 common shares at a price of CA$0.05 per share for gross proceeds of $31,051 (CA$40,000). A total of 17,414,239 warrants and 13,725 broker warrants expired unexercised.

During the three months ended July 31, 2022, upon the exercise of stock options, we issued an aggregate 250,000 common shares at a price of CA$0.13 per share for gross proceeds of $25,340 (CA$32,500), 150,000 common shares at a price of CA$0.12 per share for gross proceeds of $13,853 (CA$18,000) and 600,000 common shares at a price of CA$0.05 per share for gross proceeds of $23,272 (CA$30,000), and reclassified $48,060 from additional paid-in capital to share capital.

61

Debt Securities

Not applicable.

Other Issuances

Not applicable.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

Not applicable.

ITEM 6. EXHIBITS

Furnish the exhibits required by Item 601 of Regulation S-K (§ 229.601 of this chapter).

Exhibit Number	Description
31.1*	Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*	Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*	Inline XBRL Instance Document
101.SCH*	Inline XBRL Taxonomy Extension Schema Document
101.CAL*	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*	Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Filed herewith.

62

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	WESTERN MAGNESIUM CORPORATION
Date: October 31, 2022	By:	/s/ Sam Ataya
		Sam Ataya
		Chief Executive Officer (Principal Executive Officer)
Date: October 31, 2022	By:	/s/ Stephen Thorlakson
		Stephen Thorlakson
		Chief Financial Officer (Principal Financial and Accounting Officer)

63

EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Sam Ataya, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended July 31, 2022 of Western Magnesium Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statement made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) [omitted];

(c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

Date: October 31, 2022

/s/ Sam Ataya

Sam Ataya

Chief Executive Officer

(Principal Executive Officer)

EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Stephen Thorlakson, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended July 31, 2022 of Western Magnesium Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statement made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) [omitted];

(c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

Date: October 31, 2022

/s/ Stephen Thorlakson

Stephen Thorlakson

Chief Financial Officer

(Principal Financial and Accounting Officer)

EX-32.1

Exhibit 32.1

Certification of Periodic Financial Report

Pursuant to 18 U.S.C. Section 1350

as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Each of the undersigned officers of Western Magnesium Corporation (the “Company”) certifies, to his or her knowledge and solely for the purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of the Company for the quarter ended July 31, 2022 complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: October 31, 2022

/s/ Sam Ataya

Sam Ataya

Chief Executive Officer
(Principal Executive Officer)

Dated: October 31, 2022

/s/ Stephen Thorlakson

Stephen Thorlakson

Chief Financial Officer
(Principal Financial and Accounting Officer)

XML

Cover - shares	9 Months Ended
	Jul. 31, 2022	Sep. 06, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jul. 31, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--10-31
Entity File Number	000-56323
Entity Registrant Name	WESTERN MAGNESIUM CORPORATION
Entity Central Index Key	0001801762
Entity Tax Identification Number	61-1934413
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	8180 Greensboro Drive
Entity Address, Address Line Two	Suite 720
Entity Address, City or Town	McLean
Entity Address, State or Province	VA
Entity Address, Postal Zip Code	22102
City Area Code	(571)
Local Phone Number	378-0762
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		450,265,776

XML

Condensed Consolidated Balance Sheets - USD ($)	Jul. 31, 2022	Oct. 31, 2021
Current assets
Cash	$ 16,700	$ 462,360
Other receivables	94,696	151,485
Prepayments	337,525	133,647
Deposits held by related parties	349,338	486,462
Total Current assets	798,259	1,233,954
Non-current assets
Property, plant and equipment, net	4,488,001	2,574,704
Right-of-use assets, net	405,321	598,575
Mineral property costs	93,453	93,453
Reclamation and other deposits	12,729	12,826
TOTAL ASSETS	5,797,763	4,513,512
Current liabilities
Accounts payable and accrued liabilities	3,434,539	1,989,316
Due to related parties	1,520,834	1,026,817
Lease obligations – current	259,936	192,045
Provision for flow through share issuances	225,284	233,285
Convertible debenture, net	1,942,838	7,449,807
Warrant liability	57,080
Total Current liabilities	7,440,511	10,891,270
Non-current liabilities
Lease obligations – non-current	195,813	392,280
Total liabilities	7,636,324	11,283,550
Commitments and contingencies [note 9]
Shareholders’ deficit
Capital stock Authorized: 1 billion common stock at par value of $0.001 Issued and paid: 449,265,776 (2021 – 392,943,398	41,811,321	29,842,167
Additional paid-in-capital	23,188,545	15,186,480
Obligations to issue shares		209,827
Accumulated other comprehensive income	352,345	121,109
Accumulated deficit	(67,190,772)	(52,129,621)
Total shareholders’ deficit	(1,838,561)	(6,770,038)
TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT	$ 5,797,763	$ 4,513,512

XML

Condensed Consolidated Balance Sheets (Parenthetical)	Jul. 31, 2022 $ / shares shares	Oct. 31, 2021 $ / shares shares
Statement of Financial Position [Abstract]
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, par value | (per share)	$ 0.001	$ 0.001
Common stock, shares issued	449,265,776	392,943,398
Common stock, shares outstanding	449,265,776	392,943,398

XML

Condensed Consolidated Statements of Loss and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Jul. 31, 2022	Jul. 31, 2021	Jul. 31, 2022	Jul. 31, 2021
Operating expenses
Bank charges	$ 3,792	$ 4,890	$ 12,444	$ 11,044
Business development	66,883		144,212
Computer system and software	23,766	11,854	63,120	83,639
Consulting and management fees	181,193	274,094	594,829	613,048
Depreciation	193,926	62,781	436,253	159,774
Due diligence expenses		2,010		3,974
Engineering expenses	101,617	17,295	218,425	72,749
Foreign exchange loss (gain)	30,282	(35,499)	256,417	(121,726)
Interest and accretion	372,295	28,242	1,021,443	64,576
Investor relations	12,872	131,739	228,706	202,675
Legal and professional fees	320,665	257,648	1,897,719	545,234
Office and general	266,407	23,794	343,765	83,405
Property maintenance fees	15,100	15,069	15,100	15,069
Rent and facilities	119,625	68,635	295,746	153,910
Salaries and benefits	1,151,045	809,253	3,347,884	2,176,185
Stock-based compensation	32,539	1,057,013	466,368	1,057,013
Shareholder communications	7,500	(36,722)	48,201	49,512
Subsidies and recoveries	223	(477)	(78,996)	(41,724)
Transfer agent and regulatory fees	95,618	37,508	184,355	61,138
Travel expenses	137,548	107,546	359,491	218,222
Total operating expenses	3,132,896	2,836,673	9,855,482	5,407,717
Other income (expense)
Change in fair value of derivative liability		(806,853)	359,643	(790,197)
Loss on recognition of debt host liability		(140,909)	(341,553)	(140,909)
Change in fair value of warrant liability	1,837,031		(5,223,759)
Total other income (expense)	1,837,031	(947,762)	(5,205,669)	(931,106)
Net loss	(1,295,865)	(3,784,435)	(15,061,151)	(6,338,823)
Other comprehensive income (loss)
Foreign currency translation	17,273	16,068	231,236	(174,981)
Comprehensive loss	$ (1,278,592)	$ (3,768,367)	$ (14,829,915)	$ (6,513,804)
Basic and diluted loss per common share	$ (0.00)	$ (0.01)	$ (0.03)	$ (0.02)
Weighted average number of common shares outstanding – basic and diluted	444,004,303	365,235,017	494,284,490	340,461,383

XML

Condensed Consolidated Statements of Shareholders' Deficit - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Obligation to Issue Shares [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Oct. 31, 2020	$ 21,322,022	$ 4,182,037	$ 596,872	$ 399,175	$ (28,580,009)	$ (2,079,903)
Beginning balance, shares at Oct. 31, 2020	323,419,527
Shares issued pursuant to private placements [note 14[b]]	$ 5,754,705		(596,872)			5,157,833
Shares issued pursuant to private placements, shares	53,151,881
Shares issued on warrants exercised [notes 13 and 14[b]]	$ 33,131	(4,291)				28,840
Shares issued on warrants exercised, shares	524,901
Shares issued on options exercised [note 14[b]]	$ 36,150	(23,879)				12,271
Shares issued on options exercised, shares	300,000
Shares issued upon conversion of convertible debenture [notes 12[b], 12[c] and 14[b]]	$ 162,829					162,829
Shares issued upon conversion of convertible debenture, shares	1,360,959
Shares issued for equipment [note 14[b]]	$ 305,832					305,832
Shares issued for equipment, shares	1,538,461
Share issue costs [note 14[b]]	$ (573,289)					(573,289)
Stock-based compensation [note 14[d]]		1,057,013				1,057,013
Foreign currency translation				(174,981)		(174,981)
Net loss					(6,338,823)	(6,338,823)
Ending balance, value at Jul. 31, 2021	$ 27,041,380	5,210,880		224,194	(34,918,832)	(2,442,378)
Ending balance, shares at Jul. 31, 2021	380,295,729
Beginning balance, value at Oct. 31, 2021	$ 29,842,167	15,186,480	209,827	121,109	(52,129,621)	(6,770,038)
Beginning balance, shares at Oct. 31, 2021	392,943,398
Shares issued pursuant to private placements [note 14[b]]	$ 1,373,274		(598,528)			774,746
Shares issued pursuant to private placements, shares	3,842,499
Shares issued on warrants exercised [notes 13 and 14[b]]	$ 9,604,902					9,604,902
Shares issued on warrants exercised, shares	32,633,121
Shares issued on options exercised [note 14[b]]	$ 162,443	(70,263)				92,180
Shares issued on options exercised, shares	1,750,000
Shares issued upon conversion of convertible debenture [notes 12[b], 12[c] and 14[b]]	$ 888,178					888,178
Shares issued upon conversion of convertible debenture, shares	8,933,333
Share issue costs [note 14[b]]	$ (59,643)					(59,643)
Stock-based compensation [note 14[d]]		466,368				466,368
Foreign currency translation				231,236		231,236
Net loss					(15,061,151)	(15,061,151)
Shares issued for finder’s fees [notes 8[d][v] and 14[b]]
Shares issued for finder's fees, shares	9,163,425
Beneficial conversion feature on convertible debentures [note 12[d]]		240,000				240,000
Effects of change in functional currency on convertible debentures [note 12[e]]		7,370,158				7,370,158
Effects of change in functional currency on broker warrants [note 13]		(4,198)				(4,198)
Share subscriptions [note 14[f]]			388,701			388,701
Ending balance, value at Jul. 31, 2022	$ 41,811,321	$ 23,188,545		$ 352,345	$ (67,190,772)	$ (1,838,561)
Ending balance, shares at Jul. 31, 2022	449,265,776

XML

Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Jul. 31, 2022	Jul. 31, 2021	Jul. 31, 2022	Jul. 31, 2021	Oct. 31, 2021
OPERATING ACTIVITIES
Net loss	$ (1,295,865)	$ (3,784,435)	$ (15,061,151)	$ (6,338,823)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of derivative liability		806,853	(359,643)	790,197
Loss on recognition of debt host liability		140,909	341,553	140,909
Change in fair value of warrant liability	(1,837,031)		5,223,759
Cashless warrant exercise			(113,765)
Accrued interest and accretion			196,115	32,124
Amortization of debt discount			814,729
Depreciation of property, plant and equipment			258,515	22,355
Depreciation of right-of-use assets			177,738	137,419
Foreign exchange loss (gain)			23,535	(27,812)
Interest expense on lease obligations			25,905	16,946
Shares issued for equipment				165,659
Stock-based compensation	32,539	1,057,013	466,368	1,057,013
Changes in operating assets and liabilities:
Other receivables			51,963	(118,276)
Prepayments			(209,967)	(32,436)
Deposits held by related parties			121,301	(653,915)
Accounts payable and accrued liabilities			1,524,962	877,574
Due to related parties			532,489	(85,623)
Cash used in operating activities			(5,985,595)	(4,016,689)
INVESTING ACTIVITIES
Purchase of property, plant and equipment			(2,252,600)	(1,779,316)
Cash used in investing activities			(2,252,600)	(1,779,316)
FINANCING ACTIVITIES
Proceeds from issuance of shares, net of share issuance costs			5,943,775	4,773,200
Proceeds from convertible debenture			2,000,000	1,579,475
Payments of promissory note				(65,745)
Payments of lease obligations			(143,672)	(153,145)
Cash provided by financing activities			7,800,103	6,133,785
Change in cash for the period			(438,092)	337,780
Cash, beginning of the period			462,360	39,571	$ 39,571
Effect of foreign exchange on cash			(7,568)	5,892
Cash, end of the period	$ 16,700	$ 383,243	16,700	383,243	$ 462,360
Other non-cash transactions:
Shares issued for conversion of debt and interest			888,178
Shares issued for payment of finder’s fees			4,796,832
Other cash flow disclosures:
Cash paid during the period for interest			$ 10,581

XML

NATURE OF OPERATIONS AND GOING CONCERN

9 Months Ended

Jul. 31, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

NATURE OF OPERATIONS AND GOING CONCERN

1. NATURE OF OPERATIONS AND GOING CONCERN

Western Magnesium Corporation (the “Company”, or “WMC”) was incorporated under the laws of British Columbia on March 24, 1966. On May 14, 2019, the Company discontinued from the jurisdiction of the Business Corporations Act (British Columbia) and domesticated under the General Corporation Law of the State of Delaware under the name “Western Magnesium Corporation”. The Company is a reporting issuer in Canada and in the United States, listed for trading in Canada on the TSX Venture Exchange (the “TSX-V”) under the symbol “WMG.V”, in the United States on the OTCQB tier of the OTC Markets (the “OTCQB”) under the symbol “MLYF”, and in Germany on the Frankfurt Stock Exchange under the symbol “3WM”. The Company has developed proprietary magnesium production technology with the aim of becoming a premier low-cost producer of green primary magnesium metal.

As at July 31, 2022, the Company had an accumulated deficit of $67,190,772 (October 31, 2021 – $52,129,621) and working capital deficiency of $6,642,252 (October 31, 2021 – $9,657,316). For the nine months ended July 31, 2022, the Company reported a comprehensive loss of $14,829,915 (2021 – $6,513,804). The Company has not yet achieved profitable operations and expects to incur further losses from operations. The Company has financed its activities and operations through equity issuances and debt financing and expects to continue to do so to the extent such financing is available. There can be no assurance that such financing will be available under terms acceptable to the Company or at all.

These unaudited condensed consolidated financial statements (the “Financial Statements”) have been prepared under the assumption that the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will be able to meet its obligations and continue its operations for the foreseeable future and be able to realize its assets and discharge its liabilities and commitments in the normal course of business. If future financing through share or debt issuances is unavailable or if for any reason the Company is unable to continue as a going concern, it could impact the Company’s ability to realize its assets at their recognized values and to meet its obligations in the ordinary course of business at the amounts stated in these Financial Statements. These Financial Statements do not give effect to adjustments that would be necessary to the carrying values and classifications of assets and liabilities should the Company be unable to continue as a going concern. If the going concern assumption is not used, the adjustments required to report the Company’s assets and liabilities on a liquidation basis could be material to these Financial Statements.

The Company’s management has evaluated whether there is substantial doubt about the Company’s ability to continue as a going concern and has determined that substantial doubt existed as of July 31, 2022. This determination was based on the following factors: (i) the Company used cash of approximately $6 million in operations during the nine months ended July 31, 2022; (ii) the Company’s available cash as of July 31, 2022 will not be sufficient to fund its anticipated level of operations for the next 12 months; (iii) the Company will require additional financing for the fiscal year ending October 31, 2022 to continue at its expected level of operations; and (iv) if the Company fails to obtain the needed capital, it will be forced to delay, scale back, or eliminate some or all of its development activities or perhaps cease operations. In the opinion of management, these factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for at least one year from the date of these Financial Statements are issued.

In March 2020, the World Health Organization declared COVID-19 a global pandemic. In order to combat the spread of COVID-19, governments worldwide, including the Unites States and Canada, have enacted emergency measures including travel bans, legally enforced or self-imposed quarantine periods, social distancing and business and organization closures. These measures have adversely affected workforces, economies, and financial markets globally, leading to an economic downturn. The impact on the Company has not been significant but could affect the Company’s ability to raise financings in the future and restrict travel. Management continues to monitor the situation.

XML

BASIS OF PRESENTATION

9 Months Ended

Jul. 31, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

BASIS OF PRESENTATION

2. BASIS OF PRESENTATION

These Financial Statements comprise the financial statements of Western Magnesium Corporation and its wholly owned subsidiaries, Western Magnesium Corp., incorporated in Nevada, United States and Western Magnesium Canada Corporation, incorporated in British Columbia, Canada.

[a] Accounting standards

The accompanying Financial Statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) on the basis that the Company will continue as a going concern, which assumes that the Company will be able to meet its obligations as they become due and continue its operations for at least one year from the date these Financial Statements are issued. Realization values may be substantially different from carrying values as shown and these Financial Statements do not give effect to adjustments that would be necessary to the carrying values and classification of assets and liabilities should the Company be unable to continue as a going concern.

These Financial Statements have been prepared on a historical cost basis except for financial instruments that have been measured at fair value. In addition, these Financial Statements have been prepared using the accrual basis of accounting, except for cash flow information. They do not include all the information required for complete annual financial statements and should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended October 31, 2021 (the “Fiscal 2021 Financial Statements”).

[b] Functional and presentation currency

These Financial Statements are presented in United States dollars (“US dollars” or “US$”), except where otherwise indicated. The functional currency of each entity of the Company is as follows:

Entity	Functional Currency
Western Magnesium Corporation	United States dollars
Western Magnesium Corp.	United States dollars
Western Magnesium Canada Corporation	Canadian dollars (“CA$”)

During the three months ended January 31, 2022, significant changes in economic facts and circumstances have occurred in Western Magnesium Corporation’s operations which resulted in the change of its functional currency to the United States dollar from the Canadian dollar effective November 1, 2021. For both monetary and non-monetary assets and liabilities, translated balances at the end of the prior period became the new accounting basis. The rate on the date of change became the historical rate at which non-monetary assets and liabilities were translated in subsequent years. There was no effect on the cumulative translation adjustment on the consolidated basis. Previously recorded cumulative translation adjustments were not reversed. Effects of change in functional currency included the reclassifications of convertible debentures and warrants and broker warrants [notes 12[d] and [e]].

The accounts of the Company’s subsidiary Western Magnesium Canada Corporation have been translated to United States dollars with the exchange translation adjustments recorded in other comprehensive income (loss).

[c] Critical accounting estimates and judgments

The preparation of these Financial Statements in accordance with US GAAP requires the Company to make estimates and assumptions concerning the future that affect the amounts reported in the Financial Statements and accompanying notes. Management reviews these estimates and underlying assumptions on an ongoing basis, based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are adjusted for prospectively in the period in which the estimates are revised.

Estimates and assumptions where there is potential risk of material adjustments to assets and liabilities in future accounting periods include the useful lives of property, plant and equipment, recoverability of the carrying value of exploration and evaluation assets, fair value measurements for financial instruments, discount rates for leases, recoverability and measurement of deferred tax assets and liabilities, and contingent liabilities.

Significant Judgments

The preparation of these Financial Statements in accordance with US GAAP requires the Company to make judgments, apart from those involving estimates, in applying accounting policies. The most significant judgments in applying the Company’s Financial Statements include:

- the assessment of the Company’s ability to continue as a going concern and whether there are events or conditions that may give rise to substantial doubt;

- whether there are indicators of impairment of the Company’s exploration and evaluation assets and other non-current assets;

- the classification of financial instruments; and

- determination of functional currency.

XML

RECENT ACCOUNTING PRONOUNCEMENTS

9 Months Ended

Jul. 31, 2022

Accounting Changes and Error Corrections [Abstract]

RECENT ACCOUNTING PRONOUNCEMENTS

3. RECENT ACCOUNTING PRONOUNCEMENTS

New Accounting Standards Adopted During the Periods

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years, with early adoption permitted. Effective November 1, 2021, the Company adopted the new standard. There was no material impact or adjustment to these Financial Statements.

In January 2020, the FASB issued ASU 2020-01, Investments – Equity Securities (Topic 321), Investments – Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) (“ASU 2020-01”), which is intended to clarify the interactions of the accounting for equity securities under Topic 321 and investments accounted for under the equity method of accounting in Topic 323 and the accounting for certain forward contracts and purchased options accounted for under Topic 815. ASU 2020-01 is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years, with early adoption permitted. Effective November 1, 2021, the Company adopted the new standard. There was no material impact or adjustment to these Financial Statements.

New Accounting Standards Not Yet Adopted

In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”). ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments and supersedes the respective guidance within ASC 470-20 and ASC 740-10-55-51, which will result in more instruments to be accounted for as a single instrument rather than having their proceeds allocated between liability and equity accounting units. As smaller reporting companies as defined by the United States Securities and Exchange Commission (the “SEC”), ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the effect this standard will have on its Financial Statements.

XML

PROPERTY, PLANT AND EQUIPMENT

9 Months Ended

Jul. 31, 2022

Property, Plant and Equipment [Abstract]

PROPERTY, PLANT AND EQUIPMENT

4. PROPERTY, PLANT AND EQUIPMENT

	Computer Equipment		Furniture			Leasehold Improvement			Furnace & Plant Equipment			Vehicle			Total
	$		$			$			$			$			$
Cost
Balance, October 31, 2021		109,629		53,542			139,481			2,344,726			–			2,647,378
Additions		14,370		2,171			159,065			2,047,779			29,215			2,252,600
Foreign exchange effect		10		(314	)		(5,708	)		(76,255	)		(374	)		(82,641	)
Balance, July 31, 2022		124,009		55,399			292,838			4,316,250			28,841			4,817,337
Accumulated Depreciation
Balance, October 31, 2021		27,821		16,514			14,147			14,192			–			72,674
Depreciation expense		28,402		5,777			81,553			137,294			5,084			258,515
Foreign exchange effect		403		(52	)		(856	)		(906	)		(37	)		(1,853	)
Balance, July 31, 2022		56,626		22,239			94,844			150,580			5,047			329,336
Net Book Value
Balance, October 31, 2021		81,808		37,028			125,334			2,330,534			–			2,574,704
Balance, July 31, 2022		67,383		33,160			197,994			4,165,670			23,794			4,488,001

XML

RIGHT-OF-USE ASSETS

9 Months Ended

Jul. 31, 2022

Right-of-use Assets

RIGHT-OF-USE ASSETS

5. RIGHT-OF-USE ASSETS

As at July 31, 2022, the right-of-use assets were leases for the Company’s offices in Vancouver, British Columbia and McLean, Virginia, and its research and development pilot plant located in Burnaby, British Columbia. These leases terminate on March 31, 2023, February 28, 2025 and September 30, 2023, respectively. The lease for the Company’s office in Las Vegas, Nevada ended on May 31, 2021.

	Vancouver Office		Virginia Office			Nevada Office		Pilot Plant			Total
	$		$			$		$			$
Cost
Balance, October 31, 2021		156,881		292,391			24,580		384,946			858,798
Foreign exchange effect		–		(3,038	)		–		(13,208	)		(16,246	)
Balance, July 31, 2022		156,881		289,353			24,580		371,738			842,552
Accumulated Depreciation
Balance, October 31, 2021		90,277		15,529			24,580		129,837			260,223
Depreciation expense		33,456		50,562			–		93,720			177,738
Prepaid expense		–		4,557			–		–			4,557
Foreign exchange effect		–		(162	)		–		(5,125	)		(5,287	)
Balance, July 31, 2022		123,733		70,486			24,580		218,432			437,231
Net Book Value
Balance, October 31, 2021		66,604		276,862			–		255,109			598,575
Balance, July 31, 2022		33,148		218,867			–		153,306			405,321

XML

LEASE OBLIGATIONS

9 Months Ended

Jul. 31, 2022

Lease Obligations

LEASE OBLIGATIONS

6. LEASE OBLIGATIONS

On adoption of ASU 2016-02 on November 1, 2019, the Company recognized lease liabilities of $83,549 which had previously been classified as operating leases. The lease liabilities were measured at the present value of the remaining lease payments and discounted using the lessee’s incremental borrowing rate of approximately 7%.

During the year ended October 31, 2020, the Company entered into a new operating lease with respect to its research and development pilot plant located in Burnaby, British Columbia and recognized a lease liability of $354,263, which was measured by discounting lease payments using an incremental borrowing rate of approximately 6%.

During the year ended October 31, 2021, the Company renewed its operating lease with respect to its office in Vancouver, British Columbia and recognized a lease liability of $91,237, which was measured by discounting lease payments using an incremental borrowing rate of approximately 7%.

During the year ended October 31, 2021, the Company entered into a new operating lease with respect to its corporate head office in McLean, Virginia and recognized a lease liability of $260,649, which was measured by discounting lease payments using an incremental borrowing rate of approximately 7%.

	Vancouver Office			Virginia Office			Nevada Office		Pilot Plant			Total
	$			$			$		$			$
Balance, October 31, 2021		66,604			262,612			–		255,109			584,325
Lease payments		(36,087	)		(4,557	)		–		(103,028	)		(143,672	)
Interest expense		2,631			13,967			–		9,307			25,905
Foreign exchange effect		–			(2,728	)		–		(8,081	)		(10,089	)
Balance, July 31, 2022		33,148			269,294			–		153,307			455,749
Which consist of:
Current lease obligation		33,148			96,043			–		130,745			259,936
Non-current lease obligation		–			173,251			–		22,562			195,813
Balance, July 31, 2022		33,148			269,294			–		153,307			455,749

XML

MINERAL PROPERTY COSTS

9 Months Ended

Jul. 31, 2022

Extractive Industries [Abstract]

MINERAL PROPERTY COSTS

7. MINERAL PROPERTY COSTS

As at July 31, 2022, the Company had the following mining claims:

[a] Silverado Property, Nevada, United States

The Silverado property is located in the Pinto mining district of Nevada, consists of 3 patented mining claims totaling approximately 120 hectares, and is 100% owned by the Company. The carrying value of the property is $1.

[b] Tami Mosi Property, Nevada, United States

The Company holds a 100% interest in 81 unpatented lode mining claims totaling approximately 1,637 acres located in White Pine County, Nevada and four unpatented lode mining claims totaling approximately 10 acres located in the Moor Mining District, Elko County, Nevada. These mining claims are subject to a 2% net smelter royalty in favor of the prior owner of the claims. The carrying value of the property is $93,452.

XML

RELATED PARTY TRANSACTIONS

9 Months Ended

Jul. 31, 2022

Related Party Transactions [Abstract]

RELATED PARTY TRANSACTIONS

8. RELATED PARTY TRANSACTIONS

[a] Deposits held by related parties

Pursuant to vendor agreements entered on January 1, 2021, the Company provided related parties with advances that were held as deposits for anticipated future costs related to the Company’s planned magnesium research and development pilot plant and other administrative expenses (the “Pilot Plant Advances”). As at July 31, 2022, the Company had the following deposits held by related parties:

	Related Party A [i]			Related Party B [ii]			Total
	$			$			$
Balance, October 31, 2021		291,481			194,981			486,462
Advances		354,459			1,225,118			1,579,577
Costs and expenses		(312,820	)		(1,420,829	)		(1,733,649	)
Foreign exchange effect		16,218			730			16,948
Balance, July 31, 2022		349,338			–			349,338

[i] Related Party A is a company controlled by a director and officer.

[ii] Related Party B is a company controlled by an officer.

[b] Due to related parties

As at July 31, 2022, balances due to related parties totaled $1,520,834 (October 31, 2021 – $1,026,817). All advances are unsecured, non-interest bearing, and have no stated terms of repayment.

	July 31, 2022		October 31, 2021
	$		$
Wages payable to directors and officers		505,544		357,500
Benefits payable to directors and officers		725,261		539,209
Fees and expenses payable to directors and officers		290,029		127,878
Interest due to a shareholder		–		2,230
Total		1,520,834		1,026,817

[c] Key management compensation

As at July 31, 2022, the Company had eleven executives including nine senior management members. Their aggregate annualized compensation is approximately $3.3 million. During the nine months ended July 31, 2022, the Company incurred salaries, benefits, and consulting fees totaling $2,605,352 to directors and officers, and stock-based compensation of $160,700 for options granted to an officer of the Company.

[d] Transactions with related parties

[i] During the nine months ended July 31, 2022, the Company incurred consulting fees of $27,489 (CA$35,000) to a former member of senior management.

[ii] During the nine months ended July 31, 2022, the Company incurred consulting fees of $60,000 to a company controlled by an executive.

[iii] During the nine months ended July 31, 2022, the Company incurred consulting fees of $29,600 to a company controlled by an executive.

[iv] In June 2021, the Company renewed its sublease agreement with a company controlled by a director and officer for its office in Vancouver, British Columbia with a lease term from April 1, 2021 to March 31, 2023 at a monthly rent of $7,656 (CA$9,794).

[v] Pursuant to an agreement entered on August 29, 2018 and which was approved by the TSX-V on September 12, 2018, a company controlled by a director and officer is eligible to receive up to 5% of the issued and outstanding common shares of the Company as at August 28, 2018 for up to $5 million raised. The agreement was amended on January 2, 2019, extending the term from six months to three years and six months. During the year ended October 31, 2021, the commitment was met. On November 3, 2021, the Company issued 9,163,425 common shares at a price of CA$0.65 per share with a total fair value of $4,796,832 (CA$5,956,226) as share issue costs.

XML

CONTINGENT LIABILITIES AND COMMITMENTS

9 Months Ended

Jul. 31, 2022

Commitments and Contingencies Disclosure [Abstract]

CONTINGENT LIABILITIES AND COMMITMENTS

9. CONTINGENT LIABILITIES AND COMMITMENTS

[a] Contingent liabilities

[i] On September 29, 2020, James Sever filed a Notice of Civil Claim against the Company in the Supreme Court of British Columbia (the “Sever Claim”). The Sever Claim alleges that Mr. Sever had an employment and/or other similar contractual relationship with the Company, and that the Company breached such contractual relationship by way of constructive dismissal or similar conduct. The Sever Claim seeks damages in excess of $2.5 million, certain equity compensation, prejudgment garnishment, costs, interest and other non-monetary relief. On July 27, 2021, the Company filed a response to the Sever Claim. On April 5, 2022, the Company filed an amended response to the Sever Claim, which included the following pleadings: (a) British Columbia is an inappropriate and inconvenient forum for the Sever Claim; (b) to the extent that British Columbia is the appropriate forum for the Sever Claim, nonetheless: (i) the Sever Claim is barred in whole or in part by applicable doctrines of delay / statute of limitations, (ii) the Company did not constructively dismiss Mr. Sever and, instead, it was Mr. Sever that abandoned, quit or resigned from his obligations to the Company, (iii) the Company has no debts, liabilities or obligations to Mr. Sever. The Company intends to vigorously defend against the Sever Claim, and believes that the Sever Claim is without merit. As the Company cannot predict the outcome of the Sever Claim, no provision has been recognized as there is no present obligation and the probability of an outcome cannot be determined.

[ii] On December 31, 2020, GEM Yield Bahamas Limited (“GEM”) served the Company with a Notice of Intention to Arbitrate (the “New York Arbitration Notice”) before the American Arbitration Association in New York (the “GEM New York Arbitration”). The New York Arbitration Notice alleges the Company breached a Share Subscription Agreement dated November 15, 2019 entered into between the Company and GEM (the “GEM Agreement”), among other things, claiming damages of approximately $3.4 million (CA$4.2 million). On January 19, 2021, the Company filed a petition in the New York Supreme Court to stay the GEM New York Arbitration claiming the GEM Agreement was not valid. On March 19, 2021, the Court in the New York State Action ruled that there was an arbitration clause in the GEM Agreement but it was up to the arbitrator to determine if the arbitration clause was valid. Following this ruling, the New York State Action was closed. In June 2021, GEM filed a Statement of Claim in the GEM New York Arbitration, and the Company filed a Statement of Answer denying the existence of any binding agreement between the Company and GEM, among other defenses. In January 2022, the Company filed a Modified Statement of Defense and Counterclaims. On April 8, 2022, the parties agreed to consolidate this arbitration with the GEM Montreal Arbitration. The parties then filed consolidated pleadings, and both matters will be decided via arbitration in Montreal. The Company intends to vigorously defend itself in the GEM New York Arbitration and believes the allegations lack merit. As the Company cannot predict the outcome of this arbitration proceeding, no provision has been recognized in respect to the GEM New York Arbitration as there is no present obligation and the probability of an outcome cannot be determined.

[iii] On February 8, 2021, GEM instituted another arbitration against the Company before the International Centre for Dispute Resolution in Montreal Canada (the “GEM Montreal Arbitration”) and joined GEM’s affiliate, GEM Global Yield LLC SCS (“GEM Global Yield” together with GEM, the “GEM Parties”). The Statement of Claim filed by the GEM Parties alleges the Company breached a Share Subscription Agreement dated November 15, 2019 and promissory note, among other things, claiming damages of approximately $3.9 million (CA$4.9 million), in addition to costs and expenses, stemming from the Company’s alleged failure to issue to GEM Global Yield warrants to purchase up to 33 million shares of the Company’s common stock. The Company filed a Statement of Defense denying the existence of any binding agreement between the Company and GEM, among other defenses. In January 2022, the Company filed an Amended Statement of Defense and Cross-claim. On April 8, 2022, the parties agreed to consolidate this arbitration with the GEM New York Arbitration. The parties then filed consolidated pleadings, and both matters will be decided via arbitration in Montreal. The Company intends to vigorously defend itself in the GEM Montreal Arbitration and believes the allegations lack merit. As the Company cannot predict the outcome of this arbitration proceeding, no provision has been recognized in respect to the GEM Montreal Arbitration as there is no present obligation and the probability of an outcome cannot be determined.

[iv] On April 19, 2021, Lampert Advisors, LLC (“Lampert”) filed a Verified Complaint against the Company’s wholly owned subsidiary Western Magnesium Corp., a Nevada corporation (“Western Magnesium – Nevada”) in the Supreme Court of the State of New York, County of New York (the “Lampert Lawsuit”). The complaint filed in the Lampert Lawsuit alleges that Lampert entered into an agreement with Western Magnesium – Nevada to provide various financial advisory services including acquisition advisory services and act as an exclusive placement agent for a combination of debt and equity securities (the “Lampert Agreement”), that it performed all services required under that agreement and that it is owed $367,227 plus interest at the rate of 9% from February 3, 2021 and that it has a right of first refusal to act as financial advisor in connection with any debt, equity or debt restructuring assignments on terms, conditions and compensation customary for Lampert for a transaction of the type contemplated. Although Lampert claims to have personally served Western Magnesium – Nevada, the Company never received the Summons and Complaint and therefore, never submitted a response. On September 9, 2021, Lampert filed a Motion seeking the entry of a default judgment (the “Motion”). The Company opposed the Motion and filed a cross-motion to compel Lampert to accept the Company’s answer. The Court granted the Company’s cross-motion and denied Lampert’s Motion as moot. On March 4, 2022, the Company filed a Verified Amended Answer, Affirmative Defenses, and Counterclaims. The counterclaims seek at least $120,000 in damages from Lampert. The Company intends to vigorously defend against the Lampert Lawsuit and prosecute its counterclaims, and the Company believes that the claims asserted by Lampert are without merit. As the Company cannot predict the outcome of the Lampert Lawsuit, no provision has been recognized as there is no present obligation and the probability of an outcome cannot be determined.

[b] Commitments

[i] On November 1, 2016, the Company signed a contract services agreement with Lodestar Management Group, LLC (“Lodestar”), a US corporate logistics company. Lodestar provides advisory, consulting, negotiation and other management services relating to corporate management, administrative and/or operational activities of the Company. The term of the contract was for one year and has been renewed under the same terms on January 1, 2018 and 2019. The Company has agreed to compensate Lodestar in the amount of $1,800 or CA$2,500 per month by issuance of shares up until December 2019, and by cash from January 2020 onwards. The number of shares issued will be based on the share price on the day of issuance that is not lower than the CA$0.05 per share minimum requirement and will not exceed $1,800 or CA$2,500 in value. The shares will be issued on the last working day of each month for a period of twelve months. During the nine months ended July 31, 2022, the Company did not issue any shares (2021 – nil) and paid $30,624 in cash (2021 – $16,200) to Lodestar. As at July 31, 2022, outstanding owing Lodestar were 634,072 shares and $38,593 (October 31, 2021 – $53,491).

[ii] During the year ended October 31, 2020, the Company entered into a lease agreement for its research and development pilot plant in Burnaby, British Columbia with a lease term from October 1, 2020 to September 30, 2023 at a monthly rent of $16,154 (CA$20,715). In June 2021, the Company renewed its sublease agreement with a company controlled by a director and officer for its office in Vancouver, British Columbia with a lease term from April 1, 2021 to March 31, 2023 at a monthly rent of $7,637 (CA$9,794). In September 2021, the Company entered into a lease agreement for its corporate head office in McLean, Virginia with a lease term from September 14, 2021 to February 28, 2025 at a monthly rent of $9,113. The Company was abated for the first five months and was entitled to a tenant allowance of $41,010 [notes 5 and 6].

XML

PROMISSORY NOTE

9 Months Ended

Jul. 31, 2022

Promissory Note

PROMISSORY NOTE

10. PROMISSORY NOTE

During the year ended October 31, 2019, the Company received a loan of $112,895 (CA$150,000) from a related party. The loan was unsecured, bore interest at 18% and was due on demand. During the year ended October 31, 2020, the loan was increased by an additional $44,588 (CA$60,000) to $157,483 (CA$210,000), and was due on September 24, 2021. During the year ended October 31, 2021, the Company accrued interest expense of $1,639 (2020 – $16,655) and repaid the entire balance and interest totaling $65,761 (2020 – $101,066).

XML

PROVISION FOR FLOW THROUGH SHARE ISSUANCES

9 Months Ended

Jul. 31, 2022

Provision For Flow Through Share Issuances

PROVISION FOR FLOW THROUGH SHARE ISSUANCES

11. PROVISION FOR FLOW THROUGH SHARE ISSUANCES

The Company has recorded a provision in the amount of $225,284 (October 31, 2021 – $233,285) for tax and related obligations relating to flow through share issuances from prior years. The flow through share issuances were a Canadian tax-based financing incentive and the provision was in relation to a tax liability with the Federal Government of Canada and had no statute of limitations.

XML

CONVERTIBLE DEBENTURE

9 Months Ended

Jul. 31, 2022

Debt Disclosure [Abstract]

CONVERTIBLE DEBENTURE

12. CONVERTIBLE DEBENTURE

[a] July 2020 Convertible Debenture

On July 27, 2020, the Company closed a non-brokered private placement of an unsecured convertible note in the principal amount of $112,124 (CA$150,000, the “July 2020 Convertible Debenture”). The note bears interest at 12% per annum and is due on the date that is one year following the closing date. The note is convertible into common shares of the Company at the price which is the greater of CA$0.15 per common share and the market price on the date of the conversion notice. Any accrued but unpaid interest will be payable on the earlier of the maturity date and the date of conversion in cash or common shares. No finder’s fees were paid in connection with this private placement. On May 18, 2021, the Company issued a total of 1,360,959 common shares on the conversion of the July 2020 Convertible Debenture including conversion of accrued interest, and 263,973 common shares valued at $26,286 in transaction costs. The July 2020 Convertible Debenture had an effective interest rate of 37%.

[b] July 2021 Convertible Debenture

On July 15, 2021, the Company closed a non-brokered private placement of an unsecured convertible note in the principal amount of $79,542 (CA$100,000, the “July 2021 Convertible Debenture”) which it received on April 22, 2021. The note bears interest at 12% per annum and is due on the date that is one year following the closing date. The note is convertible at a price of CA$0.12 per unit, where each unit is comprised of one common share and one common share purchase warrant exercisable at a price of CA$0.20 per common share for a period of two years. Any accrued but unpaid interest will be payable on the earlier of the maturity date and the date of conversion in cash or common shares. On April 22, 2022, the Company issued a total of 933,333 units on the conversion of the July 2021 Convertible Debenture including conversion of accrued interest. The July 2021 Convertible Debenture had an effective interest rate of 594%.

[c] June 2021 Convertible Debenture

On June 15, 2021, the Company closed a non-brokered private placement of an unsecured convertible note in the principal amount of $1,500,000 (the “June 2021 Convertible Debenture”). The note bears interest at 12% per annum and matures on December 10, 2022. The June 2021 Convertible Debenture is convertible into 15,000,000 units, where each unit consists of (i) one share of the Company’ common stock, (ii) one-half of one Class A common stock purchase warrant, with each whole warrant being exercisable at a price of $0.13 until June 10, 2026, and (iii) one-half of one Class B common stock purchase warrant, with each whole warrant being exercisable at a price of $0.19 until June 10, 2026 (collectively, the “Class A and B Warrants”). In addition, the conversion price for accrued interest is the greater of (i) $0.10 and (ii) the minimum conversion price permitted by the TSX-V at the time of conversion.

As part of the offering of the June 2021 Convertible Debenture, the Company also entered into a securities purchase agreement dated June 10, 2021 (the “2021 Securities Purchase Agreement”), whereby the Company agreed to use commercially reasonable efforts to file a registration statement with the United States Securities and Exchange Commission (the “SEC”) by August 14, 2021, covering the public resale of the shares of common stock underlying such debenture and, upon its conversion, the Class A and B Warrants issuable upon such conversion (the “Underlying Shares”), and to use its best efforts to cause the registration statement to be declared effective on October 13, 2021. On December 13, 2021, the Company’s Form 10 Registration Statement filed with the SEC was declared effective.

In addition to certain covenants contained in the 2021 Securities Purchase Agreement, the terms of the June 2021 Convertible Debenture contain certain negative covenants by the Company, including, among others, sell or offer to sell any securities with non-fixed or floating price features, issue any common stock or common stock equivalents at a price lower than the conversion price herein then in effect, or issue any equity or debt instruments with anti-dilution provisions.

In the event the Company issues or sells any common stock or common stock equivalents with terms that the purchaser holding the outstanding June 2021 Convertible Debenture or the Class A and B Warrants reasonably believes are more favorable to such holder than the terms of the June 2021 Convertible Debenture or the Class A and B Warrants, then upon notice to the Company by such holder within five trading days after notice to such holder by the Company, the Company will use commercially reasonable efforts to obtain the approval of the TSX-V and any additional required regulatory approval to amend the terms of the June 2021 Convertible Debenture or the Class A and B Warrants as required, as the case may be, so as to give such holder the benefit of such more favorable terms or conditions.

The conversion price of the June 2021 Convertible Debenture and the exercise price of the Class A and B Warrants are subject to proportional adjustment in the event of stock splits, stock dividends and similar corporate events, including merger or consolidation of the Company or in a “Fundamental Transaction” as defined in the June 2021 Convertible Debenture.

The Company has granted the holders certain rights of first refusal on its future offerings for as long as the June 2021 Convertible Debenture or the Class A and B Warrants are outstanding.

The Company may prepay and satisfy the June 2021 Convertible Debenture so long as an event of default has not occurred, upon 20 days’ prior written notice received by the Company to the holder, by paying 125% of the amounts owed on the June 2021 Convertible Debenture, including all principal, interest and other fees. The holder of this debenture may, however, convert all or a portion of the debenture during the 20-day notice period.

During the nine months ended July 31, 2022, the Company issued an aggregate 8,000,000 units on partial conversion of the June 2021 Convertible Debenture, for a total of 8,000,000 common shares, 4,000,000 Class A Warrants exercisable at a price of $0.13 until June 10, 2026, and 4,000,000 Class B Warrants exercisable at a price of $0.19 until June 10, 2026 [note 13[b]]. As at July 31, 2022, the Company incurred contractual interest of $165,140 (October 31, 2021 – $70,521). The June 2021 Convertible Debenture has an effective interest rate of 1,113%.

[d] April 2022 Convertible Debenture

On April 14, 2022, the Company entered into a securities purchase agreement (the “2022 Securities Purchase Agreement”) and closed a non-brokered private placement of an unsecured convertible note in the principal amount of $2,000,000 (the “April 2022 Convertible Debenture”). The note bears interest at 15% per annum and matures on October 14, 2023. The April 2022 Convertible Debenture is convertible into 6,666,667 units, where each unit consists of one share of the Company’ common stock and one common stock purchase warrant exercisable at a price of $0.40 per share for a period of five years from the date of issuance.

The April 2022 Convertible Debenture may not be prepaid prior to maturity and contains customary events of default relating to, among other things, payment defaults, breach of representations and warranties, and breach of provisions of the 2022 Securities Purchase Agreement or the April 2022 Convertible Debenture.

In the event of default under the April 2022 Convertible Debenture, the interest rate shall increase to the lesser of 20% per annum or the maximum rate permitted under applicable law until paid and the following “Mandatory Default Amount” shall be paid, if demanded by the purchaser: the sum of (a) the greater of (i) the outstanding principal amount of the April 2022 Convertible Debenture divided by the conversion price on the date the Mandatory Default Amount is either (A) demanded (if demand or notice is required to create an event of default) or otherwise due or (B) paid in full, whichever has a lower conversion price, multiplied by the VWAP on the date the Mandatory Default Amount is either (x) demanded, (y) due, or (z) paid in full, whichever is highest, or (ii) 125% of the outstanding principal amount of the April 2022 Convertible Debenture plus (b) all other amounts, costs, expenses and liquidated damages due in respect of the April 2022 Convertible Debenture.

Pursuant to the terms of the 2022 Securities Purchase Agreement, the Company also entered into a registration rights agreement dated April 14, 2022 (the “2022 Registration Rights Agreement”). Pursuant to the terms of the 2022 Registration Rights Agreement, the Company agreed to prepare and file with the SEC a registration statement covering the resale of all shares issued or issuable upon conversion of the April 2022 Convertible Debenture, upon exercise of the respective warrants of the April 2022 Convertible Debenture, upon conversion of the June 2021 Convertible Debenture, and upon exercise of the respective warrants of the June 2021 Convertible Debenture. The Company agreed to file the registration statement with the SEC within 30 days following April 14, 2022 and to use best efforts to have the registration statement declared effective by the SEC within 60 days following April 14, 2022 if the SEC does not review it or by August 12, 2022 if the SEC reviews it. In the event the Company fails to file the registration statement or such registration statement is not declared effective within the time periods noted above or such registration statement is not kept effective while any of the securities registered pursuant to such registration statement, the Company will be obligated to pay the holder of the debentures a penalty in cash, in the amount of $20,000 on the date of such failure and on the 30th day of each month following such failure. The 2022 Registration Rights Agreement contains customary indemnification provisions. On May 25, 2022, the Company filed a Form S-1 Registration Statement with the SEC. On July 12, 2022, the Company’s Form S-1 Registration Statement filed with the SEC was declared effective.

As at July 31, 2022, the Company incurred contractual interest of $88,767 (October 31, 2021 – $nil). The April 2022 Convertible Debenture has an effective interest rate of 22%.

[e] Debt Host Liability and Embedded Derivative Liability

Certain of the Company’s convertible debentures were determined to be hybrid financial instruments comprised of a debt host liability and an embedded derivative liability, as under the conversion feature the number of shares that will or may be issued to settle the notes may vary. The Company uses the Black-Scholes Option Pricing Model based on different default risks and assumptions. The debt host liability of the convertible note will be measured at amortized cost, with the embedded derivative liability measured at fair value.

On issuance date of the July 2020 Convertible Debenture, the fair value of its debt host liability was determined to be $87,083 and the respective embedded derivative liability was valued at $25,041. Fair value adjustments were made to the embedded derivative liability of the July 2020 Convertible Debenture on conversion date of May 18, 2021, resulting in a fair value of $nil.

On issuance date of the July 2021 Convertible Debenture, it was determined to be a convertible debt instrument with a beneficial conversion feature accounted for in accordance with ASU 470-20. The Company allocated the intrinsic value of the beneficial conversion feature of the July 2021 Convertible Debenture capped at the face value of $79,542 (CA$100,000) to additional paid-in capital. On November 1, 2021, the Company’s functional currency change resulted in the reclassification of the July 2021 Convertible Debenture to a hybrid financial instrument accounted for in accordance with ASU 815-15. The embedded derivative liability was valued at $421,095 (CA$529,400), the previous beneficial conversion feature was reversed out of additional paid-in capital, and a loss of $341,553 (CA$429,400) was recognized in the statements of loss and comprehensive loss. Fair value adjustments were made to the embedded derivative liability of the July 2021 Convertible Debenture on conversion date of April 22, 2022, resulting in a fair value of $nil.

On issuance date of the June 2021 Convertible Debenture, it was determined to be a hybrid financial instrument comprised of a debt host liability and an embedded derivative liability. The embedded derivative liability was valued at $1,646,600 which exceeded the face value of the note itself of $1,500,000, the debt host liability was then assigned a face value of $1, with an immediate loss of $146,601 on recognition of the debt host liability. As at October 31, 2021, its combined value was $7,449,744. On November 1, 2021, the Company’s functional currency change resulted in the reclassification of the June 2021 Convertible Debenture from a hybrid financial instrument accounted for in accordance with ASU 815-15 to a convertible debt instrument with a beneficial conversion feature accounted for in accordance with ASU 470-20. The value of the embedded derivative liability was reclassified to additional paid-in capital. The corresponding debt discount is amortized as interest expense over the period from the issuance date to the stated maturity date using the effective interest method. During the nine months ended July 31, 2022, the Company recorded interest expense on debt discount of $814,717 which includes the full amortization of the portions of the debt which were converted in the period. As at July 31, 2022, the debt discount had a carrying value of $685,283.

On issuance date of the April 2022 Convertible Debenture, it was determined to be a convertible debt instrument with a beneficial conversion feature accounted for in accordance with ASU 470-20. The Company allocated the intrinsic value of the beneficial conversion feature of the April 2022 Convertible Debenture of $240,000 to additional paid-in capital, and the corresponding debt discount is amortized as interest expense over the period from the issuance date to the stated maturity date using the effective interest method. During the nine months ended July 31, 2022, the Company recorded interest expense on debt discount of $12. As at July 31, 2022, the debt discount had a carrying value of $239,988.

	July 2020 Convertible Debenture			July 2021 Convertible Debenture			June 2021 Convertible Debenture			April 2022 Convertible Debenture			Total
	$			$			$			$			$
Debt Host Liability
Balance, October 31, 2020		96,318			–			–			–			96,318
Fair value of debt host liability recognized		–			–			1			–			1
Accretion and interest expense		23,587			63			43			–			23,693
Conversion		(125,560	)		–			–			–			(125,560	)
Foreign currency translation		5,655			–			–			–			5,655
Balance, October 31, 2021		–			63			44			–			107
Effects of functional currency change		–			–			1,500,000			–			1,500,000
Fair value at inception		–			–			–			2,000,000			2,000,000
Accretion and interest expense		–			28,050			49,406			118,659			196,115
Conversion		–			(28,031	)		(800,000	)		–			(828,031	)
Foreign currency translation		–			(82	)		–			–			(82	)
Balance, July 31, 2022		–			–			749,450			2,118,659			2,868,109
Embedded Derivative Liability
Balance, October 31, 2020		20,123			–			–			–			20,123
Fair value of embedded derivative liability recognized		–			–			1,646,600			–			1,646,600
Fair value adjustment		(16,058	)		–			5,717,328			–			5,701,270
Conversion		(5,247	)		–			–			–			(5,247	)
Foreign currency translation		1,182			–			85,772			–			86,954
Balance, October 31, 2021		–			–			7,449,700			–			7,449,700
Effects of functional currency change		–			421,094			(7,449,700	)		–			(7,028,606	)
Fair value adjustment		–			(259,447	)		–			–			(259,447	)
Conversion		–			(158,169	)		–			–			(158,169	)
Foreign currency translation		–			(3,478	)		–			–			(3,478	)
Balance, July 31, 2022		–			–			–			–			–
Debt Discount
Balance, October 31, 2021		–			–			–			–			–
Effects of functional currency change		–			–			(1,500,000	)		–			(1,500,000	)
Fair value at inception		–			–			–			(240,000	)		(240,000	)
Amortization		–			–			814,717			12			814,729
Balance, July 31, 2022		–			–			(685,283	)		(239,988	)		(925,271	)
Combined Value of Convertible Debenture
Balance, October 31, 2020		116,441			–			–			–			116,441
Balance, October 31, 2021		–			63			7,449,744			7,449,744			7,449,807
Balance, July 31, 2022		–			–			64,167			1,878,671			1,942,838

The inputs used in the Black-Scholes Option Pricing Model are as follows:

	April 22,		November 1,		October 31,		June 15,		July 27,
	2022		2021		2021		2021		2020
Risk free rate of interest		2.65%		1.07%		1.08%		0.31%		0.26%
Expected life in years		0.23 years		0.70 years		1.11 years		1.50 year		0.74 year
Conversion exercise price		CA$0.12		CA$0.12		$0.10		$0.10		CA$0.15
Underlying share price of the Company		CA$0.36		CA$0.75		$0.59		$0.19		CA$0.13
Expected volatility		99.90%		124.34%		107.62%		87.17%		82.54%
Expected dividend rate		Nil		Nil		Nil		Nil		Nil

XML

WARRANT LIABILITY

9 Months Ended

Jul. 31, 2022

Warrant Liability

WARRANT LIABILITY

13. WARRANT LIABILITY

On November 1, 2021, the Company’s functional currency change resulted in the reclassification of its outstanding warrants and broker warrants denominated in Canadian dollar as derivative liability measured at fair value. The previous value of outstanding broker warrants of $4,198 was reversed out of additional paid-in capital, and the derivative liability of warrants and broker warrants were valued at $26,956,177 and $76,811, respectively. During the nine months ended July 31, 2022, the Company issued common share purchase warrants denominated in Canadian dollar on conversion of the July 2021 Convertible Debenture and recognized additional derivative liability of $67,155. Upon exercise of warrants and broker warrants, $5,057,112 was reclassified from derivative liability to stockholders’ deficit. Fair value adjustments of $21,985,951 were made to the warrant liability. As at July 31, 2022, the derivative liability of warrants and broker warrants were valued at $57,080 and $nil, respectively. The Company uses the Black-Scholes Option Pricing Model based on default risks and assumptions as appropriate to value its warrants and broker warrants.

	Warrants			Broker Warrants			Total
	$			$			$
Warrant Liability
Balance, October 31, 2021		–			–			–
Effects of functional currency change		26,956,177			76,811			27,032,988
Fair value at inception		67,155			–			67,155
Exercised		(5,036,522	)		(20,590	)		(5,057,112	)
Fair value adjustment		(21,929,730	)		(56,221	)		(21,985,951	)
Balance, July 31, 2022		57,080			–			57,080
Change in Fair Value of Warrant Liability
Effects of functional currency change		(26,956,177	)		(76,811	)		(27,032,988	)
Additional paid-in capital adjustment		–			4,198			4,198
Fair value at inception		(67,155	)		–			(67,155	)
Cashless warrant exercised		(113,765	)		–			(113,765	)
Fair value adjustment		21,929,730			56,221			21,985,951
Total		(5,207,367	)		(16,392	)		(5,223,759	)

XML

SHARE CAPITAL

9 Months Ended

Jul. 31, 2022

Equity [Abstract]

SHARE CAPITAL

14. SHARE CAPITAL

[a] Authorized capital

The authorized share capital consists of 1,000,000,000 common voting shares at par value of $0.001.

[b] Common shares issued

Fiscal 2021

[i] In connection with the non-brokered private placement announced on September 10, 2020:

On November 20, 2020, the Company closed the first tranche of the non-brokered private placement, issuing 5,599,171 units at a price of CA$0.13 per unit for gross proceeds of $556,876 (CA$727,892), which had been received prior to October 31, 2020 and recorded as an obligation to issue shares.

On January 15, 2021, the Company closed the second tranche of the non-brokered private placement, consisting of 7,337,914 units at a price of CA$0.13 per unit for gross proceeds of $749,435 (CA$953,930), of which $39,996 had been received prior to October 31, 2020 and recorded as an obligation to issue shares.

On January 29, 2021, the Company closed the third tranche of the non-brokered private placement consisting of 5,382,303 units at a price of CA$0.13 per unit for gross proceeds of $547,496 (CA$699,699).

On March 24, 2021, the Company closed the fourth tranche of the non-brokered private placement consisting of 6,554,172 units at a price of CA$0.13 per unit for gross proceeds of $678,270 (CA$852,042).

On April 27, 2021, the Company closed the fifth and final tranche of the non-brokered private placement consisting of 851,395 units at a price of CA$0.13 per unit for gross proceeds of $89,237 (CA$110,681).

In total, the Company issued an aggregate 25,724,955 units at a price of CA$0.13 per unit for aggregate gross proceeds of $2,621,314 (CA$3,344,244). Each unit issued consists of one common share and one common share purchase warrant entitling the holder to acquire a further common share at a price of CA$0.19 for a period of one year from the closing date of the respective financing tranche. The Company incurred aggregate share issue costs of $195,614.

[ii] On May 5, 2021, the Company announced a non-brokered private placement priced at CA$0.13 per unit to raise gross proceeds of up to CA$3,000,000. On May 28, 2021, the Company closed the first tranche of the non-brokered private placement issuing 5,223,420 units at a price of CA$0.13 per unit for gross proceeds of $561,844 (CA$679,044). On June 17, 2021, the Company closed the second and final tranche of the non-brokered private placement consisting of 17,853,506 units at a price of CA$0.13 per unit for gross proceeds of $1,880,687 (CA$2,320,956). The Company issued total of 23,076,926 units at a price of CA$0.13 per unit for total gross proceeds of $2,442,531 (CA$3,000,000). Each unit issued consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.19 for a period of one year from the date of closing of the respective financing tranche. The Company incurred aggregate share issue costs of $154,336.

[iii] On May 18, 2021, the Company issued a total of 1,360,959 common shares on the conversion of the July 2020 Convertible Debenture including accrued interest and 263,973 common shares valued at $26,286 in transaction costs.

[iv] On June 7, 2021, the Company issued 1,538,461 common shares at a price of CA$0.24 per share with a total fair value of $305,832 (CA$369,231) for equipment.

[v] On July 16, 2021, the Company closed a non-brokered private placement and issued 4,350,000 units at a price of CA$0.20 per unit for gross proceeds of $690,860 (CA$870,000). Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.30 for a period of one year from the date of closing. The Company incurred aggregate share issue costs of $48,319.

[vi] On August 11, 2021, the Company closed a non-brokered private placement and issued 3,827,601 units at a price of CA$0.55 per unit for gross proceeds of $1,683,336 (CA$2,105,180). Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.65 for a period of eighteen months from the date of closing. The Company incurred aggregate share issue costs of $124,923, and an additional $8,444 in the following fiscal year.

[vii] During the year ended October 31, 2021, the Company issued a total of 7,014,969 common shares on the exercise of common share purchase warrants at a price ranging from CA$0.05 to CA$0.21 per share for gross proceeds of $887,520 (CA$1,120,130). A total of 525,173 warrants expired unexercised.

[viii] During the year ended October 31, 2021, the Company issued a total of 2,630,000 common shares on the exercise of stock options at a price ranging from CA$0.05 to CA$0.16 per share for gross proceeds of $140,734 (CA$175,800).

[ix] With respect to the exercises of common share purchase warrants and options, the Company reclassified $4,291 and $121,932, respectively, from additional paid-in capital to share capital during the year ended October 31, 2021.

Fiscal 2022

[i] Pursuant to an agreement entered on August 29, 2018 and which was approved by the TSX-V on September 12, 2018, a company controlled by a director and officer was eligible to receive up to 5% of the issued and outstanding common shares of the Company as at August 28, 2018 for up to $5 million raised. The agreement was amended on January 2, 2019, extending the term from six months to three years and six months. During the year ended October 31, 2021, the commitment was met. On November 3, 2021, the Company issued 9,163,425 common shares at a price of CA$0.65 per share with a total fair value of $4,796,832 (CA$5,956,226) as share issue costs.

[ii] On November 4, 2021, the Company issued 1,000,000 units on partial conversion of the June 2021 Convertible Debenture, for a total of 1,000,000 common shares, 500,000 Class A Warrants and 500,000 Class B Warrants. On December 13, 2021, the Company issued a further 1,000,000 units on partial conversion of the June 2021 Convertible Debenture, for a total of 1,000,000 common shares, 500,000 Class A Warrants and 500,000 Class B Warrants. On January 20, 2022, the Company issued a further 1,000,000 units on partial conversion of the June 2021 Convertible Debenture, for a total of 1,000,000 common shares, 500,000 Class A Warrants and 500,000 Class B Warrants. Each Class A Warrant is exercisable at a price of $0.13 until June 10, 2026 and each Class B Warrant is exercisable at a price of $0.19 until June 10, 2026. The Company incurred aggregate share issue costs of $1,361.

[iii] On November 26, 2021, the Company closed a non-brokered private placement and issued 1,375,499 units at a price of $0.55 per unit for gross proceeds of $756,524. Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of $0.75 for a period of one year from the date of closing. The Company incurred aggregate share issue costs of $26,656.

[iv] During the three months ended January 31, 2022, upon exercise of common share purchase warrants, the Company issued an aggregate 15,159,448 common shares at a price CA$0.19 per share for gross proceeds of $2,279,136 (CA$2,880,295), 200,000 common shares at a price of CA$0.05 per share for gross proceeds of $7,830 (CA$10,000), and 30,000 common shares at a price of CA$0.30 per share for gross proceeds of $6,981 (CA$9,000). The Company issued a total of 15,389,448 common shares for gross proceeds of $2,293,946 (CA$2,899,295). A total of 2,428,363 warrants expired unexercised.

[v] On March 10, 2022, the Company issued 1,000,000 units on partial conversion of the June 2021 Convertible Debenture, for a total of 1,000,000 common shares, 500,000 Class A Warrants and 500,000 Class B Warrants. On April 27, 2022, the Company issued a further 2,000,000 units on partial conversion of the June 2021 Convertible Debenture, for a total of 2,000,000 common shares, 1,000,000 Class A Warrants and 1,000,000 Class B Warrants. Each Class A Warrant is exercisable at a price of $0.13 until June 10, 2026 and each Class B Warrant is exercisable at a price of $0.19 until June 10, 2026.

[vi] On April 22, 2022, the Company issued a total of 933,333 common shares and 933,333 common share purchase warrants exercisable at a price of CA$0.20 for a period of two years on the conversion the July 2021 Convertible Debenture including CA$100,000 principal amount and CA$12,000 accrued interest.

[vii] During the three months ended April 30, 2022, upon the exercise of common share purchase warrants, the Company issued an aggregate 929,005 common shares at a price of CA$0.19 per share for gross proceeds of $929,005 (CA$1,177,755), 2,082,025 common shares at a price of CA$0.05 per share for gross proceeds of $81,354 (CA$104,101), and 30,960 common shares at a price of CA$0.30 per share for gross proceeds of $7,357 (CA$9,288). A total of 3,191,933 warrants and 40,000 broker warrants expired unexercised.

[viii] During the three months ended April 30, 2022, the Company issued a total of 750,000 common shares on the exercise of stock options at a price of CA$0.05 per share for gross of $29,715 (CA$37,500), and reclassified $22,203 from additional paid-in capital to share capital.

[ix] On April 18, 2022, the Company announced a non-brokered private placement priced at $0.25 per unit to raise gross proceeds of up to $3,000,000. On May 9, 2022, the Company closed the first tranche of the non-brokered private placement and issued 1,727,000 units at a price of $0.25 per unit for gross proceeds of $431,750. On June 3, 2022, the Company closed the second and final tranche of the non-brokered private placement and issued 740,000 units at a price of $0.25 per unit for gross proceeds of $185,000. The Company issued a total of 2,467,000 units for total gross proceeds of $616,750. Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of $0.45 for a period of one year from the date of closing of the respective financing tranche. The Company incurred aggregate share issue costs of $23,182.

[x] On June 8, 2022, the Company issued 1,000,000 units on partial conversion of the June 2021 Convertible Debenture, for a total of 1,000,000 common shares, 500,000 Class A Warrants and 500,000 Class B Warrants. On July 13, 2022, the Company issued a further 1,000,000 units on partial conversion of the June 2021 Convertible Debenture, for a total of 1,000,000 common shares, 500,000 Class A Warrants and 500,000 Class B Warrants. Each Class A Warrant is exercisable at a price of $0.13 until June 10, 2026 and each Class B Warrant is exercisable at a price of $0.19 until June 10, 2026.

[xi] During the three months ended July 31, 2022, upon the exercise of common share purchase warrants, the Company issued an aggregate 8,131,975 common shares at a price of CA$0.19 per share for gross proceeds of $1,205,077 (CA$1,545,075) and 800,000 common shares at a price of CA$0.05 per share for gross proceeds of $31,051 (CA$40,000). A total of 17,414,239 warrants and 13,725 broker warrants expired unexercised.

[xii] During the three months ended July 31, 2022, upon the exercise of stock options, the Company issued an aggregate 250,000 common shares at a price of CA$0.13 per share for gross proceeds of $25,340 (CA$32,500), 150,000 common shares at a price of CA$0.12 per share for gross proceeds of $13,853 (CA$18,000) and 600,000 common shares at a price of CA$0.05 per share for gross proceeds of $23,272 (CA$30,000), and reclassified $48,060 from additional paid-in capital to share capital.

[c] Common share purchase warrants

Common share purchase warrants attached to units as part of a unit placement were assigned a $nil value.

A summary of the changes in the Company’s common share purchase warrants during the nine months ended July 31, 2022 are as follows:

Expiry Date	Exercise Price ($)	Weighted Average Life (Years)		October 31, 2021		Granted		Exercised			Expired/ Cancelled			July 31, 2022
November 22, 2021	CA$0.19		–		4,160,021		–		(4,080,573	)		(79,448	)		–
January 17, 2022	CA$0.19		–		7,267,914		–		(5,959,396	)		(1,308,518	)		–
January 31, 2022	CA$0.19		–		5,382,303		–		(4,341,906	)		(1,040,397	)		–
February 21, 2022	CA$0.05		–		1,505,200		–		(200,000	)		(1,305,200	)		–
March 24, 2022	CA$0.19		–		6,341,872		–		(4,515,139	)		(1,826,733	)		–
March 27, 2022	CA$0.05		–		982,025		–		(882,025	)		(100,000	)		–
April 27, 2022	CA$0.19		–		791,395		–		(791,395	)		–			–
May 9, 2022	CA$0.05		–		1,813,725		–		(1,800,000	)		(13,725	)		–
May 30, 2022	CA$0.19		–		5,223,420		–		(4,070,006	)		(1,153,414	)		–
June 17, 2022	CA$0.19		–		17,703,506		–		(5,731,721	)		(11,971,785	)		–
July 18, 2022	CA$0.30		–		4,350,000		–		(60,960	)		(4,289,040	)		–
August 14, 2022	CA$0.05		0.04		200,000		–		(200,000	)		–			–
February 13, 2023	CA$0.65		0.54		3,827,601		–		–			–			3,827,601
April 22, 2024	CA$0.20		1.73		–		933,333		–			–			933,333
Subtotal					59,548,982		933,333		(32,633,121	)		(23,088,260	)		31,120,873
Weighted average exercise price					CA$0.22		CA$0.20		CA$0.18			CA$0.20			CA$0.56
November 27, 2022	US$0.75		0.33		–		1,375,499		–			–			1,375,499
May 9, 2023	US$0.45		0.77		–		1,727,000		–			–			1,727,000
Jun 3, 2023	US$0.45		0.84		–		740,000		–			–			740,000
June 10, 2026	US$0.13		3.86		–		4,000,000		–			–			1,500,000
June 10, 2026	US$0.19		3.86		–		4,000,000		–			–			1,500,000
Subtotal					–		11,842,499		–			–			11,842,499
Weighted average exercise price					–		US$0.29		–			–			US$0.29
Total					59,548,982		12,775,832		(32,633,121	)		(5,660,296	)		38,496,372

A summary of the changes in the Company’s common share purchase warrants during the nine months ended July 31, 2021 are as follows:

Expiry Date	Exercise Price ($)	Weighted Average Life (Years)		October 31, 2020		Granted		Exercised			Expired/ Cancelled			July 31, 2021
August 31, 2021*	CA$0.21		0.08		3,643,791		–		–			–			3,643,791
November 22, 2021	CA$0.19		0.31		–		5,599,171		–			–			5,599,171
January 17, 2022	CA$0.19		0.46		–		7,400,214		(70,000	)		(62,300	)		7,267,914
January 31, 2022	CA$0.19		0.50		–		5,382,303		–			–			5,382,303
February 21, 2022	CA$0.05		0.56		1,505,200		–		–			–			1,505,200
March 24, 2022	CA$0.19		0.65		–		6,554,172		–			–			6,554,172
March 27, 2022	CA$0.05		0.65		1,482,025		–		–			–			1,482,025
April 27, 2022	CA$0.19		0.74		–		851,395		–			–			851,395
May 9, 2022	CA$0.05		0.77		2,368,626		–		(54,901	)		–			2,313,725
May 30, 2022	CA$0.19		0.82		–		5,223,420		–			–			5,223,420
June 17, 2022	CA$0.19		0.88		–		17,853,506		–			–			17,853,506
July 18, 2022	CA$0.30		0.96		–		4,350,000		–			–			4,350,000
August 14, 2022	CA$0.05		1.04		1,110,000		–		(400,000	)		–			710,000
Total					10,109,642		53,214,181		(524,901	)		(62,300	)		62,736,622
Weighted average exercise price					CA$0.11		CA$0.19		CA$0.07			CA$0.19			CA$0.19

* The Company received approval of the TSX-V on January 13, 2021 and amended the expiry date of 3,643,791 warrants, extending the expiry date from January 17, 2021 to August 31, 2021, subject to acceleration if the closing price of the Company’s shares exceeds CA$0.30 per common share for at least 10 consecutive trading days.

[d] Stock options

The Company has adopted an incentive stock option plan, effective on August 8, 2017 and as amended on August 8, 2018, under the rules of the TSX-V pursuant to which it is authorized to grant stock options to executive officers, directors, employees and consultants, enabling them to acquire up to 20% of the total shares outstanding of the Company (the “2017 Stock Option Plan”). Under the 2017 Stock Option Plan, the option exercise price of any option granted shall not be less than the discounted market price of the Company’s common shares. For the purposes of the 2017 Stock Option Plan, the discounted market price is calculated in accordance with the policies of the TSX-V at the time of the grant of the options. Stock options granted are subject to a maximum term of 5 years. All options granted shall vest immediately, except for those options granted to persons performing investor relations activities for the Company. Pursuant to the policies of the TSX-V, shares issued upon the exercise of options are restricted from trading during the 4-month period subsequent to the exercise of options.

On June 11, 2021, the Company adopted the 2021 Equity Incentive Plan which replaces the 2017 Stock Option for providing stock-based compensation to directors, officers, employees, consultants, and advisors of the Company and no further options will be granted under the 2017 Stock Option Plan. Under the 2021 Equity Incentive Plan, the Company is authorized to issue up to 27,312,368 shares of the Company. In addition, any common shares reserved for issuance under the 2017 Stock Option Plan that are forfeited as a result of the expiration or termination of any awards under that plan after the date of adoption of the 2021 Equity Incentive Plan will be added to the 2021 Equity Incentive Plan. As of July 31, 2022, 6,780,000 stock options forfeited under the 2017 Stock Option Plan were added to the 2021 Equity Incentive Plan (October 31, 2021 – 1,730,000), resulting in 34,092,368 stock options as the maximum number of common shares available under the 2021 Equity Incentive Plan (October 31, 2021 – 29,042,368). The 2021 Equity Incentive Plan provides for various equity-based and cash-based incentive awards, including incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock and restricted stock units, performance awards, dividend equivalents and other equity-based or cash-based awards.

On December 30, 2020, the Company granted 15,650,000 stock options pursuant to its 2017 Stock Option Plan to its directors, officers, employees and consultants at a price of CA$0.13 per share, of which 9,500,000 were exercisable for a period of five years and 6,150,000 were exercisable for a period of two years. However, these options exceeded the maximum allowed under the Company’s 2017 Stock Option Plan. On June 11, 2021, the Company received shareholders’ approval to amend the Company’s 2017 Stock Option Plan to increase the number of common shares reserved for issuance under such plan and rectified the grant of these options.

On August 30, 2021, the Company granted 21,700,000 incentive and non-statutory stock options pursuant to its 2021 Equity Incentive Plan to its directors, officers, employees and consultants. These options are exercisable at a price of CA$0.70 per share for a period of five years.

On October 1, 2021, the Company granted 1,450,000 incentive and non-statutory stock options pursuant to its 2021 Equity Incentive Plan to its officer and employee and consultants. These options are exercisable at a price of CA$0.50 per share for a period of five years.

On December 3, 2021, the Company granted 250,000 incentive stock options pursuant to its 2021 Equity Incentive Plan to an employee. These options are exercisable at a price of CA$0.58 per share for a period of five years.

On March 7, 2022, the Company granted 500,000 incentive stock options pursuant to its 2021 Equity Incentive Plan to an officer. These options are exercisable at a price of CA$0.40 per share for a period of five years.

On April 8, 2022, the Company granted 500,000 incentive stock options pursuant to its 2021 Equity Incentive Plan to employees. These options are exercisable at a price of CA$0.40 per share for a period of five years.

As at July 31, 2022, 10,042,368 common shares remained available for grant under the 2021 Equity Incentive Plan.

During the nine months July 31, 2022, the Company recognized a stock-based compensation totaling $466,368 (2021 – $1,057,013) in relation to the grant of its stock options.

The weighted average grant date fair value of the stock options granted during the nine months ended July 31, 2022 was CA$0.37 (2021 – CA$0.09) per option. Option pricing models require the use of highly subjective estimates and assumptions including expected stock price volatility. Changes in the underlying assumptions can materially affect the fair value estimates. The fair value of stock options was estimated on the measurement date using the Black-Scholes Option Pricing Model. The assumptions used to calculate the fair value were as follows:

	2022	2021
Risk free rate of interest	1.34 – 2.59%	0.20% – 1.07%
Expected life of options	5 years	2 to 5 years
Exercise price of options	CA$0.40 – CA$0.58	CA$0.13 – CA$0.70
Expected annualized volatility	134.93% – 136.08%	130.88% – 140.05%
Expected dividend rate	Nil	Nil

A summary of the changes in the Company’s stock options during the nine months ended July 31, 2022 are as follows:

Expiry Date	Exercise Price (CA$)		Weighted Average Life (Years)		Outstanding as at October 31, 2021		Granted		Exercised			Expired/ Cancelled			Outstanding as at July 31, 2022			Vested as at July 31, 2022
March 27, 2022		0.05		–		1,500,000		–		(750,000	)		(750,000	)		–			–
December 30, 2022		0.13		0.42		6,000,000		–		(250,000	)		(650,000	)		5,100,000			5,100,000
August 12, 2023		0.05		1.03		2,290,000		–		–			(750,000	)		1,540,000			1,540,000
December 3, 2023		0.05		1.34		6,450,000		–		(600,000	)		(1,500,000	)		4,350,000			4,350,000
May 22, 2024		0.12		1.81		7,900,000		–		–			(850,000	)		7,050,000			7,050,000
November 3, 2024		0.15		2.26		700,000		–		–			–			700,000			700,000
November 24, 2024		0.16		2.32		320,000		–		–			(300,000	)		20,000			20,000
March 26, 2025		0.11		2.65		100,000		–		–			–			100,000			100,000
April 23, 2025		0.12		2.73		3,350,000		–		(150,000	)		(250,000	)		2,950,000			2,950,000
December 30, 2025		0.13		3.42		9,500,000		–		–			–			9,500,000			9,500,000
August 30, 2026		0.70		4.08		21,700,000		–		–			(350,000	)		21,350,000			21,312,500
October 1, 2026		0.50		4.17		1,450,000		–		–			–			1,450,000			1,450,000
December 3, 2026		0.58		4.35		–		250,000		–			–			250,000			250,000
March 7, 2027		0.40		4.60		–		500,000		–			–			500,000			500,000
April 8, 2027		0.40		4.69		–		500,000		–			–			500,000			500,000
Total						61,260,000		1,250,000		(1,750,000	)		(5,400,000	)		55,360,000			55,322,500
Weighted average exercise price						CA$0.33		CA$0.44		CA$0.07			CA$0.12			CA$0.36			CA$0.36
Aggregate intrinsic value					$	19,994,025									($	8,475,724	)	($	8,459,933	)
Weighted average remaining life						3.46										2.96			2.96

A summary of the changes in the Company’s nonvested stock options during the nine months ended July 31, 2022 are as follows:

Expiry Date	Fair Value Per Share (CA$)		Weighted Average Life (Years)		Nonvested as at October 31, 2021		Granted		Vested			Expired/ Cancelled			Nonvested as at July 31, 2022
December 30, 2022		0.07		0.42		162,500		–		(162,500	)		–			–
August 30, 2026		0.56		4.08		300,000		–		(187,500	)		(75,000	)		37,500
Total						462,500		–		(350,000	)		(75,000	)		37,500
Weighted average grant date fair value – per option						CA$0.39		–		CA$0.33			CA$0.56			CA$0.56
Weighted average grant date fair value – total					$	144,131		–	$	90,209		$	32,652		$	16,326

A summary of the changes in the Company’s stock options during the nine months ended July 31, 2021 are as follows:

Expiry Date	Exercise Price (CA$)		Weighted Average Life (Years)		Outstanding as at October 31, 2020		Granted		Exercised			Expired/ Cancelled			Outstanding as at July 31, 2021		Vested as at July 31, 2021
February 11, 2021		0.05		0.03		800,000		–		–			(800,000	)		–		–
August 16, 2021		0.05		0.54		600,000		–		–			–			600,000		600,000
March 27, 2022		0.05		1.15		1,750,000		–		–			–			1,750,000		1,750,000
August 26, 2022		0.13		–		500,000		–		–			(500,000	)		–		–
December 30, 2022		0.13		1.91		–		6,150,000		–			–			6,150,000		5,825,000
April 19, 2023		0.05		2.21		800,000		–		–			–			800,000		800,000
August 12, 2023		0.05		2.53		3,120,000		–		(300,000	)		–			2,820,000		2,820,000
December 3, 2023		0.05		2.84		7,000,000		–		–			–			7,000,000		7,000,000
May 22, 2024		0.12		3.31		7,950,000		–		–			–			7,950,000		7,950,000
November 3, 2024		0.15		3.76		700,000		–		–			–			700,000		700,000
November 24, 2024		0.16		3.82		900,000		–		–			–			900,000		900,000
March 26, 2025		0.11		4.15		300,000		–		–			–			300,000		300,000
April 23, 2025		0.12		4.23		4,000,000		–		–			(300,000	)		3,700,000		3,700,000
December 30, 2025		0.13		4.92		–		9,500,000		–			–			9,500,000		9,500,000
Total						28,420,000		15,650,000		(300,000	)		(1,600,000	)		42,170,000		41,845,000
Weighted average exercise price						CA$0.09		CA$0.13		CA$0.05			CA$0.09			CA$0.10		CA$0.10
Aggregate intrinsic value					$	801,922									$	6,819,812	$	6,774,173
Weighted average remaining life						3.18										2.80		2.81

[e] Share-based payments and other reserves

The share-based payments and other reserves are used to recognize the fair value of stock options granted to directors, officers, employees and consultants as part of their remuneration, as well as those of broker warrants issued in relation to the Company’s financings. When stock options and broker warrants are subsequently exercised, the fair value of such stock options and broker warrants in additional paid-in capit0al is credited to share capital.

On November 1, 2021, the Company’s functional currency change resulted in the reclassification of its outstanding warrants and broker warrants denominated in Canadian dollar as derivative liability measured at fair value. The previous value of outstanding broker warrants was reversed out of additional paid-in capital.

On November 1, 2021, the Company’s functional currency change resulted in the reclassification of the June 2021 Convertible Debenture from a hybrid financial instrument to a convertible debt instrument with a beneficial conversion feature. The value of the embedded derivative liability was reclassified to additional paid-in capital. During the nine months ended July 31, 2022, the Company also allocated the intrinsic value of the beneficial conversion feature of the April 2022 Convertible Debenture to additional paid-in capital.

[f] Obligations to issue shares

The Company received advance share subscriptions in respect of non-brokered private placements closed in a subsequent period.

[g] Dilutive common shares

As at July 31, 2022, potentially dilutive common shares relating to common share purchase warrants and stock options outstanding totaling 71,963,433 (October 31, 2021 – 120,808,982) were not included in the computation of loss per share as the effect would be anti-dilutive.

	July 31, 2022		October 31, 2021
Common share purchase warrants		16,603,433		59,548,982
Stock options		55,360,000		61,260,000
Total		71,963,433		120,808,982

XML

FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT

9 Months Ended

Jul. 31, 2022

Fair Value Disclosures [Abstract]

FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT

15. FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT

The Company’s classification of its financial instruments is as follows:

Financial Instruments	Measurement Method	Associated Risk	Fair Value at July 31, 2022 ($)
Cash	FVTPL	Credit and currency		16,700
Other receivables	Amortized cost	Credit and currency		94,696
Deposits held by related parties	Amortized cost	Credit and currency		349,338
Accounts payable and accrued liabilities	Amortized cost	Currency		3,434,539
Due to related parties	Amortized cost	Currency		1,520,834
Convertible debenture, net	Amortized cost and FVTPL	Currency		1,942,838
Warrants liability	FVTPL	Currency		57,080

[a] Fair value

The fair value of financial instruments is the amount of consideration that would be agreed upon in an arm’s length transaction between knowledgeable, willing parties who are under no compulsion to act. The fair value of current financial instruments except derivative liability approximates their carrying values as long as they are short-term in nature or bear interest at market rates.

[b] Fair value hierarchy

Financial instruments that are held at fair value are categorized based on a valuation hierarchy which is determined by the valuation methodology utilized. The fair value hierarchy under US GAAP is based on the following three levels of inputs, of which the first two are considered observable and the last unobservable:

Level 1 – Quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level 2 – Observable inputs other than Level 1, quoted prices for similar assets or liabilities in active prices whose inputs are observable or whose significant value drivers are observable; and

Level 3 – Assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.

The Company evaluates its financial instruments and other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815. The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market at each balance sheet date and recorded as a liability and the change in fair value is recorded in the consolidated statements of loss and comprehensive loss. Upon conversion or exercise of a derivative instrument, the instrument is marked-to-market at the conversion date and then that fair value is reclassified to equity.

The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instruments that become subject to reclassification are reclassified at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified on the consolidated balance sheets as current or non-current based on whether or not settlement of the derivative instrument is expected within 12 months of the balance sheet date.

The Company uses the Black-Scholes Option Pricing Model to value derivative liabilities. This model uses Level 3 inputs in the fair value hierarchy established by ASC 820 Fair Value Measurement. The inputs used in determining the fair value of the embedded derivative are disclosed in note 12[e].

[c] Financial risk management

The Company’s board of directors has the overall responsibility for the establishment and oversight of the Company’s risk management framework. The Company’s risk management policies are established to identify and analyze the risks faced by the Company, to set appropriate risk limits and controls, and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and in response to the Company’s activities. Management regularly monitors compliance with the Company’s risk management policies and procedures and reviews the adequacy of the risk management framework in relation to the risks faced by the Company.

In the normal course of operations, the Company is exposed to various risks such as interest rate, foreign exchange, commodity, credit, and liquidity. To manage these risks, management determines what activities must be undertaken to minimize potential exposure to risks. The objectives of the Company in managing risks are as follows:

● Maintaining sound financial condition;

● Financing operations; and

● Ensuring liquidity to all operations.

In order to satisfy these objectives, the Company has adopted the following policies:

● Recognize and observe the extent of operating risk within the business; and

● Identify the magnitude of the impact of market risk factors on the overall risk of the business and take advantage of natural risk reductions that arise from these relationships.

[i] Interest rate risk

Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in the market interest rates. The Company is exposed to interest rate risk on its cash on deposits with banks and, from time to time, on its holdings of short-term investments. As of July 31, 2022, the Company had $16,700 (October 31, 2021 − $462,360) of cash on deposits with banks. The Company had no short-term investment as at July 31, 2022 and October 31, 2021. Given the level of cash held by the Company, fluctuations in the market interest rates had no significant impact on its interest income for the nine months ended July 31, 2022.

[ii] Foreign currency risk

The Company is exposed to foreign currency risk on fluctuations related to cash, other receivables, accounts payable, due to related parties and convertible debenture that are denominated in Canadian dollar. The Company has not entered into foreign exchange derivative contracts. A significant change in the currency exchange rates between the US dollar relative to the Canadian dollar could have a material effect on the Company’s financial position, results of operations, or cash flows.

Based on the Company net exposures as at July 31, 2022, assuming that all other variables remain constant, a 5% appreciation or deterioration of the Canadian dollar against the US dollar would result in an increase or decrease of $124,237 in the Company’s net income (loss) and comprehensive income (loss).

The Company had the following assets and liabilities denominated in Canadian dollar:

	July 31, 2022
	CA$
Cash		4,757
Other receivables		123,701
Accounts payable and accrued liabilities		(2,309,520	)
Due to related parties		(1,005,314	)
Total		(3,186,376	)

[iii] Commodity price risk

The value of the Company’s magnesium production business and its exploration and evaluation assets are dependent on the price of magnesium and the outlook for this mineral. Market prices for these metals historically have fluctuated widely and are affected by numerous factors outside the Company’s control, including but not limited to, levels of worldwide production, short-term changes in supply and demand, industrial and retail demand, as well as certain other factors related specifically to magnesium. If magnesium prices decline for a prolonged period below the cost of production, it may not be economically feasible to continue towards production.

[iv] Credit risk

Credit risk is the risk of loss if counterparties do not fulfill their contractual obligations. The Company’s credit risk is primarily attributable to cash and deposits held by related parties. The Company limits its exposure to credit risk on cash as these financial instruments are held with major Canadian and international banks. Deposits held by related parties were in relation to vendor agreements entered on January 1, 2021 where the Company provided related parties with advances that were held as deposits for anticipated future costs related to the Company’s planned magnesium research and development pilot plant and other administrative expenses [note 8[a]]. Other receivables consist primarily of GST due from the Federal Government of Canada. Management believes the credit risk concentration with respect to other receivables is remote. The carrying amount of financial assets recorded in the financial statements, net of any allowances, represents the Company’s maximum exposure to credit risk.

[v] Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they come due. The Company’s exposure to liquidity risk is dependent on its purchasing commitments and obligations and its ability to raise funds to meet commitments and sustain operations. The Company manages liquidity risk by continuously monitoring its actual and forecasted working capital requirements to ensure there is capital to meet short-term and long-term obligations.

As of July 31, 2022 and October 31, 2021, the Company had working capital deficiency of $6,642,252 and $9,657,316, respectively. As disclosed in note 1 to these Financial Statements, the ability of the Company to continue as a going concern is dependent on many factors. The Company’s management has evaluated whether there is substantial doubt about the Company’s ability to continue as a going concern and has determined that substantial doubt existed for at least one year from the date of these Financial Statements are issued. The Company has financed its activities and operations through equity issuances and debt financing and expects to continue to do so to the extent such financing is available. There can be no assurance that such financing will be available under terms acceptable to the Company or at all. Liquidity risk has been assessed as high.

XML

SEGMENTED INFORMATION

9 Months Ended

Jul. 31, 2022

Segment Reporting [Abstract]

SEGMENTED INFORMATION

16. SEGMENTED INFORMATION

The Company focuses on plant operations and magnesium production and continues to move towards the buildout of its pilot plant facility and the development of a full-scale commercial magnesium production facility. The Company also owns mining claims for the exploration and development of mineral property interests. Geographic information for the Company’s assets is as follows:

	July 31, 2022		October 31, 2021
	$		$
Canada – property, plant and equipment		4,458,609		2,546,383
United States – property, plant and equipment		29,392		28,321
United States – mineral property costs		93,453		93,453
		4,581,454		2,668,157
Canada – other assets		311,300		1,554,827
United States – other assets		905,009		290,528
		1,216,309		1,845,355
Total Assets		5,797,763		4,513,512

XML

SUBSEQUENT EVENTS

9 Months Ended

Jul. 31, 2022

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

17. SUBSEQUENT EVENTS

On August 5, 2022, the Company granted 1,000,000 non-statutory stock options pursuant to its 2021 Equity Incentive Plan to a consultant. These options are exercisable at a price of CA$0.16 per share for a period of two years.

On August 5, 2022, the Board of Directors of the Company accepted the resignation of a director. The size of the board is effectively reduced from six to five directors.

On August 17, 2022, the Company issued 1,000,000 units on partial conversion of the June 2021 Convertible Debenture, for a total of 1,000,000 common shares, 500,000 Class A Warrants exercisable at a price of $0.13 until June 10, 2026, and 500,000 Class B Warrants exercisable at a price of $0.19 until June 10, 2026.

On August 26, 2022, the Board of Directors of the Company accepted the termination of its independent registered public accounting firm (the “Firm”). During the Firm’s tenure, there were no disagreements on any matter of accounting principles or practices, financial statement disclosure, or auditing scope of procedure which disagreement if not resolved to the satisfaction of the Firm would have caused it to make reference to the subject matter of the disagreement in connection with its reports on the financial statements, and there were no “reportable events” (as defined in Item 304(a)(1)(v) of Regulation S-K).

On August 29, 2022, the Chief Financial Officer’s contract with the Company was terminated and a new interim Chief Financial Officer was appointed effective September 8, 2022.

XML

PROPERTY, PLANT AND EQUIPMENT (Tables)

9 Months Ended

Jul. 31, 2022

Property, Plant and Equipment [Abstract]

SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT

	Computer Equipment		Furniture			Leasehold Improvement			Furnace & Plant Equipment			Vehicle			Total
	$		$			$			$			$			$
Cost
Balance, October 31, 2021		109,629		53,542			139,481			2,344,726			–			2,647,378
Additions		14,370		2,171			159,065			2,047,779			29,215			2,252,600
Foreign exchange effect		10		(314	)		(5,708	)		(76,255	)		(374	)		(82,641	)
Balance, July 31, 2022		124,009		55,399			292,838			4,316,250			28,841			4,817,337
Accumulated Depreciation
Balance, October 31, 2021		27,821		16,514			14,147			14,192			–			72,674
Depreciation expense		28,402		5,777			81,553			137,294			5,084			258,515
Foreign exchange effect		403		(52	)		(856	)		(906	)		(37	)		(1,853	)
Balance, July 31, 2022		56,626		22,239			94,844			150,580			5,047			329,336
Net Book Value
Balance, October 31, 2021		81,808		37,028			125,334			2,330,534			–			2,574,704
Balance, July 31, 2022		67,383		33,160			197,994			4,165,670			23,794			4,488,001

XML

RIGHT-OF-USE ASSETS (Tables)

9 Months Ended

Jul. 31, 2022

Right-of-use Assets

SCHEDULE OF RIGHT-OF-USE ASSETS

	Vancouver Office		Virginia Office			Nevada Office		Pilot Plant			Total
	$		$			$		$			$
Cost
Balance, October 31, 2021		156,881		292,391			24,580		384,946			858,798
Foreign exchange effect		–		(3,038	)		–		(13,208	)		(16,246	)
Balance, July 31, 2022		156,881		289,353			24,580		371,738			842,552
Accumulated Depreciation
Balance, October 31, 2021		90,277		15,529			24,580		129,837			260,223
Depreciation expense		33,456		50,562			–		93,720			177,738
Prepaid expense		–		4,557			–		–			4,557
Foreign exchange effect		–		(162	)		–		(5,125	)		(5,287	)
Balance, July 31, 2022		123,733		70,486			24,580		218,432			437,231
Net Book Value
Balance, October 31, 2021		66,604		276,862			–		255,109			598,575
Balance, July 31, 2022		33,148		218,867			–		153,306			405,321

XML

LEASE OBLIGATIONS (Tables)

9 Months Ended

Jul. 31, 2022

Lease Obligations

SCHEDULE OF OPERATING LEASE

	Vancouver Office			Virginia Office			Nevada Office		Pilot Plant			Total
	$			$			$		$			$
Balance, October 31, 2021		66,604			262,612			–		255,109			584,325
Lease payments		(36,087	)		(4,557	)		–		(103,028	)		(143,672	)
Interest expense		2,631			13,967			–		9,307			25,905
Foreign exchange effect		–			(2,728	)		–		(8,081	)		(10,089	)
Balance, July 31, 2022		33,148			269,294			–		153,307			455,749
Which consist of:
Current lease obligation		33,148			96,043			–		130,745			259,936
Non-current lease obligation		–			173,251			–		22,562			195,813
Balance, July 31, 2022		33,148			269,294			–		153,307			455,749

XML

RELATED PARTY TRANSACTIONS (Tables)

9 Months Ended

Jul. 31, 2022

Related Party Transactions [Abstract]

SCHEDULE OF DEPOSITS HELD BY RELATED PARTY

	Related Party A [i]			Related Party B [ii]			Total
	$			$			$
Balance, October 31, 2021		291,481			194,981			486,462
Advances		354,459			1,225,118			1,579,577
Costs and expenses		(312,820	)		(1,420,829	)		(1,733,649	)
Foreign exchange effect		16,218			730			16,948
Balance, July 31, 2022		349,338			–			349,338

[i] Related Party A is a company controlled by a director and officer.

[ii] Related Party B is a company controlled by an officer.

SCHEDULE OF DUE TO RELATED PARTIES

	July 31, 2022		October 31, 2021
	$		$
Wages payable to directors and officers		505,544		357,500
Benefits payable to directors and officers		725,261		539,209
Fees and expenses payable to directors and officers		290,029		127,878
Interest due to a shareholder		–		2,230
Total		1,520,834		1,026,817

XML

CONVERTIBLE DEBENTURE (Tables)

9 Months Ended

Jul. 31, 2022

Debt Disclosure [Abstract]

SCHEDULE OF DERIVATIVE INSTRUMENTS

	July 2020 Convertible Debenture			July 2021 Convertible Debenture			June 2021 Convertible Debenture			April 2022 Convertible Debenture			Total
	$			$			$			$			$
Debt Host Liability
Balance, October 31, 2020		96,318			–			–			–			96,318
Fair value of debt host liability recognized		–			–			1			–			1
Accretion and interest expense		23,587			63			43			–			23,693
Conversion		(125,560	)		–			–			–			(125,560	)
Foreign currency translation		5,655			–			–			–			5,655
Balance, October 31, 2021		–			63			44			–			107
Effects of functional currency change		–			–			1,500,000			–			1,500,000
Fair value at inception		–			–			–			2,000,000			2,000,000
Accretion and interest expense		–			28,050			49,406			118,659			196,115
Conversion		–			(28,031	)		(800,000	)		–			(828,031	)
Foreign currency translation		–			(82	)		–			–			(82	)
Balance, July 31, 2022		–			–			749,450			2,118,659			2,868,109
Embedded Derivative Liability
Balance, October 31, 2020		20,123			–			–			–			20,123
Fair value of embedded derivative liability recognized		–			–			1,646,600			–			1,646,600
Fair value adjustment		(16,058	)		–			5,717,328			–			5,701,270
Conversion		(5,247	)		–			–			–			(5,247	)
Foreign currency translation		1,182			–			85,772			–			86,954
Balance, October 31, 2021		–			–			7,449,700			–			7,449,700
Effects of functional currency change		–			421,094			(7,449,700	)		–			(7,028,606	)
Fair value adjustment		–			(259,447	)		–			–			(259,447	)
Conversion		–			(158,169	)		–			–			(158,169	)
Foreign currency translation		–			(3,478	)		–			–			(3,478	)
Balance, July 31, 2022		–			–			–			–			–
Debt Discount
Balance, October 31, 2021		–			–			–			–			–
Effects of functional currency change		–			–			(1,500,000	)		–			(1,500,000	)
Fair value at inception		–			–			–			(240,000	)		(240,000	)
Amortization		–			–			814,717			12			814,729
Balance, July 31, 2022		–			–			(685,283	)		(239,988	)		(925,271	)
Combined Value of Convertible Debenture
Balance, October 31, 2020		116,441			–			–			–			116,441
Balance, October 31, 2021		–			63			7,449,744			7,449,744			7,449,807
Balance, July 31, 2022		–			–			64,167			1,878,671			1,942,838

SCHEDULE OF OPTION PRICING MODEL

The inputs used in the Black-Scholes Option Pricing Model are as follows:

	April 22,		November 1,		October 31,		June 15,		July 27,
	2022		2021		2021		2021		2020
Risk free rate of interest		2.65%		1.07%		1.08%		0.31%		0.26%
Expected life in years		0.23 years		0.70 years		1.11 years		1.50 year		0.74 year
Conversion exercise price		CA$0.12		CA$0.12		$0.10		$0.10		CA$0.15
Underlying share price of the Company		CA$0.36		CA$0.75		$0.59		$0.19		CA$0.13
Expected volatility		99.90%		124.34%		107.62%		87.17%		82.54%
Expected dividend rate		Nil		Nil		Nil		Nil		Nil

XML

WARRANT LIABILITY (Tables)

9 Months Ended

Jul. 31, 2022

Warrant Liability

SCHEDULE OF WARRANTS LIABILITY

	Warrants			Broker Warrants			Total
	$			$			$
Warrant Liability
Balance, October 31, 2021		–			–			–
Effects of functional currency change		26,956,177			76,811			27,032,988
Fair value at inception		67,155			–			67,155
Exercised		(5,036,522	)		(20,590	)		(5,057,112	)
Fair value adjustment		(21,929,730	)		(56,221	)		(21,985,951	)
Balance, July 31, 2022		57,080			–			57,080
Change in Fair Value of Warrant Liability
Effects of functional currency change		(26,956,177	)		(76,811	)		(27,032,988	)
Additional paid-in capital adjustment		–			4,198			4,198
Fair value at inception		(67,155	)		–			(67,155	)
Cashless warrant exercised		(113,765	)		–			(113,765	)
Fair value adjustment		21,929,730			56,221			21,985,951
Total		(5,207,367	)		(16,392	)		(5,223,759	)

XML

SHARE CAPITAL (Tables)

9 Months Ended

Jul. 31, 2022

Equity [Abstract]

SUMMARY OF CHANGES IN COMMON SHARE PURCHASE WARRANTS

A summary of the changes in the Company’s common share purchase warrants during the nine months ended July 31, 2022 are as follows:

Expiry Date	Exercise Price ($)	Weighted Average Life (Years)		October 31, 2021		Granted		Exercised			Expired/ Cancelled			July 31, 2022
November 22, 2021	CA$0.19		–		4,160,021		–		(4,080,573	)		(79,448	)		–
January 17, 2022	CA$0.19		–		7,267,914		–		(5,959,396	)		(1,308,518	)		–
January 31, 2022	CA$0.19		–		5,382,303		–		(4,341,906	)		(1,040,397	)		–
February 21, 2022	CA$0.05		–		1,505,200		–		(200,000	)		(1,305,200	)		–
March 24, 2022	CA$0.19		–		6,341,872		–		(4,515,139	)		(1,826,733	)		–
March 27, 2022	CA$0.05		–		982,025		–		(882,025	)		(100,000	)		–
April 27, 2022	CA$0.19		–		791,395		–		(791,395	)		–			–
May 9, 2022	CA$0.05		–		1,813,725		–		(1,800,000	)		(13,725	)		–
May 30, 2022	CA$0.19		–		5,223,420		–		(4,070,006	)		(1,153,414	)		–
June 17, 2022	CA$0.19		–		17,703,506		–		(5,731,721	)		(11,971,785	)		–
July 18, 2022	CA$0.30		–		4,350,000		–		(60,960	)		(4,289,040	)		–
August 14, 2022	CA$0.05		0.04		200,000		–		(200,000	)		–			–
February 13, 2023	CA$0.65		0.54		3,827,601		–		–			–			3,827,601
April 22, 2024	CA$0.20		1.73		–		933,333		–			–			933,333
Subtotal					59,548,982		933,333		(32,633,121	)		(23,088,260	)		31,120,873
Weighted average exercise price					CA$0.22		CA$0.20		CA$0.18			CA$0.20			CA$0.56
November 27, 2022	US$0.75		0.33		–		1,375,499		–			–			1,375,499
May 9, 2023	US$0.45		0.77		–		1,727,000		–			–			1,727,000
Jun 3, 2023	US$0.45		0.84		–		740,000		–			–			740,000
June 10, 2026	US$0.13		3.86		–		4,000,000		–			–			1,500,000
June 10, 2026	US$0.19		3.86		–		4,000,000		–			–			1,500,000
Subtotal					–		11,842,499		–			–			11,842,499
Weighted average exercise price					–		US$0.29		–			–			US$0.29
Total					59,548,982		12,775,832		(32,633,121	)		(5,660,296	)		38,496,372

A summary of the changes in the Company’s common share purchase warrants during the nine months ended July 31, 2021 are as follows:

Expiry Date	Exercise Price ($)	Weighted Average Life (Years)		October 31, 2020		Granted		Exercised			Expired/ Cancelled			July 31, 2021
August 31, 2021*	CA$0.21		0.08		3,643,791		–		–			–			3,643,791
November 22, 2021	CA$0.19		0.31		–		5,599,171		–			–			5,599,171
January 17, 2022	CA$0.19		0.46		–		7,400,214		(70,000	)		(62,300	)		7,267,914
January 31, 2022	CA$0.19		0.50		–		5,382,303		–			–			5,382,303
February 21, 2022	CA$0.05		0.56		1,505,200		–		–			–			1,505,200
March 24, 2022	CA$0.19		0.65		–		6,554,172		–			–			6,554,172
March 27, 2022	CA$0.05		0.65		1,482,025		–		–			–			1,482,025
April 27, 2022	CA$0.19		0.74		–		851,395		–			–			851,395
May 9, 2022	CA$0.05		0.77		2,368,626		–		(54,901	)		–			2,313,725
May 30, 2022	CA$0.19		0.82		–		5,223,420		–			–			5,223,420
June 17, 2022	CA$0.19		0.88		–		17,853,506		–			–			17,853,506
July 18, 2022	CA$0.30		0.96		–		4,350,000		–			–			4,350,000
August 14, 2022	CA$0.05		1.04		1,110,000		–		(400,000	)		–			710,000
Total					10,109,642		53,214,181		(524,901	)		(62,300	)		62,736,622
Weighted average exercise price					CA$0.11		CA$0.19		CA$0.07			CA$0.19			CA$0.19

* The Company received approval of the TSX-V on January 13, 2021 and amended the expiry date of 3,643,791 warrants, extending the expiry date from January 17, 2021 to August 31, 2021, subject to acceleration if the closing price of the Company’s shares exceeds CA$0.30 per common share for at least 10 consecutive trading days.

SCHEDULE OF FAIR VALUE ASSUMPTIONS

	2022	2021
Risk free rate of interest	1.34 – 2.59%	0.20% – 1.07%
Expected life of options	5 years	2 to 5 years
Exercise price of options	CA$0.40 – CA$0.58	CA$0.13 – CA$0.70
Expected annualized volatility	134.93% – 136.08%	130.88% – 140.05%
Expected dividend rate	Nil	Nil

SCHEDULE OF STOCK OPTIONS ACTIVITY

A summary of the changes in the Company’s stock options during the nine months ended July 31, 2022 are as follows:

Expiry Date	Exercise Price (CA$)		Weighted Average Life (Years)		Outstanding as at October 31, 2021		Granted		Exercised			Expired/ Cancelled			Outstanding as at July 31, 2022			Vested as at July 31, 2022
March 27, 2022		0.05		–		1,500,000		–		(750,000	)		(750,000	)		–			–
December 30, 2022		0.13		0.42		6,000,000		–		(250,000	)		(650,000	)		5,100,000			5,100,000
August 12, 2023		0.05		1.03		2,290,000		–		–			(750,000	)		1,540,000			1,540,000
December 3, 2023		0.05		1.34		6,450,000		–		(600,000	)		(1,500,000	)		4,350,000			4,350,000
May 22, 2024		0.12		1.81		7,900,000		–		–			(850,000	)		7,050,000			7,050,000
November 3, 2024		0.15		2.26		700,000		–		–			–			700,000			700,000
November 24, 2024		0.16		2.32		320,000		–		–			(300,000	)		20,000			20,000
March 26, 2025		0.11		2.65		100,000		–		–			–			100,000			100,000
April 23, 2025		0.12		2.73		3,350,000		–		(150,000	)		(250,000	)		2,950,000			2,950,000
December 30, 2025		0.13		3.42		9,500,000		–		–			–			9,500,000			9,500,000
August 30, 2026		0.70		4.08		21,700,000		–		–			(350,000	)		21,350,000			21,312,500
October 1, 2026		0.50		4.17		1,450,000		–		–			–			1,450,000			1,450,000
December 3, 2026		0.58		4.35		–		250,000		–			–			250,000			250,000
March 7, 2027		0.40		4.60		–		500,000		–			–			500,000			500,000
April 8, 2027		0.40		4.69		–		500,000		–			–			500,000			500,000
Total						61,260,000		1,250,000		(1,750,000	)		(5,400,000	)		55,360,000			55,322,500
Weighted average exercise price						CA$0.33		CA$0.44		CA$0.07			CA$0.12			CA$0.36			CA$0.36
Aggregate intrinsic value					$	19,994,025									($	8,475,724	)	($	8,459,933	)
Weighted average remaining life						3.46										2.96			2.96

 

A summary of the changes in the Company’s stock options during the nine months ended July 31, 2021 are as follows:

Expiry Date	Exercise Price (CA$)		Weighted Average Life (Years)		Outstanding as at October 31, 2020		Granted		Exercised			Expired/ Cancelled			Outstanding as at July 31, 2021		Vested as at July 31, 2021
February 11, 2021		0.05		0.03		800,000		–		–			(800,000	)		–		–
August 16, 2021		0.05		0.54		600,000		–		–			–			600,000		600,000
March 27, 2022		0.05		1.15		1,750,000		–		–			–			1,750,000		1,750,000
August 26, 2022		0.13		–		500,000		–		–			(500,000	)		–		–
December 30, 2022		0.13		1.91		–		6,150,000		–			–			6,150,000		5,825,000
April 19, 2023		0.05		2.21		800,000		–		–			–			800,000		800,000
August 12, 2023		0.05		2.53		3,120,000		–		(300,000	)		–			2,820,000		2,820,000
December 3, 2023		0.05		2.84		7,000,000		–		–			–			7,000,000		7,000,000
May 22, 2024		0.12		3.31		7,950,000		–		–			–			7,950,000		7,950,000
November 3, 2024		0.15		3.76		700,000		–		–			–			700,000		700,000
November 24, 2024		0.16		3.82		900,000		–		–			–			900,000		900,000
March 26, 2025		0.11		4.15		300,000		–		–			–			300,000		300,000
April 23, 2025		0.12		4.23		4,000,000		–		–			(300,000	)		3,700,000		3,700,000
December 30, 2025		0.13		4.92		–		9,500,000		–			–			9,500,000		9,500,000
Total						28,420,000		15,650,000		(300,000	)		(1,600,000	)		42,170,000		41,845,000
Weighted average exercise price						CA$0.09		CA$0.13		CA$0.05			CA$0.09			CA$0.10		CA$0.10
Aggregate intrinsic value					$	801,922									$	6,819,812	$	6,774,173
Weighted average remaining life						3.18										2.80		2.81

 

SCHEDULE OF NON-VESTED STOCK OPTIONS

A summary of the changes in the Company’s nonvested stock options during the nine months ended July 31, 2022 are as follows:

Expiry Date	Fair Value Per Share (CA$)		Weighted Average Life (Years)		Nonvested as at October 31, 2021		Granted		Vested			Expired/ Cancelled			Nonvested as at July 31, 2022
December 30, 2022		0.07		0.42		162,500		–		(162,500	)		–			–
August 30, 2026		0.56		4.08		300,000		–		(187,500	)		(75,000	)		37,500
Total						462,500		–		(350,000	)		(75,000	)		37,500
Weighted average grant date fair value – per option						CA$0.39		–		CA$0.33			CA$0.56			CA$0.56
Weighted average grant date fair value – total					$	144,131		–	$	90,209		$	32,652		$	16,326

SCHEDULE OF POTENTIALLY DILUTIVE COMMON SHARES

	July 31, 2022		October 31, 2021
Common share purchase warrants		16,603,433		59,548,982
Stock options		55,360,000		61,260,000
Total		71,963,433		120,808,982

XML

FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Tables)

9 Months Ended

Jul. 31, 2022

Fair Value Disclosures [Abstract]

SCHEDULE OF CLASSIFICATION OF FINANCIAL INSTRUMENTS

The Company’s classification of its financial instruments is as follows:

Financial Instruments	Measurement Method	Associated Risk	Fair Value at July 31, 2022 ($)
Cash	FVTPL	Credit and currency		16,700
Other receivables	Amortized cost	Credit and currency		94,696
Deposits held by related parties	Amortized cost	Credit and currency		349,338
Accounts payable and accrued liabilities	Amortized cost	Currency		3,434,539
Due to related parties	Amortized cost	Currency		1,520,834
Convertible debenture, net	Amortized cost and FVTPL	Currency		1,942,838
Warrants liability	FVTPL	Currency		57,080

SCHEDULE OF FOREIGN CURRENCY RISK

The Company had the following assets and liabilities denominated in Canadian dollar:

	July 31, 2022
	CA$
Cash		4,757
Other receivables		123,701
Accounts payable and accrued liabilities		(2,309,520	)
Due to related parties		(1,005,314	)
Total		(3,186,376	)

XML

SEGMENTED INFORMATION (Tables)

9 Months Ended

Jul. 31, 2022

Segment Reporting [Abstract]

SCHEDULE OF ASSETS INFORMATION

	July 31, 2022		October 31, 2021
	$		$
Canada – property, plant and equipment		4,458,609		2,546,383
United States – property, plant and equipment		29,392		28,321
United States – mineral property costs		93,453		93,453
		4,581,454		2,668,157
Canada – other assets		311,300		1,554,827
United States – other assets		905,009		290,528
		1,216,309		1,845,355
Total Assets		5,797,763		4,513,512

XML

NATURE OF OPERATIONS AND GOING CONCERN (Details Narrative) - USD ($)	9 Months Ended
	Jul. 31, 2022	Jul. 31, 2021	Oct. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 67,190,772		$ 52,129,621
Working capital deficit	6,642,252		$ 9,657,316
Comprehensive income (loss)	14,829,915	$ 6,513,804
Cash	$ 6,000,000

XML

SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($)	9 Months Ended
	Jul. 31, 2022	Jul. 31, 2021	Oct. 31, 2021
Property, Plant and Equipment [Line Items]
Property, plant and equipment cost, beginning balance	$ 2,647,378
Additions	2,252,600
Foreign exchange effect	(82,641)
Property, plant and equipment cost, ending balance	4,817,337
Property, plant and equipment accumulated depreciation, beginning balance	72,674
Depreciation expense	258,515	$ 22,355
Foreign exchange effect	(1,853)
Property, plant and equipment accumulated depreciation, ending balance	329,336
Property, plant and equipment net book value	4,488,001		$ 2,574,704
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment cost, beginning balance	109,629
Additions	14,370
Foreign exchange effect	10
Property, plant and equipment cost, ending balance	124,009
Property, plant and equipment accumulated depreciation, beginning balance	27,821
Depreciation expense	28,402
Foreign exchange effect	403
Property, plant and equipment accumulated depreciation, ending balance	56,626
Property, plant and equipment net book value	67,383		81,808
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment cost, beginning balance	53,542
Additions	2,171
Foreign exchange effect	(314)
Property, plant and equipment cost, ending balance	55,399
Property, plant and equipment accumulated depreciation, beginning balance	16,514
Depreciation expense	5,777
Foreign exchange effect	(52)
Property, plant and equipment accumulated depreciation, ending balance	22,239
Property, plant and equipment net book value	33,160		37,028
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment cost, beginning balance	139,481
Additions	159,065
Foreign exchange effect	(5,708)
Property, plant and equipment cost, ending balance	292,838
Property, plant and equipment accumulated depreciation, beginning balance	14,147
Depreciation expense	81,553
Foreign exchange effect	(856)
Property, plant and equipment accumulated depreciation, ending balance	94,844
Property, plant and equipment net book value	197,994		125,334
Furnace and Plant Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment cost, beginning balance	2,344,726
Additions	2,047,779
Foreign exchange effect	(76,255)
Property, plant and equipment cost, ending balance	4,316,250
Property, plant and equipment accumulated depreciation, beginning balance	14,192
Depreciation expense	137,294
Foreign exchange effect	(906)
Property, plant and equipment accumulated depreciation, ending balance	150,580
Property, plant and equipment net book value	4,165,670		2,330,534
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment cost, beginning balance
Additions	29,215
Foreign exchange effect	(374)
Property, plant and equipment cost, ending balance	28,841
Property, plant and equipment accumulated depreciation, beginning balance
Depreciation expense	5,084
Foreign exchange effect	(37)
Property, plant and equipment accumulated depreciation, ending balance	5,047
Property, plant and equipment net book value	$ 23,794

XML

SCHEDULE OF RIGHT-OF-USE ASSETS (Details) - USD ($)	9 Months Ended
	Jul. 31, 2022	Jul. 31, 2021	Oct. 31, 2021
Beginning balance, Cost	$ 858,798
Foreign exchange effect	(16,246)
Ending balance, Cost	842,552
Beginning balance, Accumulated Depreciation	260,223
Depreciation expense	177,738	$ 137,419
Prepaid expense	4,557
Foreign exchange effect	(5,287)
Ending balance, Accumulated Depreciation	437,231
Net book value	405,321		$ 598,575
Vancouver Office [Member]
Beginning balance, Cost	156,881
Foreign exchange effect
Ending balance, Cost	156,881
Beginning balance, Accumulated Depreciation	90,277
Depreciation expense	33,456
Prepaid expense
Foreign exchange effect
Ending balance, Accumulated Depreciation	123,733
Net book value	33,148		66,604
Virginia Office [Member]
Beginning balance, Cost	292,391
Foreign exchange effect	(3,038)
Ending balance, Cost	289,353
Beginning balance, Accumulated Depreciation	15,529
Depreciation expense	50,562
Prepaid expense	4,557
Foreign exchange effect	(162)
Ending balance, Accumulated Depreciation	70,486
Net book value	218,867		276,862
Nevada Office [Member]
Beginning balance, Cost	24,580
Foreign exchange effect
Ending balance, Cost	24,580
Beginning balance, Accumulated Depreciation	24,580
Depreciation expense
Prepaid expense
Foreign exchange effect
Ending balance, Accumulated Depreciation	24,580
Net book value
Pilot Plant [Member]
Beginning balance, Cost	384,946
Foreign exchange effect	(13,208)
Ending balance, Cost	371,738
Beginning balance, Accumulated Depreciation	129,837
Depreciation expense	93,720
Prepaid expense
Foreign exchange effect	(5,125)
Ending balance, Accumulated Depreciation	218,432
Net book value	$ 153,306		$ 255,109

XML

SCHEDULE OF OPERATING LEASE (Details) - USD ($)	9 Months Ended
	Jul. 31, 2022	Oct. 31, 2021
Lease obligation, beginning	$ 584,325
Lease payments	(143,672)
Interest expense	25,905
Foreign exchange effect	(10,089)
Lease obligation, ending	455,749
Current lease obligation	259,936	$ 192,045
Non-current lease obligation	195,813	$ 392,280
Vancouver Office [Member]
Lease obligation, beginning	66,604
Lease payments	(36,087)
Interest expense	2,631
Foreign exchange effect
Lease obligation, ending	33,148
Current lease obligation	33,148
Non-current lease obligation
Virginia Office [Member]
Lease obligation, beginning	262,612
Lease payments	(4,557)
Interest expense	13,967
Foreign exchange effect	(2,728)
Lease obligation, ending	269,294
Current lease obligation	96,043
Non-current lease obligation	173,251
Nevada Office [Member]
Lease obligation, beginning
Lease payments
Interest expense
Foreign exchange effect
Lease obligation, ending
Current lease obligation
Non-current lease obligation
Pilot Plant [Member]
Lease obligation, beginning	255,109
Lease payments	(103,028)
Interest expense	9,307
Foreign exchange effect	(8,081)
Lease obligation, ending	153,307
Current lease obligation	130,745
Non-current lease obligation	$ 22,562

XML

LEASE OBLIGATIONS (Details Narrative) - USD ($)	Jul. 31, 2022	Oct. 31, 2021	Oct. 31, 2020	Nov. 02, 2019
Operating lease, liability	$ 455,749	$ 584,325		$ 83,549
Lessee, operating lease, discount rate				7.00%
British Columbia [Member]
Operating lease, liability		$ 91,237	$ 354,263
Lessee, operating lease, discount rate		7.00%	6.00%
McLean,Virginia [Member]
Operating lease, liability		$ 260,649
Lessee, operating lease, discount rate		7.00%

XML

MINERAL PROPERTY COSTS (Details Narrative)	Jul. 31, 2022 USD ($) a ha	Oct. 31, 2021 USD ($)
Reserve Quantities [Line Items]
Mineral properties, net	$ 93,453	$ 93,453
Silverado Property [Member]
Reserve Quantities [Line Items]
Area of land | ha	120
Ownership percentage	100.00%
Carrying value of property	$ 1
TamiMosi Property [Member]
Reserve Quantities [Line Items]
Ownership percentage	100.00%
Royalty percentage	2.00%
Mineral properties, net	$ 93,452
TamiMosi Property [Member] | White Pine County [Member]
Reserve Quantities [Line Items]
Area of land | a	1,637
TamiMosi Property [Member] | Moor Mining District [Member]
Reserve Quantities [Line Items]
Area of land | a	10

XML

SCHEDULE OF DEPOSITS HELD BY RELATED PARTY (Details)	9 Months Ended
	Jul. 31, 2022 USD ($)
Related Party Transaction [Line Items]
Beginning balance	$ 486,462
Advances	1,579,577
Costs and expenses	(1,733,649)
Foreign exchange effect	16,948
Ending balance	349,338
Related Party A [Member]
Related Party Transaction [Line Items]
Beginning balance	291,481	[1]
Advances	354,459	[1]
Costs and expenses	(312,820)	[1]
Foreign exchange effect	16,218	[1]
Ending balance	349,338	[1]
Related Party B [Member]
Related Party Transaction [Line Items]
Beginning balance	194,981	[2]
Advances	1,225,118	[2]
Costs and expenses	(1,420,829)	[2]
Foreign exchange effect	730	[2]
Ending balance		[2]

[1] Related Party A is a company controlled by a director and officer.

[2] Related Party B is a company controlled by an officer.

XML

SCHEDULE OF DUE TO RELATED PARTIES (Details) - USD ($)	Jul. 31, 2022	Oct. 31, 2021
Related Party Transactions [Abstract]
Wages payable to directors and officers	$ 505,544	$ 357,500
Benefits payable to directors and officers	725,261	539,209
Fees and expenses payable to directors and officers	290,029	127,878
Interest due to a shareholder		2,230
Total	$ 1,520,834	$ 1,026,817

XML

RELATED PARTY TRANSACTIONS (Details Narrative)					1 Months Ended		9 Months Ended
	Nov. 03, 2021 USD ($) shares	Nov. 03, 2021 CAD ($) $ / shares shares	Sep. 12, 2018	Aug. 28, 2018 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2021 CAD ($)	Jul. 31, 2022 USD ($)	Jul. 31, 2022 CAD ($)	Jul. 31, 2021 USD ($)	Oct. 31, 2021 USD ($)
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Due to related parties							$ 1,520,834			$ 1,026,817
Stock based compensation							3,300,000
Number of common stock issued, value							774,746		$ 5,157,833
Directors and Officers [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Salaries management and consulting fees							2,605,352
Directors and Officers [Member] | Sublease Agreement [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Lease description					lease term from April 1, 2021 to March 31, 2023	lease term from April 1, 2021 to March 31, 2023
Payments for rent					$ 7,637	$ 9,794
Directors and Officers [Member] | Sublease Agreement [Member] | Vancouver, British Columbia [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Lease description					lease term from April 1, 2021 to March 31, 2023	lease term from April 1, 2021 to March 31, 2023
Payments for rent					$ 7,656	$ 9,794
Officer [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Stock based compensation							160,700
Management [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Consulting fees							27,489	$ 35,000
Executive Officer [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Consulting fees							60,000
Executive [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Consulting fees							$ 29,600
Director and Officer [Member] | Related Party Agreement [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Equity method investment, ownership percentage			5.00%
Number of common stock issued, value	$ 4,796,832	$ 5,956,226		$ 5,000,000
Number of common stock issued, shares | shares	9,163,425	9,163,425
Share price | $ / shares		$ 0.65

XML

CONTINGENT LIABILITIES AND COMMITMENTS (Details Narrative)							1 Months Ended			9 Months Ended			12 Months Ended
	Mar. 04, 2022 USD ($)	Feb. 08, 2021 USD ($) shares	Feb. 08, 2021 CAD ($) shares	Dec. 31, 2020 USD ($)	Dec. 31, 2020 CAD ($)	Sep. 29, 2020 USD ($)	Sep. 30, 2021 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2021 CAD ($)	Jul. 31, 2022 USD ($) shares	Jul. 31, 2022 CAD ($) shares	Jul. 31, 2021 USD ($) shares	Oct. 31, 2020 USD ($)	Oct. 31, 2020 CAD ($)	Apr. 22, 2022 CAD ($)	Nov. 03, 2021 $ / shares	Oct. 31, 2021 USD ($)	Apr. 19, 2021 USD ($)	Nov. 01, 2016 USD ($)	Nov. 01, 2016 CAD ($) $ / shares
Loss Contingencies [Line Items]
Loss contingency, damages sought, value		$ 3,900,000	$ 4,900,000	$ 3,400,000	$ 4,200,000
Debt instrument, face amount															$ 100,000
Number of shares issued price per share | $ / shares																$ 0.65
Cash										$ 6,000,000
Tenant allowance										41,010
Lodestar Management Group LLC [Member]
Loss Contingencies [Line Items]
Debt instrument, face amount										38,593							$ 53,491
Commitment of cash or arrangments amount																			$ 1,800	$ 2,500
Number of shares issued price per share | $ / shares																				$ 0.05
Issuance of share based minimum requirement										$ 1,800	$ 2,500
Number of shares issued | shares										0	0
Cash										$ 30,624		$ 16,200
Number of shares outstanding | shares										634,072
Lampert Agreement [Member]
Loss Contingencies [Line Items]
Debt instrument, face amount																		$ 367,227
Debt instrument, interest rate																		9.00%
Lease Agreement [Member]
Loss Contingencies [Line Items]
Loss contingency, damages sought, value	$ 120,000
Lease term description							lease term from September 14, 2021 to February 28, 2025						lease term from October 1, 2020 to September 30, 2023	lease term from October 1, 2020 to September 30, 2023
Payments for rent							$ 9,113						$ 16,154	$ 20,715
Sublease Agreement [Member] | Directors and Officers [Member]
Loss Contingencies [Line Items]
Lease term description								lease term from April 1, 2021 to March 31, 2023	lease term from April 1, 2021 to March 31, 2023
Payments for rent								$ 7,637	$ 9,794
Maximum [Member]
Loss Contingencies [Line Items]
Loss contingency, damages sought, value						$ 2,500,000
Warrant to purchase common stock | shares		33,000,000	33,000,000

XML

PROMISSORY NOTE (Details Narrative)	9 Months Ended		12 Months Ended
	Jul. 31, 2022 USD ($)	Jul. 31, 2021 USD ($)	Oct. 31, 2021 USD ($)	Oct. 31, 2020 USD ($)	Oct. 31, 2020 CAD ($)	Oct. 31, 2019 USD ($)	Oct. 31, 2019 CAD ($)	Oct. 31, 2020 CAD ($)
Short-Term Debt [Line Items]
Proceeds from related party loan	$ 1,579,577
Repayments of debt		$ 65,745
Promissory Note [Member]
Short-Term Debt [Line Items]
Proceeds from related party loan						$ 112,895	$ 150,000
Percentage of unsecured loan interest						18.00%	18.00%
Additional increase in promissory note loan				$ 44,588	$ 60,000
Loans payable				$ 157,483				$ 210,000
Maturity date				Sep. 24, 2021	Sep. 24, 2021
Interest and debt expense			$ 1,639	$ 16,655
Repayments of debt			$ 65,761	$ 101,066

XML

PROVISION FOR FLOW THROUGH SHARE ISSUANCES (Details Narrative) - USD ($)	Jul. 31, 2022	Oct. 31, 2021
Provision For Flow Through Share Issuances
Provision for tax and related obligations	$ 225,284	$ 233,285

XML

SCHEDULE OF DERIVATIVE INSTRUMENTS (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Jul. 31, 2022	Jul. 31, 2021	Jul. 31, 2022	Jul. 31, 2021	Oct. 31, 2021
Short-Term Debt [Line Items]
Accretion and interest expense	$ 372,295	$ 28,242	$ 1,021,443	$ 64,576
Foreign currency translation	17,273	16,068	231,236	(174,981)
Fair value adjustment		$ (806,853)	359,643	(790,197)
Amortization			814,729
Debt Host Liability [Member]
Short-Term Debt [Line Items]
Balance, beginning			107	96,318	$ 96,318
Fair value of debt host liability recognized					1
Accretion and interest expense			196,115		23,693
Conversion			(828,031)		(125,560)
Foreign currency translation			(82)		5,655
Effects of functional currency change			1,500,000
Fair value at inception			2,000,000
Balance, ending	2,868,109		2,868,109		107
Debt Host Liability [Member] | July 2020 Convertible Debenture [Member]
Short-Term Debt [Line Items]
Balance, beginning				96,318	96,318
Fair value of debt host liability recognized
Accretion and interest expense					23,587
Conversion					(125,560)
Foreign currency translation					5,655
Effects of functional currency change
Fair value at inception
Balance, ending
Debt Host Liability [Member] | July 2021 Convertible Debenture [Member]
Short-Term Debt [Line Items]
Balance, beginning			63
Fair value of debt host liability recognized
Accretion and interest expense			28,050		63
Conversion			(28,031)
Foreign currency translation			(82)
Effects of functional currency change
Fair value at inception
Balance, ending					63
Debt Host Liability [Member] | June 2021 Convertible Debenture [Member]
Short-Term Debt [Line Items]
Balance, beginning			44
Fair value of debt host liability recognized					1
Accretion and interest expense			49,406		43
Conversion			(800,000)
Foreign currency translation
Effects of functional currency change			1,500,000
Fair value at inception
Balance, ending	749,450		749,450		44
Debt Host Liability [Member] | April 2022 Convertible debenture [Member]
Short-Term Debt [Line Items]
Balance, beginning
Fair value of debt host liability recognized
Accretion and interest expense			118,659
Conversion
Foreign currency translation
Effects of functional currency change
Fair value at inception			2,000,000
Balance, ending	2,118,659		2,118,659
Embedded Derivative Liability [Member]
Short-Term Debt [Line Items]
Balance, beginning			7,449,700	20,123	20,123
Conversion			(158,169)		(5,247)
Foreign currency translation			(3,478)		86,954
Effects of functional currency change			(7,028,606)
Balance, ending					7,449,700
Fair value of embedded derivative liability recognized					1,646,600
Fair value adjustment			(259,447)		5,701,270
Embedded Derivative Liability [Member] | July 2020 Convertible Debenture [Member]
Short-Term Debt [Line Items]
Balance, beginning				20,123	20,123
Conversion					(5,247)
Foreign currency translation					1,182
Effects of functional currency change
Balance, ending
Fair value of embedded derivative liability recognized
Fair value adjustment					(16,058)
Embedded Derivative Liability [Member] | July 2021 Convertible Debenture [Member]
Short-Term Debt [Line Items]
Balance, beginning
Conversion			(158,169)
Foreign currency translation			(3,478)
Effects of functional currency change			421,094
Balance, ending
Fair value of embedded derivative liability recognized
Fair value adjustment			(259,447)
Embedded Derivative Liability [Member] | June 2021 Convertible Debenture [Member]
Short-Term Debt [Line Items]
Balance, beginning			7,449,700
Conversion
Foreign currency translation					85,772
Effects of functional currency change			(7,449,700)
Balance, ending					7,449,700
Fair value of embedded derivative liability recognized					1,646,600
Fair value adjustment					5,717,328
Embedded Derivative Liability [Member] | April 2022 Convertible debenture [Member]
Short-Term Debt [Line Items]
Balance, beginning
Conversion
Foreign currency translation
Effects of functional currency change
Balance, ending
Fair value of embedded derivative liability recognized
Fair value adjustment
Debt Discount [Member]
Short-Term Debt [Line Items]
Effects of functional currency change			(1,500,000)
Fair value at inception			(240,000)
Balance, beginning
Amortization			814,729
Balance, ending	(925,271)		(925,271)
Debt Discount [Member] | July 2020 Convertible Debenture [Member]
Short-Term Debt [Line Items]
Effects of functional currency change
Fair value at inception
Balance, beginning
Amortization
Balance, ending
Debt Discount [Member] | July 2021 Convertible Debenture [Member]
Short-Term Debt [Line Items]
Effects of functional currency change
Fair value at inception
Balance, beginning
Amortization
Balance, ending
Debt Discount [Member] | June 2021 Convertible Debenture [Member]
Short-Term Debt [Line Items]
Effects of functional currency change			(1,500,000)
Fair value at inception
Balance, beginning
Amortization			814,717
Balance, ending	(685,283)		(685,283)
Debt Discount [Member] | April 2022 Convertible debenture [Member]
Short-Term Debt [Line Items]
Effects of functional currency change
Fair value at inception			(240,000)
Balance, beginning
Amortization			12
Balance, ending	(239,988)		(239,988)
Combined Value of Convertible Debenture [Member]
Short-Term Debt [Line Items]
Balance, beginning			7,449,807	116,441	116,441
Balance, ending	1,942,838		1,942,838		7,449,807
Combined Value of Convertible Debenture [Member] | July 2020 Convertible Debenture [Member]
Short-Term Debt [Line Items]
Balance, beginning				116,441	116,441
Balance, ending
Combined Value of Convertible Debenture [Member] | July 2021 Convertible Debenture [Member]
Short-Term Debt [Line Items]
Balance, beginning			63
Balance, ending					63
Combined Value of Convertible Debenture [Member] | June 2021 Convertible Debenture [Member]
Short-Term Debt [Line Items]
Balance, beginning			7,449,744
Balance, ending	64,167		64,167		7,449,744
Combined Value of Convertible Debenture [Member] | April 2022 Convertible debenture [Member]
Short-Term Debt [Line Items]
Balance, beginning			7,449,744
Balance, ending	$ 1,878,671		$ 1,878,671		$ 7,449,744

XML

SCHEDULE OF OPTION PRICING MODEL (Details)	9 Months Ended
	Jul. 31, 2022 $ / shares	Jul. 31, 2021	Jul. 31, 2022 $ / shares
Short-Term Debt [Line Items]
Expected life in years	5 years
Expected dividend rate
April 22, 2022 [Member]
Short-Term Debt [Line Items]
Risk free rate of interest	2.65%
Expected life in years	2 months 23 days
Conversion exercise price			$ 0.12
Underlying share price of the Company			0.36
Expected volatility	99.90%
Expected dividend rate
November 1, 2021 [Member]
Short-Term Debt [Line Items]
Risk free rate of interest	1.07%
Expected life in years	8 months 12 days
Conversion exercise price			0.12
Underlying share price of the Company			0.75
Expected volatility	124.34%
Expected dividend rate
October 31, 2021 [Member]
Short-Term Debt [Line Items]
Risk free rate of interest	1.08%
Expected life in years	1 year 1 month 9 days
Conversion exercise price	$ 0.10
Underlying share price of the Company	$ 0.59
Expected volatility	107.62%
Expected dividend rate
June 15, 2021 [Member]
Short-Term Debt [Line Items]
Risk free rate of interest	0.31%
Expected life in years	1 year 6 months
Conversion exercise price	$ 0.10
Underlying share price of the Company	$ 0.19
Expected volatility	87.17%
Expected dividend rate
July 27, 2020 [Member]
Short-Term Debt [Line Items]
Risk free rate of interest	0.26%
Expected life in years	8 months 26 days
Conversion exercise price			0.15
Underlying share price of the Company			$ 0.13
Expected volatility	82.54%
Expected dividend rate

XML

CONVERTIBLE DEBENTURE (Details Narrative)						9 Months Ended			12 Months Ended
	Jun. 08, 2022 shares	Apr. 22, 2022 CAD ($) $ / shares shares	Apr. 14, 2022 USD ($) $ / shares shares	Jun. 15, 2021 USD ($) shares	May 18, 2021 USD ($) shares	Jul. 31, 2022 USD ($) $ / shares shares	Jul. 31, 2022 CAD ($) shares	Jul. 31, 2021 USD ($) shares	Oct. 31, 2021 USD ($)	Jul. 31, 2022 CAD ($) shares	Nov. 03, 2021 $ / shares	Jul. 15, 2021 USD ($)	Jul. 15, 2021 CAD ($) $ / shares	Jul. 27, 2020 USD ($)	Jul. 27, 2020 CAD ($) $ / shares
Short-Term Debt [Line Items]
Debt instrument, face amount		$ 100,000
Common stock, value issued						$ 41,811,321			$ 29,842,167
Warrants exercisable price | $ / shares		$ 0.20
Penalty cash						6,000,000
Beneficial conversion feature was reversed out of additional paid-in capital						240,000
Debt host liability share, face value | $ / shares											$ 0.65
Amortization of debt discount premium						$ 814,729
Common Stock [Member]
Short-Term Debt [Line Items]
Number of shares issued | shares						3,842,499	3,842,499	53,151,881
Beneficial conversion feature was reversed out of additional paid-in capital
July 2020 Convertible Debenture [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount														$ 112,124	$ 150,000
Debt instrument, interest rate percentage														12.00%	12.00%
Debt instrument, conversion price | $ / shares															$ 0.15
Number of shares issued | shares					1,360,959
Conversion of stock, shares issued | shares					263,973
Common stock, value issued					$ 26,286
Effective interest rate percentage					37.00%
Debt instrument, fair value						87,083
Embedded derivative liability						25,041
July 2021 Convertible Debenture [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount												$ 79,542	$ 100,000
Debt instrument, interest rate percentage												12.00%	12.00%
Debt instrument, conversion price | $ / shares													$ 0.12
Conversion of stock, shares issued | shares		933,333
Effective interest rate percentage		594.00%
Warrants exercisable price | $ / shares													$ 0.20
Convertible debenture face value						79,542	$ 100,000
Embedded derivative liability						421,095				$ 529,400
Beneficial conversion feature was reversed out of additional paid-in capital						$ 341,553	$ 429,400
June 2021 Convertible Debenture [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount				$ 1,500,000
Debt instrument, interest rate percentage				12.00%
Number of shares issued | shares	1,000,000					8,000,000	8,000,000
Debt instrument maturity date				Dec. 10, 2022
Conversion of convertiable debenture | shares				15,000,000
Debt conversion, description						each unit consists of (i) one share of the Company’ common stock, (ii) one-half of one Class A common stock purchase warrant, with each whole warrant being exercisable at a price of $0.13 until June 10, 2026, and (iii) one-half of one Class B common stock purchase warrant, with each whole warrant being exercisable at a price of $0.19 until June 10, 2026 (collectively, the “Class A and B Warrants”). In addition, the conversion price for accrued interest is the greater of (i) $0.10 and (ii) the minimum conversion price permitted by the TSX-V at the time of conversion	each unit consists of (i) one share of the Company’ common stock, (ii) one-half of one Class A common stock purchase warrant, with each whole warrant being exercisable at a price of $0.13 until June 10, 2026, and (iii) one-half of one Class B common stock purchase warrant, with each whole warrant being exercisable at a price of $0.19 until June 10, 2026 (collectively, the “Class A and B Warrants”). In addition, the conversion price for accrued interest is the greater of (i) $0.10 and (ii) the minimum conversion price permitted by the TSX-V at the time of conversion
Contractual interest						$ 165,140			70,521
Debt instrument interest rate description						effective interest rate of 1,113%	effective interest rate of 1,113%
Debt instrument, fair value						$ 1,500,000
Embedded derivative liability						$ 1,646,600
Debt host liability share, face value | $ / shares						$ 1
Loss on recognition of debt liability						$ 146,601
Convertible debt combined value									7,449,744
Amortization of debt discount premium						814,717
Debt discount carry value						$ 685,283
June 2021 Convertible Debenture [Member] | Common Class A [Member]
Short-Term Debt [Line Items]
Warrants exercisable price | $ / shares						$ 0.13
Number of warrants exercisable | shares	500,000					4,000,000				4,000,000
June 2021 Convertible Debenture [Member] | Common Class B [Member]
Short-Term Debt [Line Items]
Warrants exercisable price | $ / shares						$ 0.19
Number of warrants exercisable | shares	500,000					4,000,000				4,000,000
June 2021 Convertible Debenture [Member] | Common Stock [Member]
Short-Term Debt [Line Items]
Number of shares issued | shares	1,000,000					8,000,000	8,000,000
April 2022 Convertible debenture [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount			$ 2,000,000
Debt instrument, interest rate percentage			15.00%
Effective interest rate percentage						22.00%				22.00%
Debt instrument maturity date			Oct. 14, 2023
Contractual interest						$ 88,767
Penalty cash			$ 20,000
Convertible debenture face value						240,000
Debt discount carry value						239,988
Interest expense						$ 12
April 2022 Convertible debenture [Member] | Common Stock [Member]
Short-Term Debt [Line Items]
Number of shares issued | shares			6,666,667
Warrants exercisable price | $ / shares			$ 0.40
Warrants term			5 years

XML

SCHEDULE OF WARRANTS LIABILITY (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jul. 31, 2022	Jul. 31, 2021	Jul. 31, 2022	Jul. 31, 2021
Class of Warrant or Right [Line Items]
Balance at beginning
Fair value adjustment		$ (806,853)	359,643	$ (790,197)
Balance at end	57,080		57,080
Additional paid-in capital adjustment			(4,198)
Total	(1,837,031)		5,223,759
Warrants [Member]
Class of Warrant or Right [Line Items]
Fair value adjustment			67,155
Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Balance at beginning
Effects of functional currency change			27,032,988
Fair value at inception			67,155
Exercised			(5,057,112)
Fair value adjustment			(21,985,951)
Balance at end	57,080		57,080
Warrant Liability [Member] | Warrants [Member]
Class of Warrant or Right [Line Items]
Balance at beginning
Effects of functional currency change			26,956,177
Fair value at inception			67,155
Exercised			(5,036,522)
Fair value adjustment			(21,929,730)
Balance at end	57,080		57,080
Warrant Liability [Member] | Broker Warrants [Member]
Class of Warrant or Right [Line Items]
Balance at beginning
Effects of functional currency change			76,811
Fair value at inception
Exercised			(20,590)
Fair value adjustment			(56,221)
Balance at end
Change in Fair Value of Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Fair value adjustment			21,985,951
Effects of functional currency change			(27,032,988)
Additional paid-in capital adjustment			4,198
Fair value at inception			(67,155)
Cashless warrant exercised			(113,765)
Total			(5,223,759)
Change in Fair Value of Warrant Liability [Member] | Warrants [Member]
Class of Warrant or Right [Line Items]
Fair value adjustment			21,929,730
Effects of functional currency change			(26,956,177)
Additional paid-in capital adjustment
Fair value at inception			(67,155)
Cashless warrant exercised			(113,765)
Total			(5,207,367)
Change in Fair Value of Warrant Liability [Member] | Broker Warrants [Member]
Class of Warrant or Right [Line Items]
Fair value adjustment			56,221
Effects of functional currency change			(76,811)
Additional paid-in capital adjustment			4,198
Fair value at inception
Cashless warrant exercised
Total			$ (16,392)

XML

WARRANT LIABILITY (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended
	Nov. 01, 2021	Jul. 31, 2022	Jul. 31, 2021	Jul. 31, 2022	Jul. 31, 2021	Nov. 02, 2021
Warrant outstanding				$ (4,198)
Additional derivative liability			$ (806,853)	359,643	$ (790,197)
Brokers Warrants [Member]
Warrant outstanding	$ 4,198
Warrants [Member]
Derivative Liability		57,080		57,080		$ 26,956,177
Additional derivative liability				67,155
Exercise of common share purchase warrants				5,057,112
Derivative, Loss on Derivative				21,985,951
Broker Warrants [Member]
Derivative Liability						$ 76,811

XML

SUMMARY OF CHANGES IN COMMON SHARE PURCHASE WARRANTS (Details)	9 Months Ended
	Jul. 31, 2022 $ / shares shares	Jul. 31, 2022 $ / shares $ / shares shares	Jul. 31, 2021 $ / shares shares		Jul. 31, 2022 $ / shares	Apr. 22, 2022 $ / shares
Class of Warrant or Right [Line Items]
Exercise price | $ / shares						$ 0.20
Purchase Warrant 1 [Member]
Class of Warrant or Right [Line Items]
Common share purchase warrants, Beginning balance	59,548,982	59,548,982
Granted	933,333	933,333
Exercised	(32,633,121)	(32,633,121)
Expired/Cancelled	(23,088,260)	(23,088,260)
Common share purchase warrants, Ending balance	31,120,873	31,120,873
Weighted average exercise price, beginning | $ / shares		$ 0.22
Weighted average exercise price, granted | $ / shares		0.20
Weighted average exercise price, exercised | $ / shares		0.18
Weighted average exercise price, expired/cancelled | $ / shares		0.20
Weighted average exercise price, ending | $ / shares		$ 0.56
Purchase Warrant 2 [Member]
Class of Warrant or Right [Line Items]
Common share purchase warrants, Beginning balance
Granted	11,842,499	11,842,499
Exercised
Expired/Cancelled
Common share purchase warrants, Ending balance	11,842,499	11,842,499
Weighted average exercise price, beginning | $ / shares
Weighted average exercise price, granted | $ / shares	0.29
Weighted average exercise price, exercised | $ / shares
Weighted average exercise price, expired/cancelled | $ / shares
Weighted average exercise price, ending | $ / shares	$ 0.29
Purchase Warrant [Member]
Class of Warrant or Right [Line Items]
Common share purchase warrants, Beginning balance	59,548,982	59,548,982	10,109,642
Granted	12,775,832	12,775,832	53,214,181
Exercised	(32,633,121)	(32,633,121)	(524,901)
Expired/Cancelled	(5,660,296)	(5,660,296)	(62,300)
Common share purchase warrants, Ending balance	38,496,372	38,496,372	62,736,622
Weighted average exercise price, beginning | $ / shares			$ 0.11
Weighted average exercise price, granted | $ / shares			0.19
Weighted average exercise price, exercised | $ / shares			0.07
Weighted average exercise price, expired/cancelled | $ / shares			0.19
Weighted average exercise price, ending | $ / shares			$ 0.19
November 22, 2021 [Member]
Class of Warrant or Right [Line Items]
Expiry Date	Nov. 22, 2021	Nov. 22, 2021	Nov. 22, 2021
Common share purchase warrants, Beginning balance	4,160,021	4,160,021
Granted			5,599,171
Exercised	(4,080,573)	(4,080,573)
Expired/Cancelled	(79,448)	(79,448)
Common share purchase warrants, Ending balance			5,599,171
Exercise price | $ / shares			$ 0.19		$ 0.19
Weighted Average Life (Years)			3 months 21 days
January 17, 2022 [Member]
Class of Warrant or Right [Line Items]
Expiry Date	Jan. 17, 2022	Jan. 17, 2022	Jan. 17, 2022
Common share purchase warrants, Beginning balance	7,267,914	7,267,914
Granted			7,400,214
Exercised	(5,959,396)	(5,959,396)	(70,000)
Expired/Cancelled	(1,308,518)	(1,308,518)	(62,300)
Common share purchase warrants, Ending balance			7,267,914
Exercise price | $ / shares			$ 0.19		0.19
Weighted Average Life (Years)			5 months 15 days
January 31, 2022 [Member]
Class of Warrant or Right [Line Items]
Expiry Date	Jan. 31, 2022	Jan. 31, 2022	Jan. 31, 2022
Common share purchase warrants, Beginning balance	5,382,303	5,382,303
Granted			5,382,303
Exercised	(4,341,906)	(4,341,906)
Expired/Cancelled	(1,040,397)	(1,040,397)
Common share purchase warrants, Ending balance			5,382,303
Exercise price | $ / shares			$ 0.19		0.19
Weighted Average Life (Years)			6 months
February 21, 2022 [Member]
Class of Warrant or Right [Line Items]
Expiry Date	Feb. 21, 2022	Feb. 21, 2022	Feb. 21, 2022
Common share purchase warrants, Beginning balance	1,505,200	1,505,200	1,505,200
Granted
Exercised	(200,000)	(200,000)
Expired/Cancelled	(1,305,200)	(1,305,200)
Common share purchase warrants, Ending balance			1,505,200
Exercise price | $ / shares			$ 0.05		0.05
Weighted Average Life (Years)			6 months 21 days
March 24, 2022 [Member]
Class of Warrant or Right [Line Items]
Expiry Date	Mar. 24, 2022	Mar. 24, 2022	Mar. 24, 2022
Common share purchase warrants, Beginning balance	6,341,872	6,341,872
Granted			6,554,172
Exercised	(4,515,139)	(4,515,139)
Expired/Cancelled	(1,826,733)	(1,826,733)
Common share purchase warrants, Ending balance			6,554,172
Exercise price | $ / shares			$ 0.19		0.19
Weighted Average Life (Years)			7 months 24 days
March 27, 2022 [Member]
Class of Warrant or Right [Line Items]
Expiry Date	Mar. 27, 2022	Mar. 27, 2022	Mar. 27, 2022
Common share purchase warrants, Beginning balance	982,025	982,025	1,482,025
Granted
Exercised	(882,025)	(882,025)
Expired/Cancelled	(100,000)	(100,000)
Common share purchase warrants, Ending balance			1,482,025
Exercise price | $ / shares			$ 0.05		0.05
Weighted Average Life (Years)			7 months 24 days
April 27, 2022 [Member]
Class of Warrant or Right [Line Items]
Expiry Date	Apr. 27, 2022	Apr. 27, 2022	Apr. 27, 2022
Common share purchase warrants, Beginning balance	791,395	791,395
Granted			851,395
Exercised	(791,395)	(791,395)
Expired/Cancelled
Common share purchase warrants, Ending balance			851,395
Exercise price | $ / shares			$ 0.19		0.19
Weighted Average Life (Years)			8 months 26 days
May 9, 2022 [Member]
Class of Warrant or Right [Line Items]
Expiry Date	May 09, 2022	May 09, 2022	May 09, 2022
Common share purchase warrants, Beginning balance	1,813,725	1,813,725	2,368,626
Granted
Exercised	(1,800,000)	(1,800,000)	(54,901)
Expired/Cancelled	(13,725)	(13,725)
Common share purchase warrants, Ending balance			2,313,725
Exercise price | $ / shares			$ 0.05		0.05
Weighted Average Life (Years)			9 months 7 days
May 30, 2022 [Member]
Class of Warrant or Right [Line Items]
Expiry Date	May 30, 2022	May 30, 2022	May 30, 2022
Common share purchase warrants, Beginning balance	5,223,420	5,223,420
Granted			5,223,420
Exercised	(4,070,006)	(4,070,006)
Expired/Cancelled	(1,153,414)	(1,153,414)
Common share purchase warrants, Ending balance			5,223,420
Exercise price | $ / shares			$ 0.19		0.19
Weighted Average Life (Years)			9 months 25 days
June 17, 2022 [Member]
Class of Warrant or Right [Line Items]
Expiry Date	Jun. 17, 2022	Jun. 17, 2022	Jun. 17, 2022
Common share purchase warrants, Beginning balance	17,703,506	17,703,506
Granted			17,853,506
Exercised	(5,731,721)	(5,731,721)
Expired/Cancelled	(11,971,785)	(11,971,785)
Common share purchase warrants, Ending balance			17,853,506
Exercise price | $ / shares			$ 0.19		0.19
Weighted Average Life (Years)			10 months 17 days
July 18, 2022 [Member]
Class of Warrant or Right [Line Items]
Expiry Date	Jul. 18, 2022	Jul. 18, 2022	Jul. 18, 2022
Common share purchase warrants, Beginning balance	4,350,000	4,350,000
Granted			4,350,000
Exercised	(60,960)	(60,960)
Expired/Cancelled	(4,289,040)	(4,289,040)
Common share purchase warrants, Ending balance			4,350,000
Exercise price | $ / shares			$ 0.30		0.30
Weighted Average Life (Years)			11 months 15 days
August 14, 2022 [Member]
Class of Warrant or Right [Line Items]
Expiry Date	Aug. 14, 2022	Aug. 14, 2022	Aug. 14, 2022
Common share purchase warrants, Beginning balance	200,000	200,000	1,110,000
Granted
Exercised	(200,000)	(200,000)	(400,000)
Expired/Cancelled
Common share purchase warrants, Ending balance			710,000
Exercise price | $ / shares			$ 0.05		$ 0.05
Weighted Average Life (Years)	14 days	14 days	1 year 14 days		14 days
February 13, 2023 [Member]
Class of Warrant or Right [Line Items]
Expiry Date	Feb. 13, 2023	Feb. 13, 2023
Common share purchase warrants, Beginning balance	3,827,601	3,827,601
Granted
Exercised
Expired/Cancelled
Common share purchase warrants, Ending balance	3,827,601	3,827,601
Exercise price | $ / shares					$ 0.65
Weighted Average Life (Years)	6 months 14 days	6 months 14 days			6 months 14 days
April 22, 2024 [Member]
Class of Warrant or Right [Line Items]
Expiry Date	Apr. 22, 2024	Apr. 22, 2024
Common share purchase warrants, Beginning balance
Granted	933,333	933,333
Exercised
Expired/Cancelled
Common share purchase warrants, Ending balance	933,333	933,333
Exercise price | $ / shares					$ 0.20
Weighted Average Life (Years)	1 year 8 months 23 days	1 year 8 months 23 days			1 year 8 months 23 days
November 27, 2022 [Member]
Class of Warrant or Right [Line Items]
Expiry Date	Nov. 27, 2022	Nov. 27, 2022
Common share purchase warrants, Beginning balance
Granted	1,375,499	1,375,499
Exercised
Expired/Cancelled
Common share purchase warrants, Ending balance	1,375,499	1,375,499
Exercise price | $ / shares	$ 0.75	$ 0.75
Weighted Average Life (Years)	3 months 29 days	3 months 29 days			3 months 29 days
May 9, 2023 [Member]
Class of Warrant or Right [Line Items]
Expiry Date	May 09, 2023	May 09, 2023
Common share purchase warrants, Beginning balance
Granted	1,727,000	1,727,000
Exercised
Expired/Cancelled
Common share purchase warrants, Ending balance	1,727,000	1,727,000
Exercise price | $ / shares	$ 0.45	$ 0.45
Weighted Average Life (Years)	9 months 7 days	9 months 7 days			9 months 7 days
June 3, 2023 [Member]
Class of Warrant or Right [Line Items]
Expiry Date	Jun. 03, 2023	Jun. 03, 2023
Common share purchase warrants, Beginning balance
Granted	740,000	740,000
Exercised
Expired/Cancelled
Common share purchase warrants, Ending balance	740,000	740,000
Exercise price | $ / shares	$ 0.45	$ 0.45
Weighted Average Life (Years)	10 months 2 days	10 months 2 days			10 months 2 days
June 10, 2026 [Member]
Class of Warrant or Right [Line Items]
Expiry Date	Jun. 10, 2026	Jun. 10, 2026
Common share purchase warrants, Beginning balance
Granted	4,000,000	4,000,000
Exercised
Expired/Cancelled
Common share purchase warrants, Ending balance	1,500,000	1,500,000
Exercise price | $ / shares	$ 0.13	$ 0.13
Weighted Average Life (Years)	3 years 10 months 9 days	3 years 10 months 9 days			3 years 10 months 9 days
June 10, 2026 (1) [Member]
Class of Warrant or Right [Line Items]
Expiry Date	Jun. 10, 2026	Jun. 10, 2026
Common share purchase warrants, Beginning balance
Granted	4,000,000	4,000,000
Exercised
Expired/Cancelled
Common share purchase warrants, Ending balance	1,500,000	1,500,000
Exercise price | $ / shares	$ 0.19	$ 0.19
Weighted Average Life (Years)	3 years 10 months 9 days	3 years 10 months 9 days			3 years 10 months 9 days
August 31, 2021 [Member]
Class of Warrant or Right [Line Items]
Expiry Date			Aug. 31, 2021	[1]
Common share purchase warrants, Beginning balance			3,643,791	[1]
Granted				[1]
Exercised				[1]
Expired/Cancelled				[1]
Common share purchase warrants, Ending balance			3,643,791	[1]
Exercise price | $ / shares			$ 0.21	[1]
Weighted Average Life (Years)			29 days	[1]

[1] The Company received approval of the TSX-V on January 13, 2021 and amended the expiry date of 3,643,791 warrants, extending the expiry date from January 17, 2021 to August 31, 2021, subject to acceleration if the closing price of the Company’s shares exceeds CA$0.30 per common share for at least 10 consecutive trading days.

XML

SUMMARY OF CHANGES IN COMMON SHARE PURCHASE WARRANTS (Details) (Parenthetical)	Jan. 13, 2021 $ / shares shares	Jul. 31, 2022 $ / shares	Oct. 31, 2021 $ / shares
Equity [Abstract]
Class of warrant or right outstanding	3,643,791
Warrant maturity date, description	extending the expiry date from January 17, 2021 to August 31, 2021
Common stock par or stated value per share | (per share)	$ 0.30	$ 0.001	$ 0.001

XML

SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details) - $ / shares	9 Months Ended
	Jul. 31, 2022	Jul. 31, 2021
Risk free rate of interest, minimum	1.34%	0.20%
Risk free rate of interest, maximum	2.59%	1.07%
Expected life of options	5 years
Expected annualized volatility, minimum	134.93%	130.88%
Expected annualized volatility, maximum	136.08%	140.05%
Expected dividend rate
Minimum [Member]
Expected life of options		2 years
Exercise price of options	$ 0.40	$ 0.13
Maximum [Member]
Expected life of options		5 years
Exercise price of options	$ 0.58	$ 0.70

XML

SCHEDULE OF STOCK OPTIONS ACTIVITY (Details)	9 Months Ended				12 Months Ended
	Jul. 31, 2022 USD ($) shares	Jul. 31, 2022 $ / shares	Jul. 31, 2021 USD ($) shares	Jul. 31, 2021 $ / shares	Oct. 31, 2021 USD ($) shares	Oct. 31, 2021 $ / shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total outstanding, beginning balance	61,260,000		28,420,000		28,420,000
Total granted	1,250,000		15,650,000
Total exercised	(1,750,000)		(300,000)
Total expired/cancelled	(5,400,000)		(1,600,000)
Total outstanding, ending balance	55,360,000		42,170,000		61,260,000
Total vested	55,322,500		41,845,000
Weighted average remaining life, outstanding	2 years 11 months 15 days		2 years 9 months 18 days
Weighted average exercise price, beginning balance | $ / shares		$ 0.33		$ 0.09		$ 0.09
Weighted average exercise price, granted | $ / shares		0.44		0.13
Weighted average exercise price, exercised | $ / shares		0.07		0.05
Weighted average exercise price, expired/cancelled | $ / shares		0.12		0.09
Weighted average exercise price, ending balance | $ / shares		0.36		0.10		$ 0.33
Weighted average exercise price, vested | $ / shares		0.36		0.10
Aggregate intrinsic value, outstanding, beginning balance | $	$ 19,994,025		$ 801,922		$ 801,922
Aggregate intrinsic value, outstanding, ending balance | $	8,475,724		6,819,812		$ 19,994,025
Aggregate intrinsic value, vested, ending balance | $	$ 8,459,933		$ 6,774,173
Weighted average remaining life, outstanding	3 years 5 months 15 days		3 years 2 months 4 days
Weighted average remaining life, vested	2 years 11 months 15 days		2 years 9 months 21 days
Option One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expiry Date	Mar. 27, 2022		Feb. 11, 2021
Share Price | $ / shares		0.05		0.05
Total outstanding, beginning balance	1,500,000		800,000		800,000
Total granted
Total exercised	(750,000)
Total expired/cancelled	(750,000)		(800,000)
Total outstanding, ending balance					1,500,000
Total vested
Weighted average remaining life, outstanding			10 days
Option Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expiry Date	Dec. 30, 2022		Aug. 16, 2021
Share Price | $ / shares		0.13		0.05
Total outstanding, beginning balance	6,000,000		600,000		600,000
Total granted
Total exercised	(250,000)
Total expired/cancelled	(650,000)
Total outstanding, ending balance	5,100,000		600,000		6,000,000
Total vested	5,100,000		600,000
Weighted average remaining life, outstanding	5 months 1 day		6 months 14 days
Option Three [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expiry Date	Aug. 12, 2023		Mar. 27, 2022
Share Price | $ / shares		0.05		0.05
Total outstanding, beginning balance	2,290,000		1,750,000		1,750,000
Total granted
Total exercised
Total expired/cancelled	(750,000)
Total outstanding, ending balance	1,540,000		1,750,000		2,290,000
Total vested	1,540,000		1,750,000
Weighted average remaining life, outstanding	1 year 10 days		1 year 1 month 24 days
Option Four [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expiry Date	Dec. 03, 2023		Aug. 26, 2022
Share Price | $ / shares		0.05		0.13
Total outstanding, beginning balance	6,450,000		500,000		500,000
Total granted
Total exercised	(600,000)
Total expired/cancelled	(1,500,000)		(500,000)
Total outstanding, ending balance	4,350,000				6,450,000
Total vested	4,350,000
Weighted average remaining life, outstanding	1 year 4 months 2 days
Option Five [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expiry Date	May 22, 2024		Dec. 30, 2022
Share Price | $ / shares		0.12		0.13
Total outstanding, beginning balance	7,900,000
Total granted			6,150,000
Total exercised
Total expired/cancelled	(850,000)
Total outstanding, ending balance	7,050,000		6,150,000		7,900,000
Total vested	7,050,000		5,825,000
Weighted average remaining life, outstanding	1 year 9 months 21 days		1 year 10 months 28 days
Option Six [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expiry Date	Nov. 03, 2024		Apr. 19, 2023
Share Price | $ / shares		0.15		0.05
Total outstanding, beginning balance	700,000		800,000		800,000
Total granted
Total exercised
Total expired/cancelled
Total outstanding, ending balance	700,000		800,000		700,000
Total vested	700,000		800,000
Weighted average remaining life, outstanding	2 years 3 months 3 days		2 years 2 months 15 days
Option Seven [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expiry Date	Nov. 24, 2024		Aug. 12, 2023
Share Price | $ / shares		0.16		0.05
Total outstanding, beginning balance	320,000		3,120,000		3,120,000
Total granted
Total exercised			(300,000)
Total expired/cancelled	(300,000)
Total outstanding, ending balance	20,000		2,820,000		320,000
Total vested	20,000		2,820,000
Weighted average remaining life, outstanding	2 years 3 months 25 days		2 years 6 months 10 days
Option Eight [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expiry Date	Mar. 26, 2025		Dec. 03, 2023
Share Price | $ / shares		0.11		0.05
Total outstanding, beginning balance	100,000		7,000,000		7,000,000
Total granted
Total exercised
Total expired/cancelled
Total outstanding, ending balance	100,000		7,000,000		100,000
Total vested	100,000		7,000,000
Weighted average remaining life, outstanding	2 years 7 months 24 days		2 years 10 months 2 days
Option Nine [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expiry Date	Apr. 23, 2025		May 22, 2024
Share Price | $ / shares		0.12		0.12
Total outstanding, beginning balance	3,350,000		7,950,000		7,950,000
Total granted
Total exercised	(150,000)
Total expired/cancelled	(250,000)
Total outstanding, ending balance	2,950,000		7,950,000		3,350,000
Total vested	2,950,000		7,950,000
Weighted average remaining life, outstanding	2 years 8 months 23 days		3 years 3 months 21 days
Option Ten [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expiry Date	Dec. 30, 2025		Nov. 03, 2024
Share Price | $ / shares		0.13		0.15
Total outstanding, beginning balance	9,500,000		700,000		700,000
Total granted
Total exercised
Total expired/cancelled
Total outstanding, ending balance	9,500,000		700,000		9,500,000
Total vested	9,500,000		700,000
Weighted average remaining life, outstanding	3 years 5 months 1 day		3 years 9 months 3 days
Option Eleven [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expiry Date	Aug. 30, 2026		Nov. 24, 2024
Share Price | $ / shares		0.70		0.16
Total outstanding, beginning balance	21,700,000		900,000		900,000
Total granted
Total exercised
Total expired/cancelled	(350,000)
Total outstanding, ending balance	21,350,000		900,000		21,700,000
Total vested	21,312,500		900,000
Weighted average remaining life, outstanding	4 years 29 days		3 years 9 months 25 days
Option Twelve [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expiry Date	Oct. 01, 2026		Mar. 26, 2025
Share Price | $ / shares		0.50		0.11
Total outstanding, beginning balance	1,450,000		300,000		300,000
Total granted
Total exercised
Total expired/cancelled
Total outstanding, ending balance	1,450,000		300,000		1,450,000
Total vested	1,450,000		300,000
Weighted average remaining life, outstanding	4 years 2 months 1 day		4 years 1 month 24 days
Option Thirteen [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expiry Date	Dec. 03, 2026		Apr. 23, 2025
Share Price | $ / shares		0.58		0.12
Total outstanding, beginning balance			4,000,000		4,000,000
Total granted	250,000
Total exercised
Total expired/cancelled			(300,000)
Total outstanding, ending balance	250,000		3,700,000
Total vested	250,000		3,700,000
Weighted average remaining life, outstanding	4 years 4 months 6 days		4 years 2 months 23 days
Option Fourteen [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expiry Date	Mar. 07, 2027		Dec. 30, 2025
Share Price | $ / shares		0.40		$ 0.13
Total outstanding, beginning balance
Total granted	500,000		9,500,000
Total exercised
Total expired/cancelled
Total outstanding, ending balance	500,000		9,500,000
Total vested	500,000		9,500,000
Weighted average remaining life, outstanding	4 years 7 months 6 days		4 years 11 months 1 day
Option Fifteen [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expiry Date	Apr. 08, 2027
Share Price | $ / shares		$ 0.40
Total outstanding, beginning balance
Total granted	500,000
Total exercised
Total expired/cancelled
Total outstanding, ending balance	500,000
Total vested	500,000
Weighted average remaining life, outstanding	4 years 8 months 8 days

XML

SCHEDULE OF NON-VESTED STOCK OPTIONS (Details) - 9 months ended Jul. 31, 2022	USD ($) $ / shares shares	$ / shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted average grant date fair value per option, granted | $ / shares
Nonvested, beginning balance	462,500
Nonvested, granted
Nonvested, vested	(350,000)
Nonvested, expired, cancelled	(75,000)
Nonvested, ending balance	37,500
Weighted average grant date fair value per option, beginning balance | $ / shares		0.39
Weighted average grant date fair value per option, vested | $ / shares		0.33
Weighted average grant date fair value per option, expired, cancelled | $ / shares		0.56
Weighted average grant date fair value per option, ending balance | $ / shares		0.56
Weighted average grant date fair value total, beginning balance | $	$ 144,131
Weighted average grant date fair value total, granted | $
Weighted average grant date fair value total, vested | $	$ 90,209
Weighted average grant date fair value total, expired, cancelled | $ / shares	$ 32,652
Weighted average grant date fair value total, ending balance | $	$ 16,326
Option One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Non vested Expiration Date	Dec. 30, 2022
Weighted average grant date fair value per option, granted | $ / shares		0.07
Nonvested, beginning balance	162,500
Nonvested, granted
Nonvested, vested	(162,500)
Nonvested, expired, cancelled
Nonvested, ending balance
Weighted average life (years)	5 months 1 day
Option Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Non vested Expiration Date	Aug. 30, 2026
Weighted average grant date fair value per option, granted | $ / shares		$ 0.56
Nonvested, beginning balance	300,000
Nonvested, granted
Nonvested, vested	(187,500)
Nonvested, expired, cancelled	(75,000)
Nonvested, ending balance	37,500
Weighted average life (years)	4 years 29 days

XML

SCHEDULE OF POTENTIALLY DILUTIVE COMMON SHARES (Details) - shares	9 Months Ended	12 Months Ended
	Jul. 31, 2022	Oct. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	71,963,433	120,808,982
Common Share Purchase Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	16,603,433	59,548,982
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	55,360,000	61,260,000

XML

SHARE CAPITAL (Details Narrative)																																											1 Months Ended	3 Months Ended							4 Months Ended	9 Months Ended				12 Months Ended
	Jul. 31, 2022 USD ($) $ / shares shares	Jul. 13, 2022 $ / shares shares	Jun. 08, 2022 shares	Jun. 03, 2022 USD ($) shares	May 09, 2022 USD ($) shares	Apr. 18, 2022 USD ($) shares	Apr. 18, 2022 CAD ($) $ / shares shares	Apr. 08, 2022 $ / shares shares	Mar. 10, 2022 shares	Mar. 07, 2022 $ / shares shares	Jan. 20, 2022 USD ($) $ / shares shares	Dec. 13, 2021 shares	Dec. 03, 2021 $ / shares shares	Nov. 26, 2021 USD ($) $ / shares shares	Nov. 04, 2021 shares	Nov. 03, 2021 USD ($) shares	Oct. 01, 2021 $ / shares shares	Aug. 30, 2021 $ / shares shares	Aug. 11, 2021 USD ($) shares	Aug. 11, 2021 CAD ($) $ / shares shares	Jul. 16, 2021 USD ($) shares	Jul. 16, 2021 CAD ($) $ / shares shares	Jun. 17, 2021 USD ($) shares	Jun. 17, 2021 CAD ($) $ / shares shares	Jun. 07, 2021 USD ($) shares	May 28, 2021 USD ($) shares	May 28, 2021 CAD ($) $ / shares shares	May 18, 2021 USD ($) shares	May 05, 2021 CAD ($) $ / shares	Apr. 27, 2021 USD ($) shares	Apr. 27, 2021 CAD ($) $ / shares shares	Mar. 24, 2021 USD ($) shares	Mar. 24, 2021 CAD ($) $ / shares shares	Jan. 29, 2021 USD ($) shares	Jan. 29, 2021 CAD ($) $ / shares shares	Jan. 15, 2021 USD ($) shares	Jan. 15, 2021 CAD ($) shares	Dec. 30, 2020 $ / shares shares	Nov. 20, 2020 USD ($) shares	Nov. 20, 2020 CAD ($) $ / shares shares	Sep. 12, 2018	Aug. 08, 2018	Apr. 27, 2022 $ / shares shares	Jul. 31, 2022 USD ($) $ / shares shares	Jul. 31, 2022 CAD ($) shares	Apr. 30, 2022 USD ($) shares	Apr. 30, 2022 CAD ($) $ / shares shares	Jan. 31, 2022 USD ($)	Jan. 31, 2022 CAD ($) $ / shares shares	Jul. 31, 2021 USD ($)	Jul. 31, 2022 CAD ($)	Jul. 31, 2022 USD ($) $ / shares shares	Jul. 31, 2022 CAD ($) $ / shares shares	Jul. 31, 2021 USD ($) shares	Jul. 31, 2021 $ / shares	Oct. 31, 2021 USD ($) $ / shares shares	Oct. 31, 2021 CAD ($) shares	Jul. 31, 2022 $ / shares	Jun. 03, 2022 $ / shares	May 09, 2022 $ / shares	Apr. 22, 2022 CAD ($) $ / shares shares	Nov. 03, 2021 CAD ($) $ / shares shares	Oct. 31, 2021 $ / shares	Jun. 15, 2021 USD ($)	Jun. 11, 2021 shares	Jun. 07, 2021 CAD ($) $ / shares	Feb. 08, 2021 shares	Jan. 15, 2021 $ / shares	Jan. 13, 2021 $ / shares	Jul. 27, 2020 USD ($)	Jul. 27, 2020 CAD ($)	Aug. 29, 2018 USD ($)
Subsidiary, Sale of Stock [Line Items]
Common voting shares	1,000,000,000																																											1,000,000,000								1,000,000,000				1,000,000,000
Common stock par value | (per share)	$ 0.001																																											$ 0.001								$ 0.001				$ 0.001													$ 0.30
Common shares price per share | $ / shares																																																														$ 0.65
Common stock, value, subscriptions | $																																																								$ 209,827
Assets, Fair Value Disclosure																$ 4,796,832																																														$ 5,956,226
Common Stock, Shares, Issued	449,265,776															9,163,425																												449,265,776								449,265,776				392,943,398					933,333	9,163,425
Warrants exercisable price | $ / shares																																																													$ 0.20
Number of stock options granted																																																				1,250,000	1,250,000	15,650,000
Common stock, value, issued | $	$ 41,811,321																																											$ 41,811,321								$ 41,811,321				$ 29,842,167
Stock Issued During Period, Shares, Conversion of Convertible Securities		1,000,000																																									2,000,000
Proceeds from Issuance of Common Stock | $																																																				5,943,775		$ 4,773,200
Debt Instrument, Face Amount | $																																																													$ 100,000
Interest Payable | $																																																													$ 12,000
Share based compensation | $																																												32,539						$ 1,057,013		$ 466,368		$ 1,057,013
Stock options granted | $ / shares
Antidilutive securities excluded from computation of earnings per share amount																																																				71,963,433	71,963,433			120,808,982	120,808,982
2017 Stock Option Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Number of stock options granted																																						15,650,000
Options exercisable price | $ / shares																																						$ 0.13
Stock option granted terms																																										Stock options granted are subject to a maximum term of 5 years. All options granted shall vest immediately, except for those options granted to persons performing investor relations activities for the Company
2017 Stock Option Plan [Member] | Exercisable at Five Years [Member]
Subsidiary, Sale of Stock [Line Items]
Number of stock options exercisable																																						9,500,000
2017 Stock Option Plan [Member] | Exercisable at Two Years [Member]
Subsidiary, Sale of Stock [Line Items]
Number of stock options exercisable																																						6,150,000
2021 Equity Incentive Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Number of stock options granted	10,042,368							500,000		500,000			250,000				1,450,000	21,700,000
Options exercisable price | $ / shares								$ 0.40		$ 0.40			$ 0.58				$ 0.50	$ 0.70
Maximum number of common shares available																																																																	27,312,368
Options exercisable period								5 years		5 years			5 years				5 years
Class A Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants exercisable price | $ / shares		$ 0.13									$ 0.13																																$ 0.13
Warrant exercisable		500,000							500,000			500,000			500,000																												1,000,000
Class B Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Payments of stock issuance costs | $											$ 1,361
Warrants exercisable price | $ / shares		$ 0.19									$ 0.19																																$ 0.19
Warrant exercisable		500,000							500,000		500,000	500,000			500,000																												1,000,000
Director and Officer [Member] | Related Party Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued																9,163,425
Equity method investment, ownership percentage																																									5.00%
Share Price | $ / shares																																																														$ 0.65
Equity Option [Member]
Subsidiary, Sale of Stock [Line Items]
Number of stock options granted																																														750,000	750,000									2,630,000	2,630,000
Options exercisable price | $ / shares																																															$ 0.05
Proceeds from Stock Options Exercised																																														$ 29,715	$ 37,500									$ 140,734	$ 175,800
Proceeds from other equity | $																																												$ 48,060		$ 22,203										$ 121,932
Stock options granted | $ / shares																																																					$ 0.37		$ 0.09
Equity Option [Member] | Share Price One [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued																																												250,000	250,000
Common shares price per share | $ / shares																																																										$ 0.13
Proceeds from Issuance of Common Stock																																												$ 25,340	$ 32,500
Equity Option [Member] | Share Price Two [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued																																												150,000	150,000
Common shares price per share | $ / shares																																																										0.12
Proceeds from Issuance of Common Stock																																												$ 13,853	$ 18,000
Equity Option [Member] | Share Price Three [Member]
Subsidiary, Sale of Stock [Line Items]
Number of stock options granted																																												600,000	600,000
Options exercisable price | $ / shares																																																										0.05
Proceeds from Stock Options Exercised																																												$ 23,272							$ 30,000
Equipment [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued																									1,538,461
Common shares price per share | $ / shares																																																																		$ 0.24
Assets, Fair Value Disclosure																									$ 305,832																																									$ 369,231
July 2020 Convertible Debenture [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued																												1,360,959
Conversion of Stock, Shares Issued																												263,973
Conversion of Stock, Amount Issued | $																												$ 26,286
Common stock, value, issued | $																												$ 26,286
Debt Instrument, Face Amount																																																																						$ 112,124	$ 150,000
June 2021 Convertible Debentures [Member]
Subsidiary, Sale of Stock [Line Items]
Stock Issued During Period, Shares, Conversion of Units		1,000,000							1,000,000		1,000,000	1,000,000			1,000,000																												2,000,000
June 2021 Convertible Debenture [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued			1,000,000																																																	8,000,000	8,000,000
Common shares price per share | $ / shares	$ 1																																											$ 1								$ 1
Debt Instrument, Face Amount | $																																																																$ 1,500,000
June 2021 Convertible Debenture [Member] | Common Class A [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants exercisable price | $ / shares	$ 0.13																																											$ 0.13								$ 0.13
Warrant exercisable	4,000,000		500,000																																									4,000,000								4,000,000
June 2021 Convertible Debenture [Member] | Common Class B [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants exercisable price | $ / shares	$ 0.19																																											$ 0.19								$ 0.19
Warrant exercisable	4,000,000		500,000																																									4,000,000								4,000,000
Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant exercisable																																																																			33,000,000
Maximum [Member] | 2017 Stock Option Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Percentage of authorized grant stock options																																										20.00%
Maximum [Member] | 2021 Equity Incentive Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Maximum number of common shares available	34,092,368																																											34,092,368								34,092,368
Number of stock options forfeited																																																								29,042,368	29,042,368
Maximum [Member] | Director and Officers [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock, value, issued | $																																																																								$ 5,000,000
Maximum [Member] | Equity Option [Member]
Subsidiary, Sale of Stock [Line Items]
Options exercisable price | $ / shares																																																															$ 0.16
Minimum [Member] | 2021 Equity Incentive Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Maximum number of common shares available	6,780,000																																											6,780,000								6,780,000
Number of stock options forfeited																																																								1,730,000	1,730,000
Minimum [Member] | Equity Option [Member]
Subsidiary, Sale of Stock [Line Items]
Options exercisable price | $ / shares																																																															0.05
Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued																																																				3,842,499	3,842,499	53,151,881
Stock Issued During Period, Shares, Conversion of Convertible Securities									1,000,000		1,000,000	1,000,000			1,000,000																																					8,933,333	8,933,333	1,360,959
Proceeds from Issuance of Common Stock																																																$ 2,293,946	$ 2,899,295
Warrants unexercised																																																	15,389,448
Common Stock [Member] | June 2021 Convertible Debenture [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued			1,000,000																																																	8,000,000	8,000,000
Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Common Stock, Shares, Issued																																																								7,014,969
Proceeds from Warrant Exercises																																																								$ 887,520	$ 1,120,130
Common stock warrants expired unexercised																																																								525,173
Proceeds from other equity | $																																																								$ 4,291
Warrants unexercised																																																	2,428,363
Warrant [Member] | Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants exercisable price | $ / shares																																																															0.21
Warrant [Member] | Minimum [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants exercisable price | $ / shares																																																															$ 0.05
Common Stock One [Member]
Subsidiary, Sale of Stock [Line Items]
Common shares price per share | $ / shares																																																	$ 0.19
Warrant exercisable																																																	15,159,448
Proceeds from Issuance of Common Stock																																																2,279,136	$ 2,880,295
Common Stock Two [Member]
Subsidiary, Sale of Stock [Line Items]
Common shares price per share | $ / shares																																																	$ 0.05
Warrant exercisable																																																	200,000
Proceeds from Issuance of Common Stock																																																7,830	$ 10,000
Common Stock Three [Member]
Subsidiary, Sale of Stock [Line Items]
Common shares price per share | $ / shares																																																	$ 0.30
Warrant exercisable																																																	30,000
Proceeds from Issuance of Common Stock																																																$ 6,981	$ 9,000
Common Stock Purchase Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued																																												8,131,975	8,131,975	929,005	929,005
Common shares price per share | $ / shares																																															$ 0.19											0.19
Common stock warrants expired unexercised	17,414,239																																											17,414,239			3,191,933					17,414,239
Proceeds from Issuance of Common Stock																																												$ 1,205,077	$ 1,545,075	$ 929,005	$ 1,177,755
Common stock broker warrants expired unexercised	13,725																																											13,725			40,000					13,725
Common Stock Purchase Warrant One [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued																																												800,000	800,000	2,082,025	2,082,025
Common shares price per share | $ / shares																																															$ 0.05											0.05
Proceeds from Issuance of Common Stock																																												$ 31,051	$ 40,000	$ 81,354	$ 104,101
Common Stock Purchase Warrant Two [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued																																														30,960	30,960
Common shares price per share | $ / shares																																															$ 0.30
Proceeds from Issuance of Common Stock																																														$ 7,357	$ 9,288
Non Brokered Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued																			3,827,601	3,827,601	4,350,000	4,350,000																														25,724,955	25,724,955
Common shares price per share | $ / shares							$ 0.25													$ 0.55		$ 0.20							$ 0.13																													0.13
Proceeds from issuance of private placement																			$ 1,683,336	$ 2,105,180	$ 690,860	$ 870,000																														$ 2,621,314	$ 3,344,244
Issuance of shares description																			Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.65 for a period of eighteen months from the date of closing	Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.65 for a period of eighteen months from the date of closing	Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.30 for a period of one year from the date of closing	Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.30 for a period of one year from the date of closing																														Each unit issued consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.19 for a period of one year from the date of closing of the respective financing tranche	Each unit issued consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.19 for a period of one year from the date of closing of the respective financing tranche
Payments of stock issuance costs | $																			$ 124,923		$ 48,319																															$ 195,614
Additional stock issuance costs | $																																																				$ 8,444
Non Brokered Private Placement [Member] | Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Proceeds from issuance of private placement | $							$ 3,000,000																						$ 3,000,000
Non Brokered Private Placement [Member] | Share-Based Payment Arrangement, Tranche One [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued					1,727,000																					5,223,420	5,223,420												5,599,171	5,599,171
Common shares price per share | $ / shares																											$ 0.13													$ 0.13																				$ 0.25
Proceeds from issuance of private placement					$ 431,750																					$ 561,844	$ 679,044												$ 556,876	$ 727,892
Non Brokered Private Placement [Member] | Share-Based Payment Arrangement, Tranche Two [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued																																				7,337,914	7,337,914
Common shares price per share | $ / shares																																																																				$ 0.13
Proceeds from issuance of private placement																																				$ 749,435	$ 953,930
Common stock, value, subscriptions | $																																				$ 39,996
Non Brokered Private Placement [Member] | Share-Based Payment Arrangement, Tranche Three [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued																																		5,382,303	5,382,303
Common shares price per share | $ / shares																																			$ 0.13
Proceeds from issuance of private placement																																		$ 547,496	$ 699,699
Non Brokered Private Placement [Member] | Share Based Compensation Award Tranche Four [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued																																6,554,172	6,554,172
Common shares price per share | $ / shares																																	$ 0.13
Proceeds from issuance of private placement																																$ 678,270	$ 852,042
Non Brokered Private Placement [Member] | Share Based Compensation Award Tranche Five and Final [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued																														851,395	851,395
Common shares price per share | $ / shares																															$ 0.13
Proceeds from issuance of private placement																														$ 89,237	$ 110,681
Non Brokered Private Placement [Member] | Share Based Compensation Award Tranche Two and Final [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued				740,000																			17,853,506	17,853,506
Common shares price per share | $ / shares																								$ 0.13																																			$ 0.25
Proceeds from issuance of private placement				$ 185,000																			$ 1,880,687	$ 2,320,956
Non Brokered Private Placement One [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued						2,467,000	2,467,000																																													23,076,926	23,076,926
Common shares price per share | $ / shares																																																										$ 0.13
Proceeds from issuance of private placement						$ 616,750																																														$ 2,442,531	$ 3,000,000
Issuance of shares description																																																				Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of $0.45 for a period of one year from the date of closing of the respective financing tranche	Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of $0.45 for a period of one year from the date of closing of the respective financing tranche
Payments of stock issuance costs | $						$ 23,182																																														$ 154,336
Non Brokered Private Placement One [Member] | Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of shares description																																																				Each unit issued consists of one common share and one common share purchase warrant entitling the holder to acquire a further common share at a price of CA$0.19 for a period of one year from the closing date of the respective financing tranche	Each unit issued consists of one common share and one common share purchase warrant entitling the holder to acquire a further common share at a price of CA$0.19 for a period of one year from the closing date of the respective financing tranche
Private Placement [Member] | Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued														1,375,499
Common shares price per share | $ / shares														$ 0.55
Proceeds from issuance of private placement | $														$ 756,524
Payments of stock issuance costs | $														$ 26,656
Share Price | $ / shares														$ 0.75

XML

SCHEDULE OF CLASSIFICATION OF FINANCIAL INSTRUMENTS (Details)	Jul. 31, 2022 USD ($)
Fair Value Disclosures [Abstract]
Cash	$ 16,700
Other receivables	94,696
Deposits held by related parties	349,338
Accounts payable and accrued liabilities	3,434,539
Due to related parties	1,520,834
Convertible debenture, net	1,942,838
Warrant liability	$ 57,080

XML

SCHEDULE OF FOREIGN CURRENCY RISK (Details)	Jul. 31, 2022 CAD ($)
Total	$ (3,186,376)
Cash [Member]
Total assets	4,757
Other Receivable [Member]
Total assets	123,701
Accounts Payable and Accrued Liabilities [Member]
Total liabilities	(2,309,520)
Due To Related Parties [Member]
Total liabilities	$ (1,005,314)

XML

FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Details Narrative) - USD ($)	9 Months Ended
	Jul. 31, 2022	Oct. 31, 2021
Fair Value Disclosures [Abstract]
Cash	$ 16,700	$ 462,360
Short term investments	$ 0	0
Foreign currency risk rate	5.00%
Increase decrease in foreign currency transaction amount	$ 124,237
Working capital deficit	$ 6,642,252	$ 9,657,316

XML

SCHEDULE OF ASSETS INFORMATION (Details) - USD ($)	Jul. 31, 2022	Oct. 31, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]
United States – property, plant and equipment	$ 4,488,001	$ 2,574,704
United States – mineral property costs	93,453	93,453
Property, plant and equipment net	4,581,454	2,668,157
Other assets	1,216,309	1,845,355
Total Assets	5,797,763	4,513,512
CANADA
Revenues from External Customers and Long-Lived Assets [Line Items]
United States – property, plant and equipment	4,458,609	2,546,383
Other assets	311,300	1,554,827
UNITED STATES
Revenues from External Customers and Long-Lived Assets [Line Items]
United States – property, plant and equipment	29,392	28,321
United States – mineral property costs	93,453	93,453
Other assets	$ 905,009	$ 290,528

XML

SUBSEQUENT EVENTS (Details Narrative)										9 Months Ended
	Aug. 17, 2022 $ / shares shares	Aug. 05, 2022 $ / shares shares	Jul. 31, 2022 shares	Jun. 08, 2022 shares	Apr. 08, 2022 $ / shares shares	Mar. 07, 2022 $ / shares shares	Dec. 03, 2021 $ / shares shares	Oct. 01, 2021 $ / shares shares	Aug. 30, 2021 $ / shares shares	Jul. 31, 2022 shares	Jul. 31, 2021 shares	Jul. 13, 2022 $ / shares shares	Apr. 27, 2022 $ / shares shares	Apr. 22, 2022 $ / shares	Mar. 10, 2022 shares	Jan. 20, 2022 $ / shares shares	Dec. 13, 2021 shares	Nov. 04, 2021 shares
Subsequent Event [Line Items]
Options granted										1,250,000	15,650,000
Warrants exercisable price | $ / shares														$ 0.20
Class A Warrants [Member]
Subsequent Event [Line Items]
Number of warrants exercisable												500,000	1,000,000		500,000		500,000	500,000
Warrants exercisable price | $ / shares												$ 0.13	$ 0.13			$ 0.13
Class B Warrants [Member]
Subsequent Event [Line Items]
Number of warrants exercisable												500,000	1,000,000		500,000	500,000	500,000	500,000
Warrants exercisable price | $ / shares												$ 0.19	$ 0.19			$ 0.19
Common Stock [Member]
Subsequent Event [Line Items]
Number of shares issued										3,842,499	53,151,881
June 2021 Convertible Debenture [Member]
Subsequent Event [Line Items]
Number of shares issued				1,000,000						8,000,000
June 2021 Convertible Debenture [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Number of shares issued				1,000,000						8,000,000
2021 Equity Incentive Plan [Member]
Subsequent Event [Line Items]
Options granted			10,042,368		500,000	500,000	250,000	1,450,000	21,700,000
Options exercisable price | $ / shares					$ 0.40	$ 0.40	$ 0.58	$ 0.50	$ 0.70
Options exercisable period					5 years	5 years	5 years	5 years
Subsequent Event [Member] | June 2021 Convertible Debenture [Member]
Subsequent Event [Line Items]
Number of shares issued	1,000,000
Subsequent Event [Member] | June 2021 Convertible Debenture [Member] | Class A Warrants [Member]
Subsequent Event [Line Items]
Number of warrants exercisable	500,000
Warrants exercisable price | $ / shares	$ 0.13
Subsequent Event [Member] | June 2021 Convertible Debenture [Member] | Class B Warrants [Member]
Subsequent Event [Line Items]
Number of warrants exercisable	500,000
Warrants exercisable price | $ / shares	$ 0.19
Subsequent Event [Member] | June 2021 Convertible Debenture [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Number of shares issued	1,000,000
Subsequent Event [Member] | 2021 Equity Incentive Plan [Member] | Non-Statutory Stock Options [Member]
Subsequent Event [Line Items]
Options granted		1,000,000
Options exercisable price | $ / shares		$ 0.16
Options exercisable period		2 years